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Abstract 
The number of protein structures deposited in the Protein data bank is 
increasing almost exponentially and among these structures many of the proteins 
are novel with unknown function. Like Docking, Pharmacophore searching is an 
In-silico technique which is widely used for drug discovery. In pharmacophore 
searching the main focus is on the hydrogen bond interactions between the 
ligand and the target protein. The pharmacophore models are generated either 
by using the already known actives as templates or by utilizing the significant 
chemical features of the active site. 
In this thesis the pharmacophore searching has been used to find potential 
ligands/substrates for unknown proteins and then ligand binding is confirmed by 
using different biophysical techniques. In the initial phases the pharmacophore 
models were generated by using Cerius2 and Weblab Viewer pro programs. While 
in later stages more sophisticated searches were carried out by using DSV 
(Discovery studio visualizer, Accelrys®). Procedures were optimized for model 
building by using DSV, which enabled the pharmacophore searching via both the 
Vector and the Query atom methods. To validate the technique, it was first used 
on known enzymes with established function e.g. xylose reductase and shikimate 
kinase. The optimized pharmacophore model when search through the database 
successfully identified the true substrates for these enzymes among other 
ligands thereby demonstrating the attainment. 
 In addition, protein structures from the protein data bank (PDB) with unknown 
ligands (UNK) were identified and manually screened to find examples that could 
be used to test the applicability of pharmacophore searching methods. The 
diversity of structures showed that the definition of an unknown ligand is 
completely inconsistent with many examples where any non spherical density 
was labelled as unknown ligand and in most cases a single atom is labelled as an 
unknown ligand, which most likely can be an ion or a water molecule. It 
appeared that some compounds like glycerol, phosphate and citrate which co-
crystallized with the protein due to their presence in the crystallization 
conditions were also mistakenly assigned as UNK. The pharmacophore method 
worked successfully in finding suitable ligand (s) for the protein.  
III 
The technique has been used to find potential ligands for proteins with unknown 
function on three test cases e.g. TdcF, HutD and PARI. Of the potential 
pharmacophore hits obtained through database search, a number of compounds 
were either purchased or synthesised to be tested for binding affinity. Different 
biophysical techniques like DSC, ITC, CD and NMR were used for this purpose. 
Among these techniques NMR proved to be the most sensitive technique to 
differentiate binders from non-binders and to further detect weak and strong 
bonding in terms of Kd values. For TdcF among other binders the best binder was 
2-ketobutyrate with a Kd value of 200µM. In case of HutD, formyl glutamate (Kd = 
92µM) and formimino glutamate (Kd = 500µM) came out to be the best binders 
and could be the true ligands of the protein at physiological concentration. For 
PARI L-glutamate appeared to be a potential ligand for the protein as confirmed 
through the NMR experiments. Pharmacophore modelling has been successful in 
identifying potential interactions provided by the protein active site which in 
turns specifies the required features to be present in a ligand and later on the 
successful binding studies further confirm its applicability. 
While developing pharmacophore methodology and performing binding 
experiments, a number of other projects were also carried out. In a side project 
enzyme inhibition assays were carried out on an enzyme called NFGase. The Ki 
values were calculated for different inhibitors along with the type of inhibition. 
Among different substrate analogues, one compound named 1,2,4 butane 
tricarboxylic acid showed inhibition in the nano molar range (Ki = 190nM). 
The enzyme characterization of different DHQases was carried out and the X-ray 
structure of Campylobacter jejuni DHQase along with 3-Dehydro shikimate was 
determined at a resolution of 2.4Å. The enzyme assays were carried out for the 
first time for Campylobacter jejuni & Candida albicans DHQase, which gave the 
lowest Km (17µM) value for the former. The comparison of the 3 available X-ray 
structures (in complex with 3-Dehydro shikimate) indicated that the presence 
(Campylobacter jejuni DHQase, Mycobacterium tuberculosis DHQase) and 
absence (Streptomyeces coelicolor DHQase) of Gly78 residue in the active site 
suggests reasons for the observation of low and high Km values among different 
DHQases. 
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1. INTRODUCTION 
1.1 Protein from Structure to Function 
Significant research effort continues to be applied to identify the function of 
proteins within a given cell or organism. One of these approaches is to relate 
protein structure to its function by using single crystal X-ray diffraction or by 
nuclear magnetic resonance (NMR). But this is not simple as stated by Brian 
Shoichet “Even if you know what a protein looks like, this does not necessarily 
mean you know what it does”. To take the next step and ask “ whether we can 
broadly predict function of an enzyme if we know the structure” {1}. For an 
enzyme, substrate prediction is challenging and needs great care as said by 
Shoichet “But in case all you have to do is get a molecule that the enzyme 
recognizes. It doesn’t have to do the next step, which is to turn the molecule 
over, to do the catalytic reaction on it and capturing that is no joke” {1}.  
Various methodologies have been developed primarily for the pharmaceutical 
industry for the identification/design of inhibitors using the target protein 
structure as a template. In particular, pharmacophore searching allows 
hypothesis driven searching of the protein structure, but has not been applied to 
the protein structure/function problem due to the expense of this commercial 
software. Instead most approaches have used  freely available academic docking 
software and among them one of the success case includes the prediction of  
activity for a  protein(Tm0936) from Thermotoga maritima with an unknown 
function on the basis of docking as an enzyme {2}. 
 
Pharmacophore searching as implemented in the available software is very 
ligand centric, in some cases relying on the existence of a ligand bound structure 
as a starting point. This reflects its roots in the drug discovery field. The number 
of genomes sequenced is increasing from all types of organism and with each 
deposited genome; there are a significant number of sequences with no 
similarity to any known protein. By default the function of these protein are 
unknown, and the percentile of such type of sequences deposited is nearly 50% 
{3} . The prediction of function of an enzyme on the basis of sequence similarity 
is the main criterion of genome annotation, and recently the correlation 
between the sequence and structural and functional aspects of proteins have 
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been addressed {4, 5}. However sequence similarity does not always correlate 
with conserved function. This suggests that there is need of different approaches 
for exploring the uncharacterized protein in an integrated manner and 
computational structural functional approaches can prove equal to the task 
regarding functional annotation {3}. The availability of a high resolution 
structure of a protein opens different avenues for analysis of an enzyme 
mechanism and understanding the functional role of the protein.   
As the number of x-ray structures of unknown proteins deposited in the PDB is 
increasing hugely the focus is towards the use of various computational methods 
for functional annotation of these proteins {6}. Generally  the active site of an 
enzyme is present in certain cavities or pocket like structures of the enzyme {7} 
and work on these type of active site has been reviewed {8} but it has been 
noticed that within  the super families of protein there are functional 
differences which can be minor or quite significant in nature {6}. The interaction 
between the protein and ligand includes steric fit or complementarity between 
ligand and protein. Protein-ligand interactions can induce significant 
conformational changes and these physiochemical interactions involve significant 
solvent and solvation effects {9}. Approaches for predicting the function of a 
protein based on their active site includes sequence similarity, fold similarity, 
docking and pharmacophore searching.  
1.1.1  Protein Sequence comparisons 
In April 2012 there were 151,824,421 sequence records in the online database 
Gene Bank consisting of billions of individual amino acids/bases. With genome 
sequencing projects around the world this number is increasing at an 
exponential rate. For any specific protein its amino acid sequence can be 
compared against databases such as Gene Bank for similar sequences.   
Sequence alignment is a way of arranging the DNA, RNA or Protein sequences for 
the identification of similar regions that may lead to the functional, structural or 
evolutionary relation ship between the sequences. Aligned sequences of 
nucleotide or amino acid residues are typically represented as rows within a 
matrix. Gaps are inserted between the residues so that identical or similar 
characters are aligned in successive columns. 
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Figure  1.1 Sequence alignment of two human zinc finger proteins, Single capital letters = 
amino acids (a.a), Red = small, hydrophobic and aromatic a.a except Y, Blue = a.a with acidic 
side chain, Magenta = a.a with basic side chains, Green = a.a with hydroxyl, amine, amide 
and basic side chains, Gray = others, * = identical a.a,  : = conserved substitutions (same 
color group), . = semi-conserved substitution (similar shapes), image produced by using 
ClustalW {10}. 
 
Figure 1.1 shows a simple sequence alignment, produced by Clustal.W {10}, of 
two human zinc finger proteins. The sequence identity is given on the left hand 
side by Gene Bank accession number. Sequence based searches are frequently in 
use in the biological field, mainly two types of sequence searches are dominant 
including the nucleotide sequence and amino acid sequence searching. Searches 
can be limited by type of organism, e.g. human, animal, bacteria or virus. One 
of the main online tools used is BLAST (Basic local alignment search tool), which 
can be accessed at the NCBI (National Center for Biotechnology Information),   
part of the U.S. National Institutes of Health.    
One of the main objectives of sequence searches and alignment is to identify 
and align related sequences of proteins with the hope to find structure to 
function similarity provided that their function and/or structure are already 
known. The identification of the catalytic and conserved residues is made easier 
by comparison with multiple sequences. There are many online databases 
available for submitting the sequence of a novel protein and to compare it with 
thousand of other proteins whose function is already known. There is a proper 
system of scoring functions available in databases which give the leading hits in 
descending order by considering different factors like identical amino acids, 
similar amino acids, conserved amino acids and catalytic amino acids. The 
sequence based search is a valuable tool in the preliminary studies of a novel 
protein and assists in suggesting structure and function. 
At the first step of analysis, the use of sequence similarity in the 
characterization of proteins has been found to be a very powerful but sometimes 
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insufficient method to infer a protein function completely {11}. It has been 
observed that  some structurally closely related enzymes can catalyze totally 
different type of reaction {12} and conversely completely unrelated enzymes 
may catalyze overall the same reaction {13}. For instance in case of AHS (amido 
hydrolase super family),  if seen through a sequence perspective protein Tm0936  
has got similarity with the large chlorohydrolase and cytosine deaminase 
subgroup within the AHS {14}. A successful  in silico study  identified  the 
function of protein Tm0936 from Thermotoga maritima as an adenosine and 
thiomethyl adenosine deaminase {2} which on the contrary shows no sequence 
similarity with adenosine deaminases {14}. It is being stated that  approximately 
40% of newly sequenced genes have not been assigned a certain function and if 
they have, the specificity of the function is either incorrect or not the primary 
function {15}. 
1.1.2 Protein Fold similarity 
The amino acid sequence of a protein is directly responsible for the folded 
structure of the protein. Even with amino acid sequence similarity lower than 
20%, it has been observed that the folded protein structure can be still 
conserved. A number of recent advances have been made for obtaining 
functional information from protein structure. A fold relationship to an already 
characterized protein or group of proteins can give some insight into the general 
function of the uncharacterized protein. Methods of deducing function directly 
from structure, without the use of evolutionary relationships, are developing 
rapidly. All such methods can also be used with models of protein structure, but 
model accuracy imposes certain limitations {16}.  
The rapid expansion of the structural genomics field has created a new urgency 
leading to improved methods for structure-based annotation of function. 
Structural alignments, which are usually specific to protein and sometimes RNA 
sequences, are used to get information about the secondary and tertiary 
structure of the protein {17}.  These methods depend on the availability of 
structural information; they can only be used for sequences whose corresponding 
structures are known (usually through X-ray crystallography or NMR 
spectroscopy). As both protein and RNA structure are more conserved in 
evolution therefore sequence structural alignments can be more reliable 
between sequences which have >50% sequence homology but for those which 
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have diverged so extensively that sequence homology drops to 20%, the 
comparison cannot reliably detect their similarity. Structural alignments are 
used as the "gold standard" in evaluating alignments for homology-based protein 
structure prediction. They explicitly align regions of the protein sequence that 
are structurally similar rather than relying exclusively on sequence information 
{18}. A large number of structures deposited at the PDB {19} by various 
structural genomics initiatives {20} are of ‘hypothetical proteins’, i.e. proteins 
of unknown function. These proteins are classified as hypothetical when 
sequence search methods have failed to match them to those proteins that have 
been functionally characterized. However, if the 3D structure of a protein is 
known it opens up a possibility of a chance for annotating its function by means 
of its structural analysis {21}. 
Different databases like DALI (Distance mAtrix ALIgnment) {22} and SSAP 
(sequential structure alignment program) {23} are being used for the structural 
and fold alignment purposes. In each program different properties related to 
similarity like similar contact region, fragment similarity and atom to atom 
vector similarity are used.  For instance crystal structure of a protein (PDB: 
3GZI) belonging to TetR family from Shewanella Sp. PV-4 was submitted and 
annotated as a transcriptional regulator protein. A comparison of 3GZI by protein 
fold using DALI search database gave many hits like PDB entries 3DEW, 1T33, 
1BHQ, 2D6Y and 2ID6. The best hit (3DEW) is shown together with 3GZI in figure 
.1.2 
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Figure  1.2 Superposition of 3GZI (green) and 3DEW (yellow), image taken from Topsan {24} 
 
3GZI is an example where the crystal structure fortuitously contains a ligand 
which may help identify the function of the protein by means of sequence 
similarity search. The structure of 3GZI had unidentified electron density which 
when compared with PDB: 2TRT (a tetracycline binding protein) corresponded to 
the tetracycline binding site, though the ligand in the binding pocket is clearly 
different (Figure.1.3). In a co-crystallized structure it depends on the source of 
the ligand, if it is an artifact of crystallization then it is less helpful but if the 
compound has been co-purified with the protein then it represents the native 
ligand.  There are numerous examples where co-factors such as NADP, FMN are 
co-purified with an unknown protein thus providing an excellent start in 
assignment of function.   
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Figure  1.3 Superposition of 3GZI (light blue) with TerR family protein 2TRT (light yellow), the 
electron density for unidentified ligand (blue mesh) for 3GZI is located in the same region 
where tetracycline (orange stick model) is residing, image taken from Topsan {24} 
 
Structure based functional characterization is used and has had significant 
successes, but in many cases the results are not valid and some times appear to 
be incorrect {25}. Identification of a protein’s “real” substrate when it has a 
remarkable substrate diversity remains a challenge {11}. For enzymes of 
unknown function (uncharacterized), prediction of potential substrates on the 
basis of structural complementarity is principally an alternative  to 
bioinformatics based functional identification {15, 26}. In terms of possible 
protein structure along with structural genomic study the structural genomics 
initiative has generated many protein structures every year {27-30} the function 
of some of these proteins is known, but for many of them only the 3D structure  
is known which may help in understanding their  biochemical roles {11}.  
Different amino acid sequences are able to generate proteins with similar folds 
but this does not always leads to a related function {31}. Structure-based 
prediction  becomes much attractive when the target unknown protein has a 
weak similarity to proteins with known activity and this makes sequence based 
methods unreliable {32}. The functional characterization of enzymes encoded 
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within completely sequenced genomes is painstaking work and requires much 
dedication {14}. 
1.1.3 Protein functional Assignment 
The number of protein structures determined in an attempt to map the “Protein 
fold universe” is increasing at a significance pace. Despite the claim that protein 
structure is intimately related to function. The ability to read out the function 
of a protein based on its 3D structure is far from simple. Even when the function 
of a protein has been determined, correct identification of the substrate or co-
factor binding mode within the active site can prove illusive. 
Normally traditional structure based drug discovery involving in silico screening 
of compounds is carried out by using large multi-conformational libraries of drug 
like compounds against the target protein crystal structure.  The objective is the 
identification of promising lead compounds (Figure 1.4). The leads can then be 
modified in iterative rounds with library creation of derived compounds. This is 
followed by invitro screening and structure determination of enzyme-inhibitor 
key complexes which ultimately leads to the design of new compounds {33}.  
 
 
Figure  1.4 Schematic chart for pharmacophore-database searching for structure based drug 
discovery, image taken from {33} 
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More recently to probe the enzyme binding site, fragment methods have been 
used. The method involves the screening of small fragment libraries and 
identifies moieties that can be joined together or grown to form lead compounds 
{11}. Structure-based prediction of enzymatic capabilities is now an important 
issue, and many researchers worldwide are working, with the ultimate target of 
providing a suitable In silico protocol that, given an experimental structure, can 
predict its function to some reliable levels {11}. There have been extensive 
advances in computational field to understand the ligand binding mainly for the 
detection of the protein functional site.  The characterization remains the target 
of structural bioinformatics, for this purpose various productive techniques have 
been tested in recent times which are expected to be helpful in both the 
detection of functional site and for the design of new pharmaceuticals. It is 
apparent that as the nursery of  protein structure information flourishes, newly 
launched computational  tools  would be used for the functional characterization 
and structure based drug design purposes {6}. Due to the lack of complete in-
depth knowledge of the metabolic pathways, the dire need of new techniques 
for the functional characterization of enzymes regarding their mysterious 
substrates has been sensed, for which different approaches including the 
computational one’s are being launched {34}.  To cope with this, technique like 
pharmacophore based searching can prove to be effective and result oriented 
from the functional view point. It can be used as a significant tool for the 
identification of both known and unknown substrates leading to the functional 
annotation of novel proteins. 
 
1.1.4 Protein-ligand binding Interactions 
The protein and ligand are fully solvated prior to binding and do not interact. 
However in the bound state both are partially desolvated and form favorable 
interactions with each other {35}. Mostly protein-ligand interactions occur as a 
result of relatively weak forces in the form of electrostatic attractions, such as 
ion-ion, ion-dipole, dipole-dipole (hydrogen bonding), dipole-induced dipole, 
London or Dispersion forces and hydrophobic effect. The hydrophobic effect has 
been studied extensively and is important in driving protein folding and protein 
ligand binding. Many theories and models have been put forward to describe the 
hydrophobic effect and in order to support these models and theories various 
experiments have been carried out. A recent study has supported the hypothesis 
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that structured water molecules including both water molecules displaced by the 
ligands and those reorganized upon ligand binding determine the 
thermodynamics of binding of ligands to the active site of the protein. Despite 
extensive studies carried out in order to understand the hydrophobic effect, 
their molecular mechanism remains controversial, and there are still no reliable 
models for predicting its role in protein ligand binding. The hydrophobic effect is 
now understood to be a complicated phenomenon, undergoing entropy, enthalpy 
and free energy changes during protein ligand interactions {36, 37}. The 
structure of binding site of the protein has crucial importance in specifying 
potential interaction such as Hydrogen bond donor, Hydrogen bond acceptor and 
hydrophobic patches. These interaction sites are referred to as “hot spots”. For 
exploring the binding site of the protein, primarily the amino acids forming the 
cavity of a given protein describe the recognition pattern. The binding event 
takes place when the  ligand  complements to these amino acid residues in the 
three dimensional space in the binding cavity {38}. There is a large amount of 3D 
structural data available for protein ligand complexes and their corresponding 
affinities. Some of the typical features found in all of these complexes are 
1. High degree of steric complementarity between the protein and ligand 
2. High level of agreement at the ligand protein interface regarding the 
lipophilic and hydrophilic interactions 
3. Ligand binding in an energetically favorable conformation 
Typical non-covalent interactions found in protein-ligand complexes include 
hydrogen bonding, ionic interactions and (lipophilic) hydrophobic interactions. 
The lipophilic interactions are essentially between the apolar regions of protein 
and ligand. The water molecules in the lipophilic region of the binding site are 
unable to form hydrogen bonds with the protein and so may form an ordered 
network of waters within the binding site. The displacement of these ordered 
water molecules is generally accepted as contributing to the strength of 
lipophilic interactions {39}. Figure 1.5 represents some of the common non-
covalent interactions present between protein and ligand. 
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Figure  1.5 Common non-bonding interactions between the ligand and the protein usually in 
case of hydrophobic interactions the lipophilic part of protein is in contact with the 
lipophilic part of the ligand 
 
In the most well known cases hydrogen bonding phenomenon takes place when 
an electronegative donor group (e.g. O, N, S) with the capability to withdraw 
electrons from a proton in a D-H covalent bond ( D= Hydrogen bond donor 
group), leaving a net partial positive charge on the partly deshielded proton and 
thus creating an opportunity to form a electrostatic interaction between the 
partially deshielded proton and another electronegative group. Hydrogen atoms 
or protons are found almost between every pair of non-covalently bonded heavy 
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atoms in biological systems, they constitute about one half of the atoms in 
macromolecules and two-thirds of the atoms in solvating water. Apart from 
enzyme catalysis, hydrogen bonding plays a very important role in the protein-
ligand binding event and is crucial to the recognition of ligands by the protein. 
The presence of hydrogen bonding certainly stabilizes the overall structure of 
the protein and influences the binding pose of the ligand in the active site by 
enhancing the undergoing favorable interactions between the two {40}. 
Majority of the protein ligand interactions are reversible in nature. The general 
equation used for the bimolecular interaction between a ligand and a protein is 
given as  
P+L PL
k1
k2  
Where P = free form of protein and L = free form of ligand, PL = protein-ligand 
complex, k1 is the association rate (on-rate) and k2 is the dissociation rate (off-
rate) for the protein-ligand complex. The association constant Ka for the ligand 
binding is Ka = k1/k2, while the dissociation constant, Kd is given as Kd = 1/Ka = 
k2/k1. Kd value for protein-ligand reaction represents the protein binding sites to 
be half-saturated with the ligand, and is very useful in identifying the binding 
affinity, a nano-molar or low micro-molar value of Kd represents tight binding 
between the ligand and the protein , while a high micromolar or millimolar value 
of Kd represents weak binding {41, 42}. 
1.1.5 Solvent molecules and protein binding site 
In addition to the desolvation effects during binding of ligand to a protein, 
certain solvent molecules are important due to potential protein-solvent-ligand 
interactions. The interactions are mainly based on H-bond donor and acceptor 
functionalities. These water molecules are identified in moderate to high 
resolution X-ray structures but importantly not in NMR structures which 
potentially limits the utility of these structures for ligand binding predictions. 
Bound water molecules perform pivotal roles in the binding site of the protein; it 
has been shown that they are involved in mediating the protein-ligand 
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interactions. The bound water molecules in the binding pocket of the protein 
have crucial importance in the course of generation and optimization of protein 
structure based pharmacophore model. More the position of water molecule 
verified higher would be the contribution of the corresponding pharmacophore 
feature(s). If water molecules are not well defined, computer simulations may 
help in identifying the most important water molecules in the binding site, as 
there are many other factors like geometry of the binding pocket, charge 
distribution, polarity and ligand binding mode which can influence and alter the 
results. The responsibility of dealing with these water molecules largely stays in 
the hands  of a modeler to decide their inclusion or exclusion in the binding site 
{43}. 
1.2 In silico Techniques for functional annotation of 
Novel proteins 
1.2.1 Docking  
The docking methodology involves sampling, scoring and ranking multiple 
conformations and orientations (rotations and translations) of a ligand within the 
binding site of the protein. In the field of molecular modelling, docking is a 
method which predicts the preferred orientation of one molecule to a second 
when bound to each other to form a stable complex {44}.The availability of 
relatively simple to use Docking software such as GOLD {45} Autodock {46} and 
FlexX {47} are a few to name. Structural biologists now attempt to dock known 
ligands or screen libraries of compounds against newly solved structures from 
functional point of view. Knowledge of the preferred orientation in turn may be 
used to predict the strength of association or binding affinity between two 
molecules using for example scoring functions.  
In majority of the docking methods, the search is for the electronic and steric 
complementarity between the potential ligands and the protein binding site 
{48}. Docking is frequently used to predict the binding orientation of small 
molecule drug candidates to their protein targets in order to predict the affinity 
and activity of the small molecule. Hence docking plays an important role in the 
rational design of drugs {49}. Given the biological and pharmaceutical 
significance of molecular docking, considerable efforts have been directed 
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towards improving the methods used, such as speed and validity of scoring 
functions. The docking experiments are widely in use but with only limited 
success. A notable success story is that of the X-ray crystal structure of Tm0936 
and the identification of the potential substrates for this deaminase. In this 
study the X-ray structure of the enzyme had been determined as part of a broad 
structural genomics effort (PDB codes 1p1m and 1j6p), which can be assigned to 
the AHS by fold classification and due to the identity of certain active site 
residues. By sequence similarity, Tm0936 most resembles the large 
chlorohydrolase and cytosine deaminase subgroup, which is often used to 
annotate amidohydrolases of unknown function. 14 cytosine derivatives were 
tested as Tm0936 substrates and no turnover was detected for any of them. In 
an effort to find the true substrate, database of high-energy intermediates were 
docked into the structure of Tm0936. 
 
 Overall, 28 amidohydrolase reactions operating on 19 functional groups were 
modelled by these high-energy structures for each of the 4,207 metabolites that 
bore them, were converted into high-energy intermediate geometries 
(transition-state-like geometries), with their appropriate charge distributions, 
leading to the calculation of about 22,500 different forms of the metabolites. 
Modeling substrates as high energy intermediates, was particularly useful when 
docking to apo structures in these studies .The molecules best-ranked 
computationally were dominated by adenine and adenosine analogues. Four of 
these, including 5-methylthioadenosine and S-adenosylhomocysteine (SAH), were 
tested as substrates, and three had substantial catalytic rate constants. The 
enzyme has no obvious sequence similarity to any known adenosine deaminase 
and the study shows that it exploits interactions not previously identified in the 
active sites of these enzymes {2}. From the results it became clear that adenine 
nucleotide compounds were the best hits (Figure 2.1).  
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Figure  1.6 Top scoring hits from docking against Tm0936 with a large number of adenosine 
analogues, image taken from {2} 
 
The five of the top hits were assayed for biological activity and it was found that 
S-adenosyl-L-homocysteine (SAH) and 5-methyl-thioadenosine were both good 
substrates with Kcat/Km values of 5.8x10
4 M-1s-1 and 1.4x105 M-1s-1 respectively. 
Using SAH the crystal structure of the complex was determined to confirm the 
mode of binding (Figure 2.2) 
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Figure  1.7 Comparison of docking prediction and the crystallographic results. Enzyme 
carbons are colored light blue, SIH is colored red while carbons of intermediate of SAH 
(docked) are colored green for differentiation purposes. The purple sphere represents the 
divalent metal ion, image adapted from {2} 
 
Figure 2.2 shows superposition of the crystal structure of Tm0936 in complex 
with SIH (S- inosyl homocysteine) (red) and the docking predicted structure of 
the high-energy intermediate of S-adenosyl-L-homocysteine (SAH) (carbons in 
green). It was observed that the docking prediction and the actual structure of 
the complex had good agreement. On the basis of docking and enzyme activity 
results, Tm0936 was reported to be an adenosine deaminase {2}. 
In another study, substrate docking was applied for the prediction of function of 
one of the member of enolase superfamily. In this study a homology model of 
the test enzyme was used as a template for docking in place of a crystal 
structure, and the studies identified the enzyme as an N-succinyl arginine/lysine 
racemase {50}. It is suggested that Docking is likely to be useful for the general 
analysis of the newly solved structures as it can speedily identify potential 
ligands and can lead to the structural functional relationship between the new 
structure and those already in the PDB {11}. Recently a group has introduced the 
Bayesian approach by using Gaussian mixtures for the distribution of particular 
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protein atoms around ligand fragments, which showed that it can lessen the 
search for the position and type of protein atoms involved with specific ligand 
fragments, and this technique can lead to the prediction of the type of ligand 
binding site without having structural information about the protein {51}. 
Another group has developed a docking methodology that allows the 
incorporation of pharmacophore type constraints and under these constraints the 
procedure gives solutions, showing that in docking procedure the 
pharmacophore-based filters can be incorporated {52}. In some cases the 
diversified catalytic action of the enzyme in the course of metabolic pathways 
could be understood provided the functional aspects of the newly sequenced 
genes are considered {14}. The hypothesis that only a number of selected 
representatives  from large databases of ligands  are sufficient to obtain 
reasonably accurate information regarding the preferred type of substrates for a 
given enzyme or to put in a general manner the preferred binders for a protein 
receptor is worth testing {11}.  
 
Docking studies face certain challenges like the choice of database which is 
used. For a particular enzyme the database may not be having the right 
substrate in it.  Another problem is if the enzyme undergoes conformational 
changes during catalysis, as a result the conformation of the structure used may 
not be suitable for docking.  This and in many cases the weakness of scoring 
functions to discriminate between a successful hit and a false hit can produce 
misleading results {11}. Docking of 1,000,000s compounds is computer intensive 
and the subsequent scoring and ranking of hits is highly subjective. To reduce 
the number of compounds to be looked at in detail, pre-screening of compounds 
can be performed. Docking has been used extensively for finding out the 
potential ligands (drug candidates) and for detection of the correct orientation 
of a ligand in the protein active site. In comparison to docking pharmacophore 
searching seems to be a better technique as the computational cost is much less 
and the technique is much quicker relative to docking. Despite extensive use, 
both the techniques have potential draw backs which need attention when 
dealing with individual cases. Table 2.1 gives a comparative account of 
limitations associated with docking and pharmacophore searching  {48}. 
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S.No Docking Pharmacophore Searching 
1. Assuming the protein binding 
site to be rigid and the ligand 
flexible, leading to selection 
of compounds without 
visualization of their manual 
interaction 
The static model is based on the single 
conformation of the active site while in reality the 
protein structure is very dynamic and thus some of 
the constraints introduced on the basis of rigid 
model may not be present and thus the hypothesis 
may become wrong about some ligands, leading to 
false positive and non-binders 
2. Without any information 
about true actives or known 
experimental complex 
structures  
In majority cases in the 3D structure of the protein 
the average number of key interactions is typically 
limited to 4-6 in the form of geometric constraints, 
while leaving dozens of other significant 
interactions. 
3. Inability to account for role of 
bound water molecules  
Queries containing large number of exclusion 
spheres, take very long to search the database. 
4. Inability to Incorporate the 
conformational flexibility of 
the ligand and the protein 
target site 
The majority of the information contained in the 
protein structure is not utilized during the database 
search, and the result just in the form of “hit” 
(matching the query) and “no-hit” (not matching 
the query).  
5. Inefficient sampling of 
orientational space 
Any steric or electronic constraints imposed by the 
target but not defined in the query are totally 
ignored 
6. Imprecise and unreliable 
nature of scoring functions 
There is no scoring function 
Table  1.1 Potential drawbacks associated with docking and pharmacophore searching {48}  
 
1.2.2 Pharmacophore 
Pharmacophores or pharmacophore, a word which appears simple in meaning 
and concept, entails a vast amount of knowledge regarding bioactive molecules 
and their structure-activity relationship. The origins of pharmacophore dates 
back to 1900 when the term pharmacophore was first used by Paul Ehrlich {53} 
more than a century a go, describing it as  
“A molecular framework that carries (phoros) the essential features 
responsible for a drug’s (pharmacon) biological activity” 
Later on in 1970 Peter Gund {54} defined the pharmacophore as: 
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“A pharmacophore is an interpretation of a collection of chemical features 
located in the 3D space that accounts for the binding of ligands to a 
common receptor” 
According to the IUPAC recommendations {55}: 
 “A pharmacophore is the ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with a specific 
biological target and to trigger (or block) its biological response” 
It has also been defined as “In the event of binding of ligand to its biological 
target (macromolecule), complementary groups on the protein binding site 
recognize key features of the ligands and the 3 dimensional arrangements of 
these features is commonly referred to as a pharmacophore”. Alternatively 
pharmacophore is described as “specific part(s) of a molecule that confers a 
molecules biological activity”. More loosely, a compound possessing the required 
biological activity, albeit without sufficient potency or freedom from unwanted 
other actions. A lead compound having this activity can be subjected to 
systematic chemical manipulation to increase its potency, and removing the 
unwanted actions {56}. Figure 2.3 represents a typical pharmacophore model 
including different features like H-bond donor, Hydrophobic, positive ionisable 
and ring aromatic. The hit satisfies all the required features of the 
pharmacophore and thus fits in well to the model. 
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Figure  1.8 Pharmacophore model for NMDAR antagonists. (A) The antagonist molecule 
satisfying the Pharmacophore model. (B) The van der Waals volume occupied by the 
antagonist molecule along with the pharmacophore features. The spheres represent the 
tolerances for various features, image taken from {57}. 
 
1.2.3 Pharmacophore Searching 
 Pharmacophore models have been used to explore the features associated with 
protein-ligand interactions for recognition purposes in the binding site of the 
target protein {58}. Multiple pharmacophores have been used previously and 
merged together in order to promptly search the database for the removal of 
unsuitable compounds or to suggest new compounds that can be tested against 
the binding site of the target protein {59}. Pharmacophore searches have been 
overlooked in some ways in the last decade, though some of its features have 
been utilized by the scientific community. However in the pharmaceutical 
industry the application of pharmacophores is widely used in the drug discovery 
process,  which clearly exhibits the power of this technique {60}. 
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 Predominantly the pharmacophore methods can be classified into two major 
categories i.e. 
1. Protein structure based pharmacophore modeling 
 
2. Ligand-based pharmacophore modeling  
 
Protein structure based modeling which is a direct approach, majority of the 
features/constraints are introduced based on information available from the 3D 
structure of the protein binding site and has been widely used as an alternative 
tool or complimentary to high-throughput screening (HTS). It is considered a 
method to produce a small more focused library of compounds for screening 
(hundreds of compounds) rather than the 10’s of thousands to millions of 
compounds that are often screened in a blind HTS.  Protein structure based 
modeling provides added advantage of detail analysis of the binding pocket of 
the target protein. In majority cases the residues in the binding site dictate the 
shape and chemical features of the prospective ligands to fit in {38}. In case of 
indirect ligand-based models (Figure 2.4) the pharmacophores are designed as 
per chemical features of known active compounds, in which chances to judge 
and predict both the water-mediated interactions and displacement of bound 
water molecules in the binding site of the protein is very limited {43}. 
 
Figure  1.9 Ligand-based pharmacophore modeling: novel inhibitors of the Ca2+/calmodulin-
dependent protein kinase II inhibitors with alternative mappings against the 
pharmacophoric features, along with their chemical structures, image adapted from {61} 
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The general problem of finding compounds/ligands which can successfully bind 
to a receptor is a challenging one. More often it is believed that if the 3D 
structure of a given protein is known, then the route to find suitable ligands is 
comparatively easy. From the 3D structures of ligand bound or unbound proteins, 
it becomes possible to pinpoint the key residues of the protein involved in ligand 
interactions. Using this knowledge a pharmacophore can be generated to screen 
for compounds which share the common features of the pharmacophore. In brief 
the availability of the 3D structure of a protein active site offers significant 
information which is crucial in the development of pharmacophore models. 
However in practice, to find a ligand which can satisfy all the requirements in 
relation to the complex features in the active site of the protein is quite 
complicated as it is not only a matter of structural and computational biology 
but also of chemistry {48}. In pharmacophore searching it has been shown that 
the essential features contributing towards ligand binding are both from the 
protein and ligand.  In relation to the pharmacophore modeling the use of 
multiple excluded volumes is extensively used {62, 63} to supplement the 
stringency conditions on the model and to selectively describe the shape of the 
binding pocket. The purpose of introducing exclusion spheres is to avoid steric 
clashes, and the penetration of ligand structures into the space occupied by the 
amino acid residues in the binding site. It has been found that the inclusion of 
exclusion spheres in the pharmacophore models improves the pruning of 
databases so that large multi-conformational databases can be searched in 1-2 
hours.  
In order to be recognized as a useful tool, pharmacophore model has to provide 
certain information regarding protein ligand interaction. For instance the 
functional groups directly involved in the interaction, non-covalent bonding and 
inter charge distances. Different analogies have been used to describe the 
concept of pharmacophore and its role, an interesting one is Fisher’s Lock and 
Key model. When dealing with the change in conformation of glucoside on its 
contact with the enzyme, the enzyme and glucoside must fit together like the 
key in the lock, so that to have a chemical effect on each other. Though it 
represents the target protein to be a rigid structure but is still in use nowadays. 
Another representation is of “hand in a glove” which appears more precise as it 
takes into account the steric complementarity, chirality and flexibility of both 
protein and ligand {64}. 
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To make a “pharmacophore” the method relies on the identification of a limited 
number of hydrogen bond donors, hydrogen bond acceptors ionisable features 
and hydrophobic groups with in the active site. These are the essential 
interactions that a compound should make with the protein. If the “essential 
interaction” are not known then normally a series of pharmacophore are 
constructed and screened {65}. A well-defined pharmacophore model includes 
both hydrophobic volumes and hydrogen bond donor and acceptor vectors and a 
shape constraint or excluded volume (which corresponds to the extent of the 
active site cavity) {66}. By varying the tolerances on each of these interactions 
the number of potential compounds can be reduced rapidly from several 
hundred thousand to about 20-100 compounds. The strength of pharmacophore 
searching is its speed and an ability to interrogate an active site in a systematic 
way. It is possible to include or exclude ordered water molecules which may or 
may not be important for ligand binding. The method uses the Accelrys 
packages, Cerius2 and Catalyst for performing the search. These are the industry 
standard programs and no other software, free to academic institutions, are 
available which can permit this kind of search. The aim is not to optimize the 
use of this set of programs but is rather to use them to validate the application 
of this method for structure-function prediction. 
 
1.2.4 Pharmacophore generating programs 
Both protein structure based and ligand based pharmacophores have been 
created by using several computational programs, such as DS viewer pro which 
allows the manual generation of pharmacophore {67}, and LigandScout {65} an 
automated program for creating pharmacophore models from 3D complexes. a 
significant aspect of LigandScout program is that it considers the water 
molecules in the protein structure  as an integral part of the protein milieu and 
automatically identifies the protein-ligand interactions mediated through water 
molecules in the binding site {43}. One of the widely used programs is Catalyst® 
{68}, within the catalyst program the hydrogen bond donor vector is defined as 
vector from the donor atom of the ligand towards the corresponding acceptor 
atom of the binding site of the protein, and vice versa the H-bond acceptor 
vectors are defined.  
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In another method called Structure based focusing (SBF), Cerius2 {69} 
application has been used for protein structure based pharmacophore to identify 
ligands which can bind to the active site. In SBF method the interaction map of 
the active site of the protein is generated by using Ludi {70} mainly consisting of 
H-bond donor, H-bond acceptor and lipophilic features. This results in the 
creation of a 3D Catalyst query, which is then used to screen the catalyst 
database to obtain ligand hits that are probable to bind the active site {48}. The 
method shows that increase in the number of constraints in terms of query 
features decreases the number of hits. The number of hits decreased to almost 
half when a 6-query feature pharmacophore was used instead of a 4-query 
feature pharmacophore. This demonstrates that the increase in number of query 
features increases the selectivity of the query. It has been shown that the 
receptor-based pharmacophore appear less biased towards the dataset of 
compounds. It has been concluded that ligand binding to a receptor is a complex 
process, where both the ligand and the receptor have to accommodate each 
other to execute binding {71, 72}. The computational pharmacophore approach 
is challenging for the researcher as it requires preparedness towards the 
chemistry, biophysical chemistry, computational methods as well as 
computational models for analyzing various proteins {73}. 
 
1.2.5 Visualization of Hits 
3D pharmacophore models have a huge potential to be used as a visualization 
tool. The 3D representation of the pharmacophore features mapped on a 
protein-ligand complex facilitates the user to intuitively explore  the 
interactions patterns and further to make sensible adjustments {74}. By and 
large the most direct way by which a pharmacophore model can get validated is 
when exhibiting over all complementarity and consistency with the interaction 
pattern specified in the target protein. The use of eye in many cases is the 
primary and most reasonable judgment to evaluate the pharmacophore 
hypothesis. First approval is from the expert to rule in or rule out unreasonable 
solutions prior to final decisions. Visual examination of the pharmacophore 
models and the hits obtained from these models is of utmost importance. It 
remains the best approach to fulfill the loop holes often left unaccounted in  the 
computational programs {75}. 
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1.2.6   Hits Screening 
During the course of generation and optimization of pharmacophore models, 
through virtual screening the  database search gives compounds in the form of 
hits which satisfy all the constraints of the pharmacophore. These compounds 
will have a very small proportion of biologically active (confirmed through wet 
lab) and are termed as true positives (TP). A larger portion among the hits 
includes those compounds which show conformity with respect to the 
pharmacophore model but are biologically inactive (confirmed experimentally), 
these are termed as false positives (FP). Those compounds which are not 
selected as hits from the database and are biologically inactive are called true 
negatives (TN). Their would be certain compounds which are not selected as hits 
because of non-conformity to the pharmacophore model but are able to cause 
biological response and are known as false negatives (FN) {60}. 
1.2.7 Future of Pharmacophore Searching 
With the added advantages of computational cost much less than docking and 
provision of better understanding of the interaction between protein and ligand 
the prospects of this approach are very bright. Currently there are few if any 
freely available pharmacophore technologies. This is not helpful at all for the 
academic groups. The availability of pharmacophore generation models as an 
open source technology for sharing and application purposes can hugely increase 
its development. This will certainly expand the range of pharmacophore 
applications {76}. 
Experimental approaches to investigate protein ligand interactions 
Various techniques are in use nowadays to detect protein ligand binding events. 
X-ray crystallography emerges as the most preferred technique in revealing the 
intricacies of protein-ligand binding. NMR with the specificity to even measure 
the extent of binding and is thus useful to demonstrate sensible information in 
cases when the ligand binds very weakly to the target protein. Some techniques 
are aimed for measuring the thermodynamic parameters during binding e.g; 
differential scanning calorimetry (DSC) and isothermal titration calorimetry 
(ITC). If the protein is not an enzyme then tight ligand binding can be detected 
directly by using isothermal titration calorimetry (ITC). Some techniques help to 
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identify the ligands as binders or non-binders against the target protein e.g. 
surface Plasmon resonance and chemical micro arrays. Brief account is given 
below about some of the approaches which are frequently used to investigate 
protein ligand binding events. 
1.3 Biophysical techniques for binding studies 
1.3.1 X-ray Crystallography 
The leading work by Perutz and Kendrew in the 1950s on the structure of 
Haemoglobin and Myoglobin led to a slow and steady start for using X-ray 
diffraction as a useful technique for protein structure determination. In the last 
decade protein X-ray crystallography has made rapid progress. It was to more 
extent triggered by the sudden growth of interest in structural genomics and 
impressive technological advances further facilitated its development. Now a 
days it is no longer a tough task to collect the full data set in few minutes and 
thus solve the structure in hour’s time. However the bottleneck remains there 
which is to grow quality crystals and then get them diffracted at a reasonably 
high resolution {77}. X-ray crystallography has been successfully utilized for 
postulating the mechanism of action of enzymatic proteins on their substrates. 
In one of the case studies, the X-ray crystal structure of Mycobacterium 
tuberculosis shikimate kinase (SK) with bound shikimate and adenosine 
diphosphate (ADP) was determined to a resolution of 2.15Å. The X-ray structure 
showed that the binding of shikimate in a shikimate kinase occurs in a specific 
pocket lined with hydrophobic residues and interacts with several highly 
conserved charged residues. The comparison with an earlier binary SK–ADP 
complex showed that conformational changes occur on shikimate binding within 
the substrate-binding domain. The detail knowledge of shikimate binding proves 
to be an important step in designing inhibitors for SK. The potential inhibitors 
can be used as novel anti-tuberculosis agents {78}. On numerous occasions X-ray 
crystallography has proved to be a vital technique by providing valuable 
information in understanding the catalytic mechanism of different enzyme {79-
81}. Various other ligand binding {82-88} and enzyme inhibition {89-94} studies 
have been carried out by using X-ray crystallography with an aim to reveal the 
events taking place at atomic level.  3D structure allows the understanding of 
biological processes at the most basic level e.g. which molecules interact?, how 
they interact?, how enzymes catalyze reactions?, and how drugs act? In some 
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cases, it can help to understand disease at an atomic level, such as the sickling 
of red blood cells.   Protein crystallography can be divided in to 3 main steps 
(Figure 3.1) 
1. Protein crystallization 
2. X-ray data collection 
3. Structure solution 
 
Figure  1.10 Schematic diagram for protein crystallization, starting from getting crystals to 
diffraction images and finally to structure 
 
1.3.1.1 Protein crystallization 
X-ray scattering from a single molecule would include scattering from air and 
water and would be incredibly weak and extremely difficult to detect above the 
noise level. A crystal arranges huge numbers of molecules in the same 
orientation, so that scattered waves can add up in phase and raise the signal to 
a measurable level, thus a crystal acting as an amplifier (Figure 3.2).  
 
Figure  1.11 Comparison of a molecule, unit cell and crystal of a protein with respect to 
scattering 
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If a similar protein has already been crystallized then it is definitely worth trying 
the same conditions to grow crystals of the target protein. In any case if enough 
protein is available it can be subjected to one or more sparse matrix screens. 
The methods used normally for obtaining crystals are sitting drop and hanging 
drop vapor diffusion methods which have the advantage of being the least 
expensive on protein. In the former method the protein solution is mixed with 
the precipitant solutions and the protein is slowly brought to super saturation 
state thereby allowing crystals to form and grow. If the conditions are favorable, 
at some point during this process the protein becomes supersaturated and is 
driven out of solution in the form of crystals. Too often these trials result in 
precipitate or the formation of salt crystals, or nothing happens at all and the 
drops remain clear. The success rate at this stage is less than 0.1%. If one or 
more "hits" are obtained in the screens, then the conditions are further 
optimized e.g. varying the concentrations of all components in the 
crystallization, slight pH changes, using additives, switching to similar buffers or 
precipitants in order to achieve large  single crystals.  Typically it takes few days 
to several weeks to grow good crystals. 
1.3.1.2 X-ray data collection 
In order to get information about the crystal symmetry, the unit cell 
parameters, the crystal orientation and the resolution limit. The individual 
crystal is exposed to an x-ray beam and flash frozen with liquid nitrogen to avoid 
damage to the crystal. The x-rays are then focused on the crystal and the crystal 
is rotated through a small angle, typically 1 degree and the X-ray diffraction 
pattern is recorded.  
When x-rays are scattered from a crystal lattice, peaks of scattered intensity are 
observed which correspond to the Bragg’s law:  
 nλ= 2dsinθ 
where, 
λ = the wavelength of the x-ray 
d = the spacing of the crystal layers (path difference) 
θ = the incident angle (the angle between incident ray and the scatter plane) 
n = an integer 
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The law states that when the x-ray is incident onto a crystal surface, its angle of 
incidence (θ) will reflect back with a same angle of scattering (θ) when the path 
difference (d) is equal to an integer (n) of wavelength (λ), a constructive 
interference will occur. The condition for maximum intensity contained in 
Bragg's law above allows to calculate details about the crystal structure, or if 
the crystal structure is known, to determine the wavelength of the x-rays 
incident upon the crystal. 
If the diffraction pattern is very crowded, then the rotation angle is reduced so 
that each spot can be resolved on the image. This is repeated until the crystal 
has moved through at least 30 degrees and sometimes as much as 180 degrees 
depending on the crystal symmetry.  
1.3.1.3  Structure solution 
1.3.1.3.1 Fourier theory 
The diffraction pattern is related to the diffracting waves through a 
mathematical operation called the Fourier transform. The electron density is 
used as a mathematical function, and the diffraction pattern is the Fourier 
transform of that function.  To produce electron density it is necessary to have 
all the Fourier terms i.e. in the case of single crystal x-ray diffraction this is the 
full set of indexed reflections Fhkl for the x-ray dataset. However F is a complex 
number with both a real and imaginary component. The real part |F|hkl can be 
obtained from the integrated intensities from the diffraction spots. The 
imaginary component, the relative phase angle is lost. This Phase Problem arises 
as there is no practical way of measuring the relative phase angles for the 
different diffracted spots experimentally. The numbers of photons give the 
intensity, which turns out to be proportional to the square of the amplitude 
(peak height) of the diffracted wave. The relative phase angle for each 
reflection cannot be measured directly but can be deduced indirectly. There are 
basically two approaches:  
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1.3.1.3.2 Isomorphous replacement and related methods 
 
If there is no starting model, then Isomorphism Replacement method can be 
used. In this method one or more heavy atoms are introduced into specific sites 
within the unit cell without perturbing the crystal lattice. Heavy atoms are 
electron dense and give rise to measurable differences in the intensities of the 
spots in the diffraction pattern. By measuring these differences for each 
reflection, phase angles are derived by using vector summation methods. In 
practice data from one or more heavy atom derivatives is required to get good 
enough phases, hence Multiple Isomorphous Replacement (MIR). This method has 
been extended that heavy atoms can be introduced directly into the protein in 
the form of selenomethionine. The use of tunable wavelength X-ray sources 
mean that data can be collected at multiple X-ray wavelengths on the same 
crystal and the differences can be used to solve the structure.  
1.3.1.3.3 Molecular replacement method 
 
If the coordinates of a similar protein are available then the structure can be 
solved by using a process called Molecular Replacement. The method involves 
rotating and translating the available model into the new crystal system until a 
good match to experimental data is obtained. The amplitude and phases from 
this solution can be calculated to see the agreement with the experimental 
data. If the solution is good enough then the model phases can be combined with 
experimental data to produce an electron density map.  
1.3.1.4 Resolution 
In an ideal case, if the molecules throughout the crystal are in identical 
conformations and the crystal are perfectly ordered, then all the molecules 
would scatter in phase regardless of the angle of scattering and diffraction data 
would be collected limited only by the wavelength of the X-rays. This would 
result in electron density map with peaks at each of the atomic positions. But in 
reality Proteins are generally fairly flexible, and crystals have lattice disorder 
i.e. the repeating units are not necessarily perfectly aligned throughout the 
crystal. This is why when trying to see the finer details of the structure by going 
to higher scattering angles; the diffraction pattern starts to cancel out. For this 
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reason, most protein structures are limited to a level of detail where atoms are 
not resolved from one another. Thus typically tubes of electron density are seen 
for atoms that are bonded together.  
1.3.1.5 Fitting and refinement 
Early in a structure determination, the phase information is usually poor, so the 
electron density maps are not ideal and does not resolve individual atoms. As a 
result, the initial model has a lot of errors. The normal procedure is to fit a 
protein backbone first then if the resolution permits, insert the sequence. 
Fitting models to density requires the use of computer graphics programs such as 
Coot {95}. An atomic model can be improved to a great deal by a process called 
refinement, in which the atomic model is adjusted to improve the agreement 
with the measured diffraction data.  This will have the effect of improving the 
phases which results in clearer maps and therefore better models. The 
improvement of an atomic model is judged through R-factor, this is a measure of 
the agreement between the model and the data – the lower the value the better 
the model. R-factor is simply the average fractional error in the calculated 
amplitude compared to the observed amplitude. A good structure will have an R-
factor in the range of 15% to 25%.  
1.3.1.6 Validation 
In order to get the observation-to-parameter ratio for protein structures, for 
each atom there are 3 or 4 parameters (3 describing its position, possibly one 
indicating how mobile it is). At a typical resolution, there will only be about one 
observation for each parameter.  The diffraction data is supplemented with 
restraints on geometry, which keep the bond lengths, angles and close contacts 
in a reasonable range.  A valuable way to detect this is to leave out a fraction of 
the data from use in refinement, which can be used to compute an R-free, which 
is an unbiased indication of the quality of the structure. The main-chain torsion 
angles are hard to restrain in refinement but the distribution of these angles in 
the Ramachandran plot is very restricted. It is a way to visualize backbone 
dihedral angles ψ against φ of amino acid residues in protein structure. 
Ramachandran plot shows in theory which values, or conformations, of the ψ and 
φ angles are possible for an amino-acid residue in a protein. It also shows the 
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empirical distribution of data points observed in a single structure in usage for 
structure validation. The Ramachandran plot is thus a good indicator of the 
quality of a structure. Other indicators used are, the distribution of hydrophobic 
and hydrophilic amino acids. 
By and large X-ray crystallography is the most influential practical method for 
the in-depth analysis of protein-ligand interactions and also helps in 
understanding the binding mechanism from the high resolution X-ray structure. 
The idea of co-crystallizations of proteins with different ligands in order to 
experimentally determine the preferred locations of binding and binding mode is 
frequently used and has been successful in designing strong inhibitors for certain 
enzymes. In cases of enzymatic proteins, with the availability of high resolution 
structures (1.5Å-2.0Å) the electron density map of the target protein helps 
directly to identify the amino acid residues involved in binding event and also 
helps in understanding the mechanism of action. Crystal soaking experiments are 
also carried out in X-ray crystallography with the aim to find binders and their 
particular binding modes in the active site of the protein {96}. 
1.3.2 Nuclear magnetic resonance (NMR) 
NMR has recently emerged as an outstanding technique to demonstrate the 
dynamics of protein-ligand binding in terms of weak or strong binding. It is based 
on the magnetic properties of atomic nuclei and has now acquired huge 
importance in analyzing the structural dynamics of proteins {97}. Using this 
method, Fischer and Jardetzky {98} detected and characterized the binding of 
penicillin to the serum albumin. In NMR , protein-ligand investigations rely 
mainly on two aspects of binding event; one is the creation of protein–ligand 
complex, and the other is chemical shift perturbations caused due to protein 
resonances {99}. NMR spectroscopy plays a very significant role among other 
biophysical techniques used for the analysis of protein-ligand binding events. 
Various analyzing approaches either from the ligand or protein perspective have 
been used in this regard, which commonly share the capability to measure weak 
binding for specific binders {100}. Normally NMR measurements for such 
purposes are carried out by using 15N-labelled protein. Changes in chemical shifts 
as a result of addition of ligand to the protein, relative to the protein spectra 
alone demonstrate the binding event. If the chemical shifts assignment has 
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already been carried out then both the location of the binding site and the 
ligand affinity can be determined {101}.  
1.3.2.1 NMR brief overview 
Atomic nuclei with an odd number of nucleons (protons or neutrons) can have a 
magnetic dipole moment (µB) associated with their nuclear spin. In a magnetic 
field (B) they act as tiny bar magnets and tend to line up in the direction of the 
field. Nuclei of particular importance are 1H, 13C, 15N and 31P.  According to 
quantum mechanics these all nuclei are with a ½ spin and can exist in either 
parallel (low energy, E= —µBB) or anti-parallel (high energy, E= +µBB) state in a 
magnetic field. The energy separation between these two states is: 
 
∆E = 2 µBB 
 
Where B is the strength of magnetic field experienced by the nucleus, and µB is 
the component of the nuclear magnetic moment along the field axis. 
Majority of the nuclei are in lower energy state, but in the presence of applied 
magnetic field at a certain frequency, the nucleus after absorbing energy from 
the applied field may switch between the two states (Figure 3.3.) 
 
 
Figure  1.12  Possible spin states of a nucleus in a magnetic field (B) 
 
In NMR spectroscopy, samples are placed in a strong magnetic field and the 
resonant frequencies for the nuclei are determined by using an applied radio 
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frequency (RF) usually in 100MHz to GHz range. The observed resonant 
frequency (v) for a particular atomic nucleus is then recorded, which depends on 
two factors; the nature of the nucleus (µB) and the magnetic field (B). 
 
 
 
 
Figure  1.13  Schematic diagram for a typical NMR spectrometer. 
 
 
 
B is made up not just of the external applied field from the magnet (B0) but 
additional contributions from other nuclei and chemical groups. This is because 
nearby atoms and groups (acting as small magnets) will screen or shift the local 
magnetic field experienced by the nucleus. Consequently, NMR resonant 
frequencies are extremely sensitive to the chemical environment of the 
particular atomic nucleus, and this can be used to give accurate structural 
information. The chemical shift and spin-spin coupling are ways of describing 
these additional contributions. 
In a modern NMR spectrometer, the Fourier transform approach is used in which  
the applied magnetic field is kept constant and the magnetic nuclei in the 
sample are perturbed by applying a short (1-20 µs) broad-frequency microwave 
pulse that excites a range of different nuclei at once. The perturbed nuclear 
spins relax back to the equilibrium position which is called free induction decay 
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(FID), which is followed by using field coils or porbes placed close to the sample 
in the NMR spectrometer {97}. 
1.3.2.2 NMR: Two-Dimensional Spectra 
When two atoms are connected by a covalent bond, energy (or more specifically 
magnetization) transfers between the two nuclei via the bonded electrons. To 
characterize molecular structures and dynamics by NMR, the first step is to 
determine the ringing frequency (or chemical shift) for each atom in the protein. 
This is termed as chemical shift assignments. For chemical shift assignments of 
proteins, NMR spectroscopists almost invariably start with the backbone amide 
protons (1HN)—the hydrogens attached to the nitrogens in the peptide bond. In 
general, each residue of protein (with the exception of the N-terminal residue 
and prolines) has one amide proton, so there is approximately one peak for each 
residue of the protein.  In NMR, we add extra dimensions by transferring 
magnetization between coupled atoms, such as J-coupled nuclei. This is called 
“two dimensional” NMR, and it involves four basic steps (Figure 3.5) 
 
Figure  1.14 Four main steps in 1H–15N HSQC experiment to connect the chemical shift of an 
amide hydrogen to the chemical shift of covalently attached nitrogen, image adapted from 
{102} 
 
The result is a two-dimensional map of the NMR spectrum. The ringing 
frequencies (or chemical shifts) of the amide hydrogens are along the x-axis and 
the ringing frequencies for the attached nitrogens are along the y-axis. In this 
spectrum, there is a peak for each 1HN atom bonded to a 15N atom, or each “1HN–
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15N pair.” The location of the peak is at the point x = hydrogen chemical shift, y 
= nitrogen chemical shift. The cross-peak for an amino acid residue can be found 
on the two-dimensional NMR map if the chemical shifts (or ringing frequencies) 
for its amide hydrogen and nitrogen are known. By drawing horizontal and 
vertical lines from the respective chemical shift values, the residue is where the 
two lines intersect. The most important spectrum in biomolecular NMR is the 
HSQC spectra. 
1.3.2.3 HSQC spectra 
 The 1H–15N HSQC spectrum shows which protons and nitrogen atoms are 
connected by a single covalent bond. The spectrum in Figure 3.6 A is called a 1H–
15N Heteronuclear Single-Quantum Coherence correlation spectrum, or HSQC 
Here are the five most important attributes of the 1H–15N HSQC spectrum 
(a) The Axes: The x-axis gives the ringing frequency or chemical shift of 
each protons attached to a nitrogen atom. The y-axis gives the ringing 
frequency of each nitrogen atom attached to a proton. 
(b) The Cross-peaks: A cross-peak appears in the center of the spectrum 
wherever a hydrogen is bonded to the nitrogen. 
(c) Total Number of Peaks: The total number of peaks is approximately 
equal to the total number of residues in the protein. If the spectrum has 
more peaks than this, the protein is probably adopting multiple 
conformations or forming heterogeneous oligomers (i.e., heterodimer, 
heterotrimer, etc.). If the spectrum has fewer peaks than predicted, 
regions of the protein are probably dynamic, exist in multiple 
confirmations, or partially unfolded. 
(d) Peak Intensity and Shape: For “well-behaved” proteins, all peaks 
should have approximately the same line width and therefore peak 
height, like the spectrum in Figure 3.6 A. If a significant number of peaks 
are weak and broad (or completely missing), regions of the protein are 
probably dynamic and/or exist in multiple conformations. 
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(e) The Peak Pattern: Peaks should be relatively well separated with 
minimal overlap (Figure 3.6 A). This is a good sign that the protein is well 
folded and not aggregating. If peaks are sharp but largely grouped 
together between x = 7.5 and 8.5 ppm the protein is probably unfolded in 
a random coil-like configuration (Figure 3.6 B). If the peaks coalescence 
into one big blob near the center of the spectrum, the protein is probably 
aggregating or forming high-order oligomers (Figure 3.6 C). 
Figure  1.15 Representation of 1H– 15N HSQC spectra for (A) a protein properly folded into 
one configuration, (B) a completely unfolded protein, and (C) an aggregated protein in 
multiple configurations, adapted from {102}   
The 1H–15N HSQC provides substantial information about the state of the protein 
even before assigning the chemical shifts to specific atoms.  
1.3.2.4 Chemical Environment and chemical shift  
NMR has great utility in studying macromolecules and the undergoing 
interactions.  Each atom in the protein resonates at a different frequency. This 
is due to the fact that each nucleus in a molecule is surrounded by electrons and 
on top of that each atom exists in slightly different chemical environment 
relative to each other. This is the reason that if there is some binding event 
taking place inside the protein, the result is seen in the form of change in 
chemical shift values for those particular atoms whose chemical environment has 
changed due to the interaction {102}. 
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1.3.2.5 NMR sampling 
A typical protein NMR comprises of the following steps 
1) Sample preparation, sample concentration in the range of 0.2—
2.0mM (several mg/mL) is usually required and samples need to be 
enriched in isotopic forms of nuclei (13C, 15N) 
2) Data acquisition and processing; the NMR data is collected by using 
high resolution (500MHz or more) spectrometers 
3) Sequence-specific assignment: each peak in NMR spectrum 
corresponds to a particular atom (H, C, N etc) in the structure. 
These peaks are assigned to specific backbone or side chain 
residues in the sequence by using the chemical shift data and 
correlation methods e.g; correlation spectroscopy (COSY), total 
correlation spectroscopy (TOCSY), Heteronuclear single quantum 
coherence (HSQC) etc. 
4) Finally structure calculation, model building and refinement 
If the interest is only in the biophysical properties of the protein then only the 
chemical shift values for the backbone atoms of a protein need to be 
determined, while for NMR image of the entire protein, every atom in the 
protein needs to be assigned. 
NMR spectroscopy has been used in numerous studies to assess the 
conformational dynamics and thermodynamics of protein–ligand binding {103}. In 
quest of the biological role of HI0719, over 100 naturally occurring small 
molecules or structural analogues were tested for ligand and some of the 
compounds were found to bind to the putative active site, which have previously 
been proposed to be involved in isoleucine biosynthetic pathway. 15N-HSQC 
spectra were recorded during the ligand screening by mixing test compounds 
with 15N-labelled HI0719 and comparing these spectra with the spectrum 
obtained from protein alone with the same buffer conditions. The extent of 
binding (in terms of Kd value) of particular ligand was determined by monitoring 
the change in chemical shifts of HSQC cross-peaks as a function of the ligand 
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concentration {104}. In another study NMR has been used to study the functional 
analysis of ligand-protein interactions, where ERβ and its trans activation 
domain (TAD) and ligand binding domain (LBD) were examined for 
conformational changes in the absence and presence of 17β-estradiol. The 1H-
NMR spectra showed that the LBD conformation was altered in the presence of 
17 β –estradiol, which in turn may help to develop therapeutic drugs to control 
the estradiol-mediated gene expression in hormone dependent diseases {105}. 
1.3.3 High throughput screening (HTS)  
In majority of the pharmaceutical and biotechnology companies, HTS is serving a 
fundamental role in drug-discovery process, in brief the HTS process is the 
journey from target choice eventually resulting in Lead discovery. HTS is a multi-
disciplinary approach and requires strict adherence with respect to a number of 
factors. Certain steps and their organization in the course of HTS have vital 
importance in examining screening hits. To search for patterns which define lead 
series and to make the process successful the steps include biochemical assay 
methods, screening laboratories, screening robotics and for all these processes 
the technology specialists (chemist, biochemist, biologist, IT personnel) who are 
capable of maintaining, distributing, collecting and analyzing large datasets.  
 
Figure  1.16 Main steps involved in the HTS process from target choice to lead  
identification, image modified from {106} 
Through the combine efforts of all above mentioned and with the blend of 
various specialities, therapeutic targets can be passed through the lead 
discovery engine called HTS which can give rise to lead compounds (Figure 3.7). 
HTS is considered to be the heart of the drug discovery process. For the critical 
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design and implementation of HTS approach in a well organized manner it 
involves researchers from multiple disciplines of science. With the strict 
consideration of undergoing multi tasks, HTS starts with the choice of assay 
target and finally ends with the discovery of lead compounds. The outcome of 
results in the form of success and failure depends to a major extent on the 
decisions made during the whole process. In many instances the decisions have 
to been pragmatic and able to withstand the opposing forces {106}. 
1.3.3.1 Enzyme Kinetics 
With the help of industry and academia the development and optimization of 
fluorescent and/or absorbance based enzyme assays have performed a 
significant role in the screening process of hits. In HTS process in order to find 
initial actives, majority of the enzymes have been used as a drug target in the 
pharmaceutical industry. Generalized approaches are used for developing, 
validating, and troubleshooting assays which are applicable in both industrial 
and academic settings. Various enzyme classes including kinases, proteases, 
transferases, and phosphatases have been used to illustrate assay development 
approaches and solutions, which further lead to the identification of activators 
{107}. In various other examples the enzyme assays have been carried out in 
order to find suitable inhibitors, in the nano molar and pico molar range {108-
111}. Apart from HTS, one of the main characteristics of enzymes is their 
absolute and relative specificity, in the former case the enzyme can only act on 
one substrate, while in the latter case the enzyme catalyzes some structurally 
related substrates and demonstrates relative specificity over other substrates. 
substrate specificity of the enzyme is crucial in  enzyme assays and has major 
importance in identifying the capability of converting multi-substrates. Classic 
examples are of aldose reductase and amido hydrolases superfamily {14, 112}. In 
cases of specific enzymatic proteins pharmacophore searching process can be 
helpful in identifying sensible hits from the corresponding database. In order to 
test whether a hit is a potential substrate or not the hits could be routed to 
established enzyme assay. 
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1.3.4 Isothermal titration calorimetry (ITC) 
ITC is the well characterized and widely accepted technique among the 
scientific community. It is used for the measuring of thermodynamic parameters 
like enthalpy, entropy and association constants. ITC is used to measure the heat 
change as a result of incremental addition of ligand to the target protein at a 
constant temperature. Any binding interactions between the ligand and target 
protein results in a temperature change. In ITC there is sequential addition of 
ligand to the protein at constant pressure. The energy change associated with 
the addition of ligand is the change in enthalpy. The added advantage of ITC 
over other techniques is that it measures the change in enthalpy directly {42}. 
The instrument consists of 2 cells. One is a reference cell, which has only buffer 
in it and the other is the sample cell containing a known concentration of target 
protein in a buffer solution. The temperature difference  between these two 
cells is monitored and kept constant by the feedback heaters. Any change in 
temperature activates the feedback heaters to apply either increase or decrease 
in energy to the sample cell to match the reference cell. This ensures that the 
temperature difference between two cells is at minimum. The energy required 
to keep the two cells constant is called the baseline energy. Pre-selected 
volumes of the ligand are injected in both the cells. If the binding event is 
endothermic, the sample cell becomes cooler than the reference cell and energy 
is added by the feedback heater until the temperature becomes same as of 
reference cell and vice versa in exothermic binding event. The energy 
increase/decrease required to correct any imbalance is measured and recorded 
for numerous additions of known volumes of ligand until all the binding sites are 
occupied. Each of these deviations from the baseline are plotted as energy 
versus time resulting in a peak for each injection. The area of these peaks 
indicates the energy change from the baseline at each injection. This can be 
calculated by integration of the graph to give the heat evolved or absorbed 
during the binding event with respect to time. In order to get true binding 
energies same additions of ligand are carried out in the reference cell. The heat 
of dilution is calculated and subtracted. Finally a binding curve is produced 
through which various thermodynamic binding parameters, like binding constants 
(KA), reaction stoichiometry (n), enthalpy (∆H) and entropy (∆S) can be 
extracted {97}. In this work ITC served as a highly sensitive technique, 
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specifically for the determination of strong binding events. Various studies have 
been carried out by using ITC as a biophysical tool, in some analysis the toxicity 
of certain compounds over specific proteins is investigated {113}, while in some 
cases the protonation changes in trypsin and thrombin upon ligand binding {114}. 
Recently in a novel ITC method the changes in thermodynamic parameters were 
studied during the folding of  RNA coupled with magnesium uptake {115}.  
1.3.5 Differential scanning calorimetry (DSC) 
DSC is also used for the analysis of thermodynamic changes during the binding 
event of protein with the ligand. It measures the heat capacity for protein-
ligand binding by incrementally changing the temperature of the system over a 
specified range. DSC measures the difference in heat energy uptake between a 
sample solution and appropriate reference solution (buffer) with increase in 
temperature. A typical experiment comprises one (or more) scans of the sample 
solution, together with control experiments using buffer alone to establish the 
instrument baseline.  For quantitative analysis accurate sample concentrations 
are required, and parameters such as concentration, scan rate, pH, etc., may be 
changed. In DSC experiments the Tm, which appears as a transition peak on the 
DSC scan can be measured and is defined as the temperature at which one half 
of the protein is unfolded and the other half is folded. This  can be related to 
the ligand-binding event as  the ligand bound protein in solution will either be 
more or less  thermally stable causing a change in the Tm. Typically  the 
resultant increase in Tm demonstrates that the protein structure in the presence 
of ligand favors its folding and thus the stability of the protein {116}. 
DSC has been an excellent tool in providing valuable information with respect to 
ligand binding events. It has been used to study the enthalpy changes coupled 
with the thermal unfolding and refolding of human serum retinol binding protein 
(sRBP), where it witnesses the formation of stable intermediates during the 
unfolding process {117}. DSC has also been used in clarifying metal-protein 
binding modalities {118} and for investigatimg the intrinsic protein structural 
energetics dued to ligand-binding interactions {119}. 
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1.3.6 Circular Dichroism (CD) spectroscopy 
Circular dichroism (CD) is a biophysical technique for studying protein structure 
in solution. CD spectroscopy is based on the principle to measure the difference 
in absorbance of right and left-handed circularly polarized light by chiral 
chromophores (typically aromatic amino acids) and to obtain structural 
information from the spectral features produced. The composition of secondary 
structure, such as α-helices, β-sheets and turns can be estimated from the 
differential peptide bond absorbance. Various conformations give rise to 
characteristic CD spectra in the far UV region. The CD absorbance from aromatic 
residues in the near UV region provides information about the environment of 
these residues. Analysis of near UV CD spectra alone is not sufficient in provision 
of significant insight into tertiary structure but it does provide a distinctive 
fingerprint of the tertiary structure which can be further utilized to monitor 
structural changes {120}. CD spectroscopy is a versatile technique as it is helpful 
in providing structural information from different view points. It has been used 
to study the G-quadruplex folding patterns in STAT-3 which is the likely target 
for cancer therapy {121}. CD has been used to probe the effect of certain 
surfactants on structure and conformational stability of novel proteins coupled 
with pH changes {122}. To study the sequence effects on the over all structure 
of the protein as a result of mutagenesis {123} CD has provided reasonable 
insights. Although CD provides low resolution structural data compared with 
techniques such as X-ray crystallography and NMR, but its benefits such as time, 
sample concentration and cost favors it as a rapid screening technique for 
structural assessment of different proteins. The changes in CD spectra as a result 
of addition of ligand help in understanding the specific structural changes taking 
place in specific areas of the protein, which in turns helps to get some idea 
about ligand binding and its corresponding features. CD has a significant role to 
understand the undergoing structural and conformational changes at secondary 
structure level of the protein.   
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1.4  Aims and objectives of the project 
The primary intention of the project is to optimize and apply a novel approach 
for using pharmacophores and pharmacophore-based screening in search of 
discovering the function and mechanism of action of target proteins. If 
successful the technique could be used as an aid for the discovery of protein 
function from structure. A part from the interesting practical applications, the 
field of research is aimed to offer conceptual insight into the mechanism of 
molecular recognition between the proteins and the ligands.  
Mainly the objectives include. 
  
1. To address the use of pharmacophore searching for substrate 
prediction and hence functional assignment from structure. 
2. To optimize the use of existing software to allow detailed 
pharmacophores to be generated and searched against a database of 
natural products.  Therefore a number of known structures were 
chosen with known functions to validate the method and identify 
weaknesses and any problems with the method.  
3. To take a known system with a number of ligands and potential ligands 
and assess the quickest and most effective methods to characterize 
binding.  
 
4. It is proposed to use pharmacophore searching methods to interrogate 
the active sites cavities of a series of unknown protein structures with 
an aim to indentify potential compounds that would help in exploring 
the potential function of the proteins.  
 
5. Target proteins have a well defined active site cavity or cleft and 
contain sequence conserved amino acid residues. Enzymes with a 
predicted known functionality based on conserved catalytic residues 
will be considered where a suitable substrate has not been identified. 
 
6. To use it in exploring vital interactions provided by the protein binding 
site. 
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2. MATERIALS AND METHODS 
2.1 General reagents 
All the analytical grade chemicals and biochemical’s used were obtained from 
Sigma Aldrich® unless stated otherwise. 
2.2 Bacterial strains 
All the bacterial strains used during this PhD research work are listed in table 2.1 
Escherichia coli Relevant genotype Notes 
E.coli BL21 (DE3) F– ompT hsdSB (rB
- mB
-) gal 
dcm (DE3) 
General purpose expression 
host {124} 
E.coli DH5α  F– Φ80lacZdM15 d(lacZYA-
argF) U169 recA1 endA1 
hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1  
 
recA1 ensures increased insert 
stability and prevents 
unwanted recombination. 
endA1 improves the yield and 
quality of plasmid DNA 
prepared from minipreps 
{125} 
E.coli BL21 
Rossetta (DE3) 
Novagen® 
F– ompT hsdSB(rB
- mB
-) gal 
dcm lacY1 (DE3) pRARE6 
(CmR) 
general expression  host; lac 
permease mutation allows 
control of expression level, 
provides rare codon tRNAs 
{126} 
E.coli Origami 
(DE3) Novagen® 
∆ara-leu7697 ∆lacX74 
∆phoAPvuII phoR araD139 
ahpC GalE galK rpsL F'{lac+ 
(lacIq)pro} gor522::Tn10 
(TcR) trxB::kan (DE3) 
general expression  host; two 
mutations in cytoplasmic 
disulfide reduction pathway 
enhance disulfide bond 
formation in E. coli cytoplasm 
{126} 
Table  2.1 Different type of E-coli cells used for over expressing protein and their relevant 
genotype 
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2.3 Plasmids 
All the bacterial strains used during this PhD research work are listed in table 2.2 
Plasmid Source Selection Notes 
pET-FG1 Prof. Dr.Gary Sawers, 
Martin-Luther University, 
Halle, Germany 
Kanamycin T7 expression plasmid 
with N-terminal 6xHis-
tag, PDB code: 2UYN 
pTBL2 Dr. Bernhard Lokhamp, 
University of Glasgow 
Tetracycline T7 expression plasmid 
with N-terminal 6xHis-
tag, HutD, PDB code: 
1YLL 
pTBL2 Dr. Neil Patterson, University 
of Glasgow 
Tetracycline T7 expression plasmid 
with N-terminal 6xHis-
tagged NFGase, HutG, 
(PAA) 
HK100 Joint center for structural 
genomics (JCSG), The 
Scripps Research Institute, 
North Torrey Pines Road, La 
Jolla, California 92037 
Kanamycin T7 expression plasmid 
with Clone site: 
SpeedET, N-terminal 
6xHis tag, 
PDBcode:2Q7S 
pTB361 Dr. Kirsty  Stewart, 
University of Glasgow 
Tetracycline HIsdhL 
P1X-02 Chantal Abergel, CNRS, Aix-
Marseille Université 
Marseille, France 
Ampicillin T7 expression plasmid 
with N-terminal 6xHis-
tag, Candida albicans 
DHQase, PDBcode:3KIP 
PAO1 Dr. Kirsty  Stewart, 
University of Glasgow 
Ampicillin N-terminal 6x His tag, 
Helicobacter pylori Type 
II DHQase 
pET15b Dr. Kirsty  Stewart, 
University of Glasgow 
Ampicillin Streptomyeces 
coelicolor Type II 
DHQase 
pT7.7 Dr.Lewis  Evans, University 
of Glasgow 
Ampicillin Mycobacterium 
tuberculosis Type II 
DHQase 
Table  2.2 Details of plasmids, their source, selection and resultant protein 
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2.4 Plasmid purification (mini prep) 
The plasmid purification for plasmids was carried out as per protocol of 
QIAGEN® Miniprep Handbook, page 22, 2nd Edition, December 2006. 
The protocol is designed for purification of up to 20 µg of high-copy plasmid DNA 
from 1–5 ml overnight cultures of E. coli in LB (Luria-Bertani) medium. All steps 
were carried out at room temperature. 
1. Pelleted bacterial cells were resuspended in 250 µl Buffer P1 and transferred 
to a micro centrifuge tube. 
2. 250 µl of Buffer P2 was added and mix thoroughly by inverting the tube 4–6 
times. 
3. 350 µl of Buffer N3 added and mix immediately and thoroughly by inverting 
the tube 4–6 times. 
4. Centrifuged for 10 min at 13,000 rpm (~17,900 x g) in a table-top micro 
centrifuge. 
5. The supernatants from step 4 were loaded on to the QIAprep spin column by 
decanting or pipetting. 
6. Centrifuged for 30–60 s and the flow-through discarded. 
7. The QIAprep spin column was washed by adding 0.5 ml Buffer PB and 
centrifuged for 30–60 s and the flow-through discarded. 
8. QIAprep spin column was washed by adding 0.75 ml Buffer PE and centrifuged 
for 30–60 s. 
9. The flow-through discarded, and centrifuged for an additional 1 min to 
remove residual wash buffer. 
10. The QIAprep column was placed in a clean 1.5 ml micro centrifuge tube. 50 
µl Buffer EB (10 mM Tris·Cl, pH 8.5) or water was added to the center of each 
QIAprep spin column to elute DNA. The column was let to stand for 1 min and 
then centrifuged for 1 min. 
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2.5 DNA quantification 
The concentration of DNA plasmid was calculated by measuring the absorbance 
at 260 nm (A260nm) using the nanodrop spectrophotometer (Thermo Scientific). 
Concentration was calculated based upon the equation.                                 
DNA Concentration (ng/µL) = A260/0.02 {127} 
2.6 pH measurements 
 All pH measurements were made with pH meter (pH 211, Hanna Instruments) 
unless stated otherwise. The pH meter was calibrated with pH buffers: 4, 7 & 9  
2.7 Antibiotics: 
 Four different antibiotics were used namely Ampicillin, Tetracycline, 
Chloramphenicol and Kanamycin. Stock solutions of the antibiotics were 
prepared in given solvent (Table 2.3). If required the antibiotic solutions were 
sterilized by filtration through a 0.22 µm filter. The stock solutions were stored 
at -20°C. 
Antibiotic Concentration of 
stock solution 
(mg/mL) 
Concentration 
used (µg/mL) 
solvent Filter 
sterilization 
Ampicillin 100 50-100 Distilled 
water 
Yes 
Tetracycline 12.5 12.5 80% 
ethanol 
No 
Chloramphenicol 34.5 34.5 100% 
ethanol 
No 
Kanamycin 10 50 Distilled 
water 
Yes  
Table  2.3 Different antibiotic stock solution and concentrations 
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2.8 Culture media for bacterial growth 
Different E.coli strains were used for growing bacterial culture in various culture 
media. Table 2.4 gives the composition of different growth media used. 
Media Composition per Liter Instructions  
LB (Luria-Bertani 
Broth) for cultures 
10g Tryptone, 5g yeast 
extract,10g NaCl 
Sterilized by autoclaving at 15 
psi for 30 minutes at 121°C. 
LB agar (for plates) LB composition  plus 15g micro 
agar 
Sterilized by autoclaving at 15 
psi for 30 minutes. 
SOC Medium (for 
100mL) 
2g Tryptone, 0.5g yeast extract 
1mL 1M NaCl, 0.25mL 1M KCl, 
1mL Mg2+/glucose stock (1M 
MgCl2,1M MgSO4, 2M glucose) 
filter sterilized 
Dissolve all (except 
Mg/glucose stock) in 97 mL 
distilled water, autoclave, 
cool, add Mg2+/glucose stock, 
filter sterilize medium 
through 0.22 µm filter. 
Minimal Media (M9) 5X M9 (1L) 
Autoclave 
64g Na2HPO4.7 H2O OR 85.5g 
Na2HPO4.12 H2O, 15g KH2PO4, 
2.5g NaCl 
To make 500mL of M9 
100mL of 5X M9  
Plus  Filter sterilize Media 
1mL   1M MgSO4, 1mL   50mM 
CaCl2, 1.5g   Glucose, 0.5g   
NH4Cl, 400µL Thiamine 
(50mg/mL) 
First Autoclave the 5X M9 
media and then directly 
before use add the filter 
sterilized media to the cooled 
5X M9 as per composition. 
Thiamine is optional but 
definitely improves growth 
rates. Use 15N NH4Cl in case of 
labelled media preparation 
with the rest of recipe the 
same. 
Auto Induction 
Media 
Autoclave 
Phosphate buffer pH:7.2 (6g 
Na2HPO4, 3g KH2PO4 ) 
Tryptone 20g, Yeast Extract 5g, 
NaCl 5g 
Filter Sterilize media 
60% v/v Glycerol 10mL, 10% 
w/v Glucose 5mL, 8% w/v 
Lactose 25mL 
Adjust the pH of phosphate 
buffer first and then add the 
media, autoclave to sterilize , 
leave it to cool, add the filter 
sterilize media just before use 
Table  2.4 Composition of different culture Media 
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2.9  Preparation of ultra-competent E.coli (BL21 DE3) 
cells: 
Competent cells were prepared based on method by Inoue {128} with some 
modifications. The protocol followed is given below: 
50µL of BL21 (DE3) cells were taken from -80°C freezer  and cultured in 125mL 
of (preincubated at 19°C) super optimal broth (SOB) in 500mL bowelled flask in 
duplicate. The cultures were incubated at 19°C in shaking incubator until OD 
(A600) reached 0.5 (normally it takes 24-36 hours). The flask was then placed on 
ice for 10min, and then the cells pelleted by spinning at 3000xg for 10 minutes 
at 4°C. The supernatant was discarded and the cell pellet was gently 
resuspended in 40mL of ice-cold transformation buffer (TB) with 0.7mL of 
dimethyl sulfoxide (DMSO, Stored at -20°C before use). The solution containing 
cells was aliquoted in 100 and 500µL portions in eppendorfs and frozen in liquid 
nitrogen. The cells were stored at -80°C. Composition of Media: 
 
1. SOB solution: 
 0.5% yeast extract, 2% tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl2 
 10mM MgSO4 
Final SOB solution was dissolved in double distilled water and autoclaved to 
sterilize. 
2.  TB solution 
  10mM PIPES, 15mM CaCl2, 250mM KCl 
 
Final TB solution was dissolved in double distilled water and pH adjusted to 6.7 
with KOH or HCl and then MnCl2 added to 55mM. After adjusting the final volume 
the solution was sterilized by filtration with 0.45µm filter and then stored at 
4°C.  
 
The newly prepared competent cells were tested by transformation and the 
number of colonies seen gave an indication of competency of the cells. 
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2.10 Transformation protocol 
The transformation protocol was modified from Novagen pET system manual 
{126}. Briefly the required competent cell tubes were taken from the -80°C 
freezer and immediately placed on ice in such a manner that whole cell tube 
was immersed in ice except the cap. The cells were allowed to thaw on ice for 
4-5 minutes and then visually examined to see if thawed. The tube gently finger-
flicked 1-2 times to evenly resuspend the cells. 50µL aliquot of cells were 
pipetted out in pre-chilled eppendorf tubes on ice and then 2.0 µL of the 
required plasmid DNA was added and stirred gently to mix and then left on ice to 
incubate for 5 minutes. The eppendorfs tubes were then heated for exactly 30 
seconds in a 42°C water bath without shaking and then put back on ice for 2 
minutes. 250 µL of room temperature SOC was added to the eppendorf tubes 
whilst on ice. The tubes were then incubated at 37°C while shaking at 250 rpm 
for 60 minutes in shaking incubator. The cells in eppendorf were poured on to 
pre-warmed agar plates containing the appropriate antibiotic and spread 
uniformly on the plates with the help of a sterilized glass rod. The plates were 
left on the bench for several minutes to allow maximum absorption of the liquid 
and then inverted and incubated overnight in a 37°C incubator. Same procedure 
was carried out for a control plate except the addition of plasmid DNA. The 
incubated plates were visually inspected for bacterial colonies.  Whole 
procedure was carried out in sterilized bio hazard area with an open flame to 
prevent risk of bacterial cross contamination. 
 
2.11 Storage of bacterial Strains 
On temporary basis the selective antibiotic resistant agar plates with the 
bacterial strain were sealed in self sealing (nesco film) tape and stored in a cold 
room at 4°C for up to 4 weeks. For permanent storage the bacterial strains from 
overnight cultures were mixed with 100% glycerol to a final concentration of 80% 
glycerol/culture (v/v) and stored in -80°C freezer. 
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2.12 Protein over-expression  
2.12.1 Overnights and test of expression 
An individual bacterial colony was picked from an agar plate by using sterile 
inoculation loop and mixed in 10 mL of LB medium (with required antibiotic) in 
50mL culture tubes and incubated over night in a 37°C shaking incubator. Next 
day these overnights were used for test of expression by seeding them to 10mL 
of LB medium in 1:10 dilution at above mentioned conditions. OD600 of the 
cultures was monitored hourly and when reached between 0.6-0.8, the cultures 
were induced by addition of 1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). 
1mL samples were collected after each hour up to 4 hours duration. The samples 
were later on prepared for sodium dodecyl sulphate poly acrylamide gel 
electrophoresis (SDS PAGE) to check for protein over expression. 
2.12.2 Large scale growth of bacterial cultures  
An individual bacterial colony was picked from an agar plate by using sterile 
inoculation loop and mixed in 10 mL of LB medium (with required antibiotic) in 
50mL culture tubes and incubated over night in a 37°C shaking incubator. Next 
day these overnights were used for large scale growth by seeding them to 250mL 
of LB medium in 2L flasks. OD was monitored hourly and when reached between 
0.6-0.8, cultures were induced by addition of 1mM IPTG. These cultures were 
incubated overnight at 13°C. Same Protocol was followed when growing cultures 
in M9 media. In case of auto induction media cultures were grown by inoculating 
a single colony in 250mL of Auto induction media in 2L flask and incubated 
overnight in a 37°C shaking incubator. 
2.12.3 Cells harvesting 
The cells were harvested by centrifuging them for 25 minutes at a speed of 
3000xg in a sigma® 4K15 centrifuge at 4°C. The bacterial cell pellet was 
resuspended in 15mL of binding buffer and stored at -20 °C.  
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2.12.4  Cell lysis by ultrasonication 
Large scale cell lysis was carried out by using a sonicator. The frozen pellet was 
thawed at room temperature on a rotating stage. After thawing the sample a 
few mg of DNase were added and the tube was placed in slushy ice in a beaker 
to maintain the temperature at 4°C. The probe of the sonicator was fully 
immersed in the sample and the sonicator set for 30 cycles (each cycle = 30 
seconds off, 30 seconds on).  The cell lysate was then centrifuged for 25 minutes 
at a speed of 20000 rpm in a 3K30 sigma® centrifuge at 4°C. After centrifugation 
the supernatant was retained and stored on ice before subsequent purification 
steps. 
2.13 Protein purification  
2.13.1 Ni-NTA affinity chromatography or IMAC 
Ni-NTA affinity chromatography or immobilized metal affinity chromatography 
(IMAC) is a well established widely used one step purification technique for 
genetically engineered histidine tagged proteins. In this technique the stationary 
phase is mostly organic resin covalently bonded with a chelating ligand e.g; 
Nitrilo tri acetic acid (NTA), Imino di acetic acid (IDA) or tris-carboxymethyl 
ethylene diamine (TED). The ligands have the ability to form coordination 
complexes with Metal ions e.g; Cu(II), Zn(II), Ni(II), Fe(II). The chelating ligands 
have electron-pair donor atoms like N, S, O and the metal ions are electron-pair 
acceptor atoms. When the metal ion solution (Ni2SO4) is passed through the 
stationary phase the formation of metal-ligand complex takes place, which 
serves as affinity ligand for the His-tagged proteins. The metal ligand complex 
can be bidentate, tridentate, etc., as per capacity of ligand to form 
coordination bonds. The rest of the coordination bonds are formed with water 
molecules in the beginning  which are subsequently replaced by histidine 
residues of the recombinant protein {129} .The imidazole Nitrogen of histidine  
binds to the Ni2+. To ensure the binding of target protein to the column the 
procedure has to be carried out at a neutral or slightly basic pH at which the 
imidazole Nitrogen of the Histidine residues is in nonprotonated form {130}. The 
cell lysate supernatant obtained after subsequent sonication, centrifugation and 
filtration was loaded on the Ni-NTA column pre-equilibrated with the binding 
buffer (Buffer A). The non his-tagged proteins are passed through the column 
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without binding while non-specific proteins which have few surface exposed 
histidine residues, weakly bind to the column and are removed by washing buffer 
(Buffer B) which contains slightly higher amount of imidazole .The target protein 
is eluted by changing the buffer conditions, mainly by increasing the imidazole 
concentration up to 300mM, so that it competes with the imidazole of the 
histidine tag and elutes it from the column. Details of the buffer   
Binding buffer, A    =    5mM Imidazole, 50mM Tris-HCL, 300mM NaCl pH: 7.6 
Wash buffer,    B    =    20mM Imidazole, 50mM Tris-HCL, 300mM NaCl pH: 7.6 
Elution buffer, C    =    300mM Imidazole, 50mM Tris-HCL, 300mM NaCl pH: 7.6 
 
 
2.13.2 Gel filtration chromatography  
Size exclusion chromatography was carried out by using a pre-packed Superdex 
75 10/300 GL column (GE healthcare, #17-5174-01). The column was connected 
to the AKTA® chromatography system inside a cold room (AKTA Laboratory-scale 
Chromatography Systems provided by GE life sciences is for liquid 
chromatography systems which is used for protein purification at research 
laboratory scale. Systems provide more control than manual purification because 
of the ability to automatically control the flow rate and monitor the progress of 
the purification as well as to make controlled gradients and automatically 
collect fractions). After equilibration with 30 mL of running buffer at a flow rate 
of 0.5 mL/min, a 500 µL protein sample was injected into the sample loop. Size 
exclusion chromatography was then carried out at 0.5 mL/min running buffer for 
1.5 column volumes (35.34 mL) and was monitored by the UV absorbance at 280 
nm. Fractions of 0.5 mL eluant were collected and those which showed 
absorbance at 280 nm were analysed by SDS-PAGE. All the buffers used for gel 
filtration chromatography were first filtered and then degassed. The typical 
composition of the buffer for Gel filtration chromatography was 20mM Na 
Phosphate,150mM NaCl, 0.01% Na-azide pH: 7.5 unless stated otherwise. 
2.14 Dehydroquinases purification protocol 
The protein samples were purified by using the subsequent purification steps 
involving, ion exchange chromatography, hydrophobic interaction 
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chromatography (HIC), and finally Gel filtration chromatography. The details for 
ion exchange and Hydrophobic interaction chromatography, which were set 
through the AKTA® system, are given below. 
2.14.1 Ion exchange chromatography 
After centrifugation the supernatant from sonicated samples was loaded on to a 
Q-sepharose (anion exchanger) column which had previously been equilibrated 
with Buffer A (50mM Tris HCl, 1mM DTT pH: 7.8). A linear gradient of 0-600mM 
NaCl of buffer B (50mM Tris HCl, 0.6M NaCl, 1mM DTT pH: 7.8) was applied to 
elute the protein. 5 mL fractions were collected and analyzed for enzyme 
activity. Fractions containing maximum activity were pooled. For the 
precipitation of proteins (HIsdhL), 3M ammonium sulfate solution was added to 
the pooled fractions to a final concentration of 1.0M. The samples were spun at 
20000xg for the removal of precipitated protein. Finally the solution was 
concentrated to 10mL using an AMICON® protein concentrator with a 5000kDa 
molecular weight cut off (MWCO). 
 
2.14.2 Hydrophobic interaction chromatography (HIC)  
The samples obtained through ion exchange chromatography were loaded on the 
phenyl-sepharose column with a flow rate of 1mL/min. The column was pre-
equilibrated with buffer B (1.4M (NH4)2 SO4, 50mM Phosphate, 1mM DTT pH: 
6.8). Initially the column was washed with 10 column volumes of buffer B and 
then a linear gradient from 1.4-0.0 M (NH4)2 SO4 was applied along with buffer A 
(50mM Phosphate, 1mM DTT pH: 6.8). 5mL fractions were collected 
concentrated and then analyzed for enzyme activity. Fractions containing 
maximum activity were pooled and concentrated down at 20000xg and then 
loaded on to gel filtration superdex 200 column as a final purification step. 
 
2.14.3 Gel filtration chromatography on superdex 200 column 
The pooled fractions obtained through HIC were  loaded on superdex 200 (gel 
filtration) column equilibrated in buffer C (50mM Tris HCl, 200mM NaCl, 1mM 
DTT pH: 7.8) at a flow rate of 2mL/min. The Protein was eluted using buffer C. 
2mL fractions were collected. Collected fractions were pooled and subjected to 
enzyme assays for checking activity.  
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2.15 Protein characterization 
2.15.1  SDS-PAGE 
 SDS-PAGE is a routine method to detect protein expression and purity. The 
NuPAGE® system (Invitrogen), consisting of 12% Bis-Tris Novex Mini-gels and an 
Xcell SureLockTM Mini-Cell was used for all SDS-PAGE. The system was assembled 
according to the manufacturer’s instructions. 
 
2.15.2 Sample preparation for SDS Gel Electrophoresis 
In case of test of expression, 1mL samples of the induced and uninduced 
bacterial cells were centrifuged. The supernatant and the pellet were retained. 
The pellet was resuspended in 50µL (equivalent to of 1/20th of the original 
sample volume) of detergent mix "bug buster" using vortex. The samples were 
left for 20 minutes at room temperature; distilled water was added dependent 
on the OD of the original sample to give consistent loading of protein on the gel. 
From each sample, 30µL of sample was added to new eppendorfs containing 10 
µL of loading buffer (which contains β-mercaptoethanol, the detergent SDS, and 
a marker dye to follow the progress of the electrophoresis) and heated for 5 
minutes at 85°C on a heat block to denature the proteins. 10 µL of prepared 
protein sample was loaded onto wells in the precast gels and molecular weight 
markers were added in certain wells for reference purposes.  
 
2.15.3 Staining and destaining procedure 
Analysis of the electrophoretic profile was performed by staining the gel with 
coomassie stain (1 g coomassie brilliant blue R-250, 50 ml glacial acetic acid,500 
ml MeOH, 450 ml H20). The gel was incubated in 100mL Coomassie stain for 20 
minutes. The background stain was removed by immersion of the gel in 200mL of 
destaining solution (10%glacial acetic acid, 10% methanol) for overnight. Images 
of the gel were taken by using the Kodak imager®. 
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2.15.4 Measurement of protein concentration via UV 
absorbance 
The A280 absorbance of protein solutions were measured by either using a Nano 
Drop 1000 (Thermo Scientific) or the JASCO V-550 spectrophotometer. It was 
noticed that the JASCO V-550 spectrophotometer gave more accurate results 
than Nano Drop 1000 therefore former was used when more accuracy was 
needed. Extinction co-efficients were calculated from amino acid sequence 
{131}. Routinely this was carried out by using the ProtParam program 
(http://web.expasy.org/protparam/). The Beer-lambert law was also used to 
calculate the protein concentration and extinction coefficient values from A280 
absorbance.  
2.15.5 Dialysis  
It is necessary to completely exchange the buffers a protein is in for a number of 
applications e.g; enzyme assay, crystallization. The protein solution was added 
to the dialysis tubing and then sealed at both ends with plastic clips. The sealed 
samples were then suspended in a large volume (1-2 Liters) of suitable buffer for 
overnight on a magnetic plate with constant stirring in cold room at 4 °C. 
 
2.15.6 PD-10 desalting column (Buffer exchange) 
Another method for buffer exchange was by using a PD-10 column. Size exclusion 
chromatography (gel filtration) is a gentle technique for the purification of 
protein sample, based on the size of pores of column. The large molecules are 
eluted first and the small one’s at the end. PD-10 desalting column was 
equilibrated with a 5 column volumes of a suitable buffer. 2.5 mL of protein 
sample was added and the flow through was discarded. Finally the elution with 
3.5 ml of elute buffer. 
2.15.7 Lyophilization (Freeze drying) 
Protein samples were dialyzed and then concentrated in a suitable buffer to a 
volume of 1-2mls by using centrifugal filter unit (centricon®) in a centrifuge 
(sigma 3K30).  The concentrated protein was placed in a round bottom flask and 
flash frozen in liquid nitrogen. The samples were swirled in the flask to 
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maximize the surface area of the frozen solid and thereby speedup freeze 
drying. The frozen sample was attached to the freeze dryer and subjected to 
vacuum drying overnight at -110°C.  Upon completion of freeze drying, solid 
protein was scrapped from the flask and stored at room temperature.  
 
2.16  Protein crystallization 
The use of crystallization technique for the determination of structure of protein 
is now widely and frequently used, since the protein structure of hemoglobin 
and myoglobin were determined by Perutz and Kendrew {132} {133}. The number 
of protein structure determined by crystallography is increasing day by day as of 
November 2012 there are some 86,334 structures held in the Protein data Bank 
(PDB) {19}. Protein crystals were grown using the sitting drop vapour diffusion 
method in a CrystchemTM 24 well plate (Hampton Research). The set up for 
sitting drop vapour diffusion method was followed as: 
Cryschem PlatesTM (Hampton Research Ltd) were used to set up crystallizations 
with up to 24 different conditions per plate. The well was prepared first and 
usually contained 1ml of a buffered precipitant solution such as polyethylene 
glycol or ammonium sulfate or a mixture of PEG and salt. Sometimes additives 
were also included such as detergents or metal ions which may enhance the 
crystallization. 1µL of the concentrated protein sample was pipetted onto a 
concave platform, followed by 1µL of the well solution. The tray was then sealed 
over by using a crystal clear tape. This was then left undisturbed for at least 24 
hours to equilibrate. At the start of the experiment, the precipitant 
concentration in the drop is half to that of the well. Equilibration then takes 
place via the vapor phase. Given the relatively large volume of the well, its 
concentration effectively remains the same. The drop in the concave platform 
however loses water vapors to the well until the precipitant concentration 
equals to that of the well. A wide range of crystallization conditions were used 
by varying the precipitant, buffer and additives concentrations. The pH levels 
types of precipitant and additives were also changed to get bigger crystals. The 
crystallization screen was left at 20 °C for an indefinite amount of time. 
Screening for crystal growth was intermittently done by using an Olympus 
(model: S240) microscope. 
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2.16.1 Streak seeding 
The technique for assisting the crystallization of proteins was carried out by 
dipping cat hair in to the drop which has crystalline precipitates. The cat hair 
was then streaked onto other clear drops and left for growth of individual 
crystals. 
 
2.17 Circular dichroism (CD) spectroscopy 
Circular Dichroism (CD) experiments were performed by Dr Sharon M Kelly 
(Protein Characterization Facility, University of Glasgow) using a JASCO J-810 
spectropolarimeter. Near UV CD spectra were recorded in quartz cuvettes of 
0.2cm or 0.5cm path lengths using the following parameters: scan rate 
10nm/min; response 2 sec; bandwidth 1.0nm; no. of scans 3. Far UV CD spectra 
were recorded in quartz cuvettes of 0.02cm path length using the following 
parameters: scan rate 50nm/min; response 0.5 sec; bandwidth 1.0nm; no. of 
scans 6. 
2.18 Isothermal titration calorimetry (ITC) and differential 
Scanning calorimetry (DSC) 
Isothermal Calorimetry (ITC) and Differential Scanning Calorimetry (DSC) 
experiments were performed by Margaret Nutley (Department of Chemistry, 
University of Glasgow) using Microcal VP-ITC and VP-DSC instruments. 
2.19 Enzyme Assays 
All enzyme assays were carried out using Jasco V-550 dual beam 
spectrophotometer. Typically a 1mL quartz cell with 1cm path length or if 
absorbance was too high a 0.5cm or 0.2cm path length cells were used. 
Measurements were made in triplicate at a wavelength of 234nm for DHQases 
and at 210nm for NFGases. The data obtained through enzyme assays was 
processed in Microsoft Excel or Origin software to calculate the Vmax, Km and Kcat 
values.  
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2.19.1 Standard 3-dehydroquinase assay  
The Standard assay to measure 3-dehydroquinase activity follows the formation 
of 3-dehydroshikimate.  Dehydroquinate is added to the protein sample, and the 
rate of conversion to 3-dehydroshikimate is monitored by the increase in A234 
absorbance. Enzyme assays for all the Dehydroquinases were carried out in 
50mM Tris buffer, pH: 7.6 at room temperature. The final concentration of 
protein in the cell was 0.3µM. The concentration of substrate (Dehydroquinate) 
in the cell was used in the range of 9.0—350 µM. The increase in absorbance at 
234nm was measured for 120 seconds. The Km, Vmax and Kcat values were 
calculated by using the Michaelis— Menten kinetics (Eq: 1) and Lineweaver—Burk 
plot (Eq: 2). 
 
 
2.19.2 Standard NFGase assay  
The Standard assay to measure NFGase (N-formyl glutamate amido hydrolase) 
activity follows the hydrolysis of N-formyl L-glutamate to formate and 
glutamate. The assay follows the hydrolysis of the amide bond and is monitored 
by the decrease in A210 absorbance. The enzyme assays for NFGase were carried 
out in PBS (Phosphate buffer saline;  137mM NaCl, 2.7mM KCl, 10.0mM 
Na2HPO4.2H2O, 2.0mM KH2PO4  ) buffer, pH: 7.4 at room temperature.  The 
concentration of substrate (N-formyl L-glutamate) in the cell was used in the 
range of 0.05—1.5 mM. The final concentration of protein in the cell was 2.0µM. 
The decrease in absorbance at 210nm was measured for 120 seconds. The Km, 
Vmax, Kcat and Ki values were calculated by using the Michaelis— Menten kinetics 
and Lineweaver—Burk plot. 
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3. Pharmacophore methodology  
3.1 Overview of pharmacophore methodology 
The generation of a pharmacophore model from a protein structure involves the 
following steps:  
1. Identification of the protein active site and the selection of a sphere of 
atom coordinates that describe it. 
2.  Visual identification of structural and chemical features within the 
active/binding site of the protein.  
3. Visual recognition of potential H-bond donor and acceptor interactions 
from the protein perspective. 
4. Selection of protein atoms within the active site to act as exclusion 
spheres limiting the conformational space available to any ligand. 
5. Search of the model pharmacophore against a database of compounds.  
6. Assessment of both of the number and quality of the hits obtained from 
pharmacophore searching, optimization of the pharmacophore and 
iteration of the procedure.  
7. Visual check of the hits obtained with naked eye, regarding their proper 
orientation in the active site, ruling out the possibility of steric clash and 
satisfying the constraints, primarily in terms of H-bond donor and 
acceptor interactions. 
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Figure  3.1 Flow chart describing the generalized scheme of events in the generation and 
optimization of a pharmacophore  
The speed of the process, both in generation of the model as well as the prompt 
search results from minutes to a few hours is an added advantage of 
pharmacophore searching over other methods such as docking. Among other 
advantages is the flexibility in the generation of the pharmacophore model. The 
ability to test hypotheses and further improvement of the model based on initial 
hits obtained from preliminary searches. An important feature is the freedom to 
vary the bond lengths and bond angles of the H-bond vector interactions within 
the allowed tolerances known for the interaction. The following computer 
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programs, databases and methodologies were used during the course of 
pharmacophore searching process for various proteins. 
3.2 Catalyst® 
Catalyst (Accelrys) version 4.9 was used to check for errors in screening the 
hypotheses against the required 3D conformational database by using the “fast 
flexible search” option available in the catalyst stockroom database tools 
window. Either too many hits or more often no hits would indicate problems 
with the generated hypothesis which could be addressed.  Default parameters 
were used throughout unless otherwise stated. 
Once the pharmacophore had been checked for correct format and for other 
errors, the catSearch option was run as a shell script in the form of following 
command: sh multi2.sh  
Two types of output in the form of .sd file format were obtained from searches 
using the following catSearch commands 
1. AllHitConfs caused all the conformers that can be mapped to the query:  
 
catSearch $1 -query $i -maxhits 300 -allHitConfs -align -sd $k 
2. BestFlexible which performed best flexible search to the query: 
catSearch $1 -query $i -maxhits 300 -bestFlexible -align -sd $k 
 The multiple conformations (AllHitConfs) option helped in finding the most 
favored orientation of the key functional groups of the ligand towards the 
binding site. However, the Best Flexible Hit was used most often to limit the 
number of Hits to a manageable number for visual inspection. 
In later more sophisticated searches; Catalyst was used to optimize certain 
parameters like type of bond between query atoms, charge on atoms and 
multiple atom types for individual query atoms of the pharmacophore model. 
Searches were carried out by using catalyst for multi-conformational database of 
compounds. The resultant pharmacophore readout was a 3D map with respect to 
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the protein structure, representing the optimum number of geometric 
constraints. The model defined the essence of the target protein binding site 
and resulted in sensible hits.  
3.3 Accelrys Discovery studio visualizer® (DSV) 
As the optimization of pharmacophoric features with respect to the protein 
binding site and ligand attributes, requires a detailed understanding of the 
intermolecular interactions, DSV is a powerful tool for in detail visual inspection 
of such interactions. DSV was used in the generation of the later more 
sophisticated pharmacophores in Vector and Query atom methods. This software 
permitted the generation of the hypotheses without the use of Cerius2 and 
packages within this interface which resulted in significant savings in time and 
effort. 
3.4 Generation of Databases 
Following databases were generated and used throughout the project unless 
otherwise stated. 
3.4.1 Generation of Aldehyde and ketone compounds database 
The database was created by using the Accelrys Catalyst Tutorials (Release 4.7), 
the generation of the database involved the following steps: 
1. Generation of  aldehyde and ketone functional group queries by using the 
hypothesis feature of the catalyst® software. 
2. Merging of the hypothesis by using the Exclude/OR Edit option of the 
catalyst software (Catalyst® Tutorials, page 327) 
3. Searching the hypothesis against available database (naturalism.bdb) by 
using the Best flexible search databases/spreadsheets option in Catalyst: 
stock room 
4. Exporting the resulting output spreadsheet in the form of  MDL structure 
data (SD format) to the home directory 
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5. Conversion of spreadsheet (.sd file format) to database file (.bdb file 
format) by using these commands (Catalyst Tutorials, page 310 & 413) 
(i)   catDB CONFIG name of SD file .bdb (this commands builds the 
database from SD file, and configures the new database by using the 
default database feature dictionary) 
(ii) catDB SD defaultdatabase.sd name of SD file.bdb (this command 
creates the database from the SD file) 
3.4.2 Generation of dipeptide and tripeptide database 
The dipeptide and tripeptide databases were generated by initially using a shell 
script to generate a string of pepide descriptions using three letter codes for 
amino acids. These were interpreted and converted using molconvert from the 
JChem suite of programs, resulting into .sd format. The .sd files for di-, and tri- 
peptides were combined into a single multi compound .sd file which was 
converted to database format (.bdb) as described earlier in section 3.4.1 (5). 
This resulted in 400 dipeptides and 8000 tripeptides resulting in the 8400 
peptides in the peptide database. Other databases used were naturalism.bdb 
(5,492 compounds) a database of smaller compounds (Mr<500) from ChEBI {134} 
and the entire ChEBI database (16,799). 
3.5 Pharmacophore generating methods 
A total of three distinct methods were used in the successive optimization of 
pharmacophore generation, dependent on the available software at the time. 
1. Cerius2,  notepad and WebLab viewer pro method 
2. DSV, Vector method 
3. DSV, Query atom method  
The methods are described in detail in sections below. 
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3.5.1 Cerius2, Notepad and WebLab viewer pro method 
This method was used in the preliminary stages of the project as a modification 
of the standard pharmacophore searching. The method was preferred for 
proteins whose structure with a ligand had been determined. During the course 
of optimization it was found very difficult to select potential interactions from 
the interaction map of the protein binding site. The method comprised of the 
following major steps: 
1) Visualizing and optimizing active site of the protein to be probed with 
respect to the x y z coordinates by using Cerius2 program (Figure 3.2) and 
generation of hydrogen atoms. These required modifying the bond order 
for cofactors such as NADP+ or ADP. 
 
Figure  3.2 Visualization and optimization of protein active site by using Cerius2 
 
2) Generation of interaction map and selection of potential interactions 
(donor, acceptor, lipophilic) manually as clustering of interactions did not 
produce reliable vectors. Further generation of exclusion spheres from 
protein atoms within the protein binding site normally of a radius of ~10Å 
(Figure 3.3) 
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Figure  3.3 Generation and optimization of potential interactions in the binding site 
(In Cerius 2 the small grey red arrows specify the possible H-bond interactions of 
the amino acids towards the potential ligand, important arrows responsible for the 
interactions were selected)  
 
3) Visualizing the generated pharmacophore in Web lab viewer pro as this 
was more flexible and could be done easily together with the 
pharmacophore (Figure 3.4). In a suitable radius around the binding site 
each atom of the protein was provided with an exclusion sphere (grey 
spheres) to avoid the steric clash of the hits with the amino acids 
surrounding the binding site.  
 
Figure  3.4 view of generated pharmacophore in WebLab viewer pro (big grey 
spheres represent the exclusion volume, while the purple and green vectors 
represent the donor and acceptor interactions in the binding site) 
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4) Optimization of H-bond vectors direction by changing the x, y, z 
coordinate position in relation to the active site residues in web lab 
viewer pro (Figure 3.5) (exclusion spheres are hidden for clarity). The 
change in position of H-bond vectors was carried out in a following way: 
First note down the x, y , z co-ordinates for the desired position of the H-
bond donor , then open the .chm file in word pad and change the x, y , z 
co-ordinates  of the head and tail of the  targeted H-bond vector 
(donor/acceptor) to the desired x, y, z co-ordinates and save the file. 
 
Figure  3.5 optimization of position of H-bond vectors in the binding site (The 
uncertainty spheres around the H-bond vectors define the tolerance limits for the 
hits which can be increased or decreased as per requirement) 
 
5) Using Catalyst and CatDB searches to search the pharmacophore against 
the multi-conformational compounds database.  
6) Visualizing  the results in WebLab viewer Pro 
 
The procedure typically could be iterated 2-3 times as certain combinations of 
certain interactions will result in no compounds while others will result in 100s. 
Further the active site can be seen in web lab viewer pro along with the 
obtained hits. Manually certain hits can be rejected or accepted based on their 
interactions in the binding site. The addition of new vectors required could be 
carried out either by going back to Cerius2 or editing the .chm files by hand. 
This method did not permit the quick and easy evaluation and optimization of 
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the Pharmacophore. Equally, the difficulty to select chemical types such as a 
carboxylate was frustrating as this led to many false positives.  
3.5.2  DSV, Vector method  
The major advantage of this method is the exclusion of the slow Cerius2 step 
and the generation of the pharmacophore within DSV. The step-wise detail of 
the methodology used for the generation of pharmacophore with a ligand in the 
active site is given below. Equally, water molecules could be used as sources of 
hydrogen bond donors or acceptors in the absence of ligand. During the course of 
optimization care was taken in satisfying the overall matching of the desired 
hydrogen bond in protein ligand interactions. Complementarity between the 
ligand and protein interface in terms of spatial occupancy and absence of any 
unfavorable interactions conferring steric conflict between the ligand and the 
binding pocket of the protein were also dealt with caution . 
3.5.2.1 Preparing the PDB file 
1) Generate hydrogens for the pdb file both for docking and for 
pharmacophore searching.  This is best done using the What If Web 
Interface. http://swift.cmbi.ru.nl/servers/html/index.html 
Navigate using side menu to Build/check/repair model (Figure 3.6) 
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Figure  3.6 Image of web interface for what if program 
 
1) Select from options in main window Prepare PDB file for docking 
programs 
 
2) Prepare PDB file window allows  to upload a PDB (Figure 3.7), obtained 
from the PDB database 
 
 
 
Figure  3.7 Image for what if weblink for uploading PDB file 
 
3) Once uploaded a PDB the program will take a few minutes to get to the 
following page (Figure 3.8). 
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Figure  3.8 Image of job done result on what if weblink 
 
4) Selecting the results page (Figure 3.9) a file predock.pdb can either be 
viewed by clicking on the link or saved by saving the link to a file. 
Rename the file to something sensible e.g. in the case of 2UYN.pdb the 
file was renamed as 2uynH.pdb  
 
 
Figure  3.9 what if weblink page image for viewing or saving the .pdb file 
 
3.5.2.2 Generating a pharmacophore search model 
1) Use Discovery Studio Visualizer (DSV) by starting the program up on the 
computer (Figure 3.10). 
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Figure  3.10 Start up image for DSV, used for viewing .pdb file 
 
 
2) Select File from the top menu and open the saved PDB file from the 
respective directory (Figure 3.11).  
 
 
 
Figure  3.11 3D view of .pdb file in DSV 
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3) A ligand in the active site helps define the pharmacophore. Either way, 
centre on the active site and select an atom which is roughly at its 
centre. 
 
a. Select View from the main menu and then Hierarchy, this shows the 
individual chains and enables to locate the ligand, selecting the ligand 
in the side menu highlights the ligand structure in the graphics 
window. 
b. Click on the  icon in the menu bar to get centered view on the 
ligand in the active site (Figure 3.12).  
 
 
Figure  3.12 Selection of ligand in the binding site of the protein (the selected 
ligand is highlighted with yellow dots) 
 
 
c. If there is no ligand in the binding site, use the graphics window to 
identify a water atom in the active site cavity and click on the  
icon for a centered view. 
 
4) To generate the exclusion spheres in a radius of about 10Å around the 
centre of the active site (Figure 3.13).   
 
a. Hide the hydrogens at this stage by selecting Chemistry then 
Hydrogens then hide from the main menu.  
b. Hide the ligand atoms by selecting from the main menu Scripts then 
Visualizations then Show/Hide Ligands.  
c. To select atoms for exclusion spheres select Edit from the main menu 
then Select. 
d. Choose Radius and specify 10 for the number of Angstroms and Apply 
and then Close. 
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e. Check by rotating the graphics window that all amino acids around the 
active site cavity are selected. The value of 10Å could be made larger 
or smaller to suit the protein in question.  
 
 
Figure  3.13 Image of window for selection of radius around the binding site in 
DSV 
 
 
f. Incase of a mistake use the Ctrl+Z command (as with Microsoft word) 
to reverse the last action.  
g. Unselect the ligand otherwise exclusion spheres will generate for the 
ligand too! Do this by holding down the Ctrl key and clicking with the 
left mouse button on the ligand highlighted in the Hierarchy window.   
h. With protein atoms still selected (highlighted with yellow dots) select 
Structure from the main menu, then Query Features, change the 
feature from centroid to ExclusionSpheres (Figure 3.14) in the menu 
and click ok  
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Figure  3.14 Image of DSV with the query feature window 
 
 
i. This generates a large number of football-like spheres for the 
pharmacophore (Figure 3.15).  The exclusion spheres are not helpful 
for visualization so hide them by selecting View from the main menu 
then Visibility in the sub menu and then selecting Hide. 
 
 
Figure  3.15 Exclusion spheres (highlighted in yellow) around the active site of 
the protein 
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3.5.2.3 Generation of hydrogen bond acceptor query feature 
1) To generate H-bond acceptor feature unhide the ligand (either using the 
Hierarchy window or the Scripts option on the main menu). Incase of no 
ligand water molecules can be used to generate H-bond acceptor 
features. 
2) Select an atom to be a hydrogen bond acceptor on the ligand, typically an 
oxygen atom (Figure 3.16) and then select Structure from the main menu, 
and then Query Features and then Acceptor. 
 
Figure  3.16 Introduction of H-bond acceptor vector from the ligand atom towards 
amino acid residue of the protein 
 
3) The acceptor vector highlighted in yellow is pointing into space and not 
towards the sensible H-bond donor atom. To change this click the right 
mouse button on the H-bond acceptor vector and select Attributes of 
Acceptor at the bottom of the menu (Figure 3.17). 
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Figure  3.17 Selection window for changing the properties of H-bond acceptor vector 
in DSV. 
 
4) The first thing to change in the Acceptor feature Attributes window is 
the Orientation of the vector. Click on the value in the window and it 
becomes a selectable menu for applying the changes (Figure 3.18). The 
default is always Projection. 
 
 
Figure  3.18 Multi options for changing the properties of acceptor feature 
 
 
5) In this case the Second Lone Pair gives a sensible vector to the arginine 
in the diagram. Change the Length from 3Å to more sensible value of 
2.75Å (Figure 3.19). 
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Figure  3.19 Changing the length of the H-bond acceptor vector fits it properly 
towards the arginine of the protein 
 
6) As long as the vector is within a small fraction of an angstrom from the 
correct position it should be fine.  The XYZ values can be changed but this 
refers to the Acceptor atom position which in this case is the ligand 
therefore no need to change it.  
7) Same procedure can be used for another acceptor atom by repeating 
steps 1-6. 2-3 vectors are reasonable for the first pharmacophore. 
8) The addition of a Location restraint is carried out by selecting the 
Acceptor Head points in the graphics window or in the Hierarchy window 
then selecting Structure on the main menu then Query Features and 
then from that menu select Location (Figure 3.20). 
Chapter  3   79 
 
Figure  3.20 Selection of arrow head of H-bond acceptor vector for generating the 
location restraint 
 
9) Due to a bug in the program the radius value for location sphere defaults 
to 1.5Å. To change this select the Location spheres individually and 
change the Radius value manually by hand to 0.8Å for the Acceptor head 
Location and 0.35Å for the Acceptor tail Location (Figure 3.21). 
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Figure  3.21 Changing the radius of location sphere around acceptor head and tail 
               
 
3.5.2.4 Generation of hydrogen bond donor query features 
 
1) The H-bond donor feature is generated in the same manner as for H-bond 
acceptor (section 3.5.2.3) except instead of selecting a hydrogen bond 
acceptor atom on the ligand, a donor atom such as hydroxyl oxygen or 
amide nitrogen is chosen. 
2) The only problem is that the donor hydrogen atom may not point in the 
correct orientation; instead the Donor Head Point could be pointing into 
space (Figure 3.22). This is a similar problem as for hydroxyl groups as an 
acceptor point.  
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Figure  3.22 H-bond donor from a ligand atom (the donor head is pointing in to the 
space) 
3) It is possible to rotate the donor vector around and hence position it close 
to a suitable hydrogen bond donor atom.  Select the middle of the bond 
between the carbon and oxygen from which the HB Donor vector 
originates. Use the torsion option    from the main menu to rotate 
around the bond and move the donor tail atom to a reasonable position 
(Figure 3.23).  
 
 
Figure  3.23 Optimization of the position of the head of H-bond donor vector by using 
the torsion icon in DSV 
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4) After optimizing the position of H-bond donor vector add Location 
restraints as described in section 3.5.2.3 (8,9) 
 
3.5.2.5 Saving the pharmacophore in .chm file format 
1) By making all the H-bond vector features visible along with the exclusion 
spheres, the pharmacophore file can be saved by selecting File from the 
main menu and then save as option (Figure 3.24).  
 
 
Figure  3.24 Saving the pharmacophore file in .chm file format by using the file, save 
as option of the main menu of DSV 
2) To search the generated pharmacophore file against the catalyst, the 
query file needs to be in .chm format. Select a suitable name and use the 
extension .chm from the Files of type option.  
 
3.5.3 DSV, Query atom method 
Query atom method can be used for the proteins which have the X-ray liganded 
structure determined, or in which a preliminary vector based approach has 
identified a fragment/molecule which has chemical features that the user may 
wish to further explore. In the generation of pharmacophore by using query 
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atom method, the initial steps involving addition of hydrogens and exclusion 
spheres are the same as described in vector method section: 3.5.2.1 & 3.5.2.2.  
After adding Hydrogens to the protein the linked query atoms are introduced 
with in the binding site of the target protein. Here for pharmacophore 
generation the protein with PDB code: 1p1m is used. The details of further steps 
involved are given below: 
1) First select the ligand as described in vector method 3.5.3.2 (3) 
2) By simple copying command(ctlr+c), copy the selected ligand  and then 
click on File in the menu top and then New and then Molecule Window, 
now paste the copied ligand simply by (ctrl+v) command (Figure 3.25). 
                        
Figure  3.25 Copying of ligand structure from the pdb file and pasting into new 
molecule window 
3) Select one of the atoms in the ligand and then click on structure in the 
main menu then query feature and with in query feature window select 
create feature and then query atom option and then in the List option to 
assign the atom type. If the atom type is not known explicitly then a 
series of potential atom types can be assigned (e.g; O, C, N) and then 
click ok (Figure 3.26). 
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Figure  3.26 Assigning multiple atoms to the each atom of the ligand 
4) Step 3 needs to be carried out in the same manner for rest of the atoms 
of the ligand to be used in the search (Figure 3.27). 
 
Figure  3.27 Assignment of multiple atoms to each query atom of the ligand 
5) To add uncertainty spheres around the individual query atoms to fix their 
location. Select the query atom and then click on structure in the main 
menu then query feature and with in query feature window select create 
feature and then in the List option select Exclusion sphere and click ok 
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(Figure 3.28). This permits the inclusion of atom linkages within the 
search with stipulating where the atom must be positioned. By 
highlighting the location sphere and then right clicking to get to the 
Exclusion feature Attributes, the radius of the location sphere can be 
increased or decreased accordingly. 
 
Figure  3.28 Introduction of location sphere (grey) around the individual query atoms 
by using the create feature of DSV (location sphere have been hidden in the 
following images for clarity viewing) 
6) To introduce bonding between the query atoms, select all the atoms by 
holding the shift key and click on all the atoms, now click on structure in 
the main menu and select query feature, within the query feature select 
the query bond option and click ok. Bonding pattern will appear around 
the query atoms (Figure 3.29). It is possible to edit the allowed type of 
bond for any given bond in the same way as carried out for multiple atom 
types in step 3. 
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Figure  3.29 Introduction of bond feature among the query atoms by using the create 
feature of DSV. 
 
7) Now by selecting the whole query copy the whole query ligand  and paste 
it in the protein graphics window of DSV® by using ctrl+a, ctrl+c, ctrl+v 
commands respectively (Figure 3.30) 
    
Figure  3.30 Introduction of query ligand in the protein graphics window. 
Chapter  3   87 
 
8) Introduce the exclusion spheres around the active site of the protein 
(Figure 3.31) as described in vector method section: 3.5.2.2 
                         
Figure  3.31 view of query ligand along with exclusion spheres in the binding site of 
the protein. 
 
9) Save the file with .chm extension as described in section 3.5.2.5 of vector 
method, the pharmacophore is now ready to be subjected to database 
search by using catalyst. 
10) Interestingly a sub-structure/fragment search can also be carried out by 
first selecting certain fragments of the query ligand and then deleting the 
selected fragments by using the delete key of the key board and then 
saving the file with a different suitable name in .chm file format. Sub 
structure/fragment based search deletes certain unimportant atoms from 
the ligand and leaving the important atoms of the ligand in the final query 
(Figure 3.32). This is an added advantage of the method and has been 
successfully used in cases of HutD and PARI proteins. 
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Figure  3.32 View of a sub-structure/fragment based query ligand in the active site of 
the protein along with the exclusion spheres. 
 
3.6 Advantages of query atom method 
The query atom method for pharmacophore generation is comparatively easy 
and friendly to use in comparison to the other two methods. It allows the user to 
understand the delicacies of the binding site, to add in sufficient information in 
the form of geometric constraints and to increase or decrease tolerance values 
on these geometric constraints. It facilitates the efficient virtual screening and 
provides ways to understand the chemical interaction between the ligand and 
the binding site of the target protein. Interestingly it has been used for the first 
time for this type of study and the results obtained in the form of hits confirm 
the  validity of this type of  pharmacophore searching and persuades the user to 
use this piece of sophisticated software for the following purposes i.e.;   
1) Using ligand information from a homologous active site architecture to 
search a new protein structure. 
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2) To specify the important interactions between the potential ligands and 
the active site of the protein which are almost certain to be retained due 
to the chemistry carried out by the protein.  
3) To combine information from multiple ligands and water molecules to 
create sophisticated searches for potential ligands. This includes the 
addition of query atoms and vectors if necessary.  
4) The ability to change the atom position uncertainty spheres, which 
defines their own uncertainty for certain interactions. This also permits 
the inclusion of connectivity of atoms without specifying an uncertainty 
sphere which means the atom type needs to be there but the exact 
position is unknown.  
The results obtained from the database search show that some parts of the 
ligand molecules are essential for interaction and they must assume a particular 
three dimensional orientation which becomes complementary to the protein 
active site in order to interact favourably. The methodology provides excellent 
approach for the optimization of the pharmacophore to attain sensible hits. By 
following the straight forward procedural steps, we have developed a simple, 
yet very effective pharmacophore model for the exploration of the binding site 
of proteins. This not only enables the perception of a pharmacophore within the 
active site but further through visual pattern recognition also helps the user to 
research the hits obtained from 3D database searches and to suggest the true 
substrate/ligand for the protein and thus the probable function of the protein. 
This type of pharmacophore modeling search enables the determination of key 
interactions sites within the three dimensional space of active site, which may 
have a crucial role in ligand binding. Based on the chemical features of the 
ligand a tighter or weaker receptor-ligand complex may form. The procedure is 
automatic and seems quite practical when dealing with a set of different 
compounds in a large database. The hits obtained help in identifying the key 
features and constraints which are consistent throughout the optimization of the 
pharmacophore and vital for fitting the ligand. In short we present a new 
method for the development of pharmacophore models that accounts both for 
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the inherent flexibility of the target active site as well as the essential chemical 
features of the ligand. 
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4. Xylose Reductase 
Xylose reductase (XR) is a NADPH or NADH dependent homodimeric 
oxidoreductase and belongs to the large monomeric aldo-keto reductase (AKR) 
super family of proteins. It is involved in the assimilation of xylose, where it 
catalyzes the first step and reduces the open chain xylose in to xylitol (Figure 
4.1). The catalytic residues involved in AKR’s activity are known and have been 
studied in the related enzyme aldose reductase{135}. There is a catalytic tetrad 
comprising of His114, Tyr-52, Asp51 and Lys81 and together they form an 
oxyanion hole in which the aldehyde or keto group of the substrate binds. The 
tyrosine acts as a general acid to protonate the oxygen of the corresponding 
aldehyde or ketone group. In comparison to other AKR’s the binding pocket of 
the enzyme is more polar and is therefore suited for a defined substrate. It has 
been observed in the crystal structure that the loop which folds over the NADPH 
co-substrate is slightly disordered in the apo form of the enzyme and becomes 
more ordered upon binding with the co-substrate in the holo form of the enzyme 
{136}. 
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Figure  4.1 Conversion of xylose to xylitol by XR in the presence of NADH or NADPH 
 
  Clinical research in the AKR’s family is principally carried out due to the ability 
of human aldose reductase to convert the open chain form of glucose to sorbitol. 
The reaction occurs when the physiological concentration of blood glucose 
increases in diabetic patients {137}. In order to understand the mechanism and 
inhibition of aldose reductase by means of different structural studies AKR’s 
have gained pivotal importance in scientific research for more than two 
decades. Currently no binding mode of the true substrate to any member of the 
AKR family has been structurally characterized which isprobably due to the low 
concentration of the active form of the substrate and weak binding. In relation 
to xylose reductases there is scarcity of information about how these enzymes 
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bind to the substrate? And which interactions are vital among the hydrophobic 
pocket and the polar substrate?  
In order to address these issues we used xylose reductase  as a test case to 
assess the pharmacophore searching method. The objectives were to help 
understand and to postulate the possible binding mode of various ligands to the 
enzyme and to see if we can correctly identify all the potential natural 
substrates of the enzyme that have been identified experimentally. The crystal 
structures of the two forms of the enzyme (apo and holo) served as good 
templates for finding the potential ligands/substrates and their probable mode 
of binding through pharmacophore based searching. Figure 4.2 shows the solid 
ribbon diagram of Xylose reductase (PDB: 1K8C) Chain : B along with the co-
factor NADP forming important H-bonds with the active site residues. 
 
Figure  4.2 Solid ribbon diagram for Xylose Reductase along with NADP in the active site, 
forming Hydrogen bonds with the active site residues of the enzyme. 
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4.1 Pharmacophore searching for xylose reductase 
With the availability of co-crystallized structure of  xylose reductases {136}, it 
was possible to locate the potential position of the substrate by using 
Pharmacophore searching . Additionally there is good experimental data 
available on a range of different aldehyde and ketone compounds which have 
been tested and confirmed as potential substrate through enzymatic assays 
{138}. Although no X-ray structure has been determined of any substrate 
analogue along with the enzyme, but a potential binding mode has been 
proposed {136}. There is therefore enough information to check the validity of 
the method of pharmacophore searching. 
The cofactor bound structure of XR (PDB: 1K8C chain:B) was used for the 
designing various pharmacophores.  Factors such as the time of search and the 
selectivity of a given pharmacophore were noted and the number of features 
were varied to try and obtain a small set of potential substrates which could be 
compared to the known substrates. The known substrates were not used to guide 
the pharmacophore searches as this would defeat the object of this test case.  
Though the software is not designed for such type of pharmacophore 
generation.Accelrys® Discovery studio visualizer (DSV), was used for the 
generation of various pharmacophores. At each stage of designing 
pharmacophore certain constraints were added for optimization purposes. The 
most important factors which were introduced from the active site during the 
course of optimization of the pharmacophore included 
 
• Hydrogen bond donor vector 
• Hydrogen bond acceptor vector 
• Exclusion Spheres  around the active site 
• Radius of the area of exclusion spheres around the active site 
• Use of certain water molecules in and around the active site 
• New database of compounds containing aldehyde/ketone functional group 
 
With the aim to get an optimized pharmacophore, a number of pharmacophore 
models were generated. The detail account of each pharmacophore model is 
given below. 
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4.1.1 Pharma xylo 1 
In order to generate the pharmacophore the DSV, Vector method was used as 
described in section 3.5.2. On the basis of information available about the 
recognition sites and mechanism of aldo/keto reductases. The enzyme has a 
catalytic tetrad which includes Tyr52, Lys80, Asp51 and His114. Among them 
Tyr52 and His114 form part of the anion hole in which the aldehyde or ketone 
group of the substrate binds {139}. A hydrogen bond acceptor vector was added 
from the hydroxyl of Tyr52 which also corresponds to a water position in the 
crystal structure (Figure 4.2). Another hydrogen bond acceptor vector was 
introduced from a water molecule which formed a hydrogen bond with the 
nitrogen of a conserved Asn310 (Figure 4.2). Further the angle and arrow 
direction of hydrogen bond acceptor vectors were optimized. The 
pharmacophore was then search against the small metabolite database 
(Naturalism.bdb). The hits obtained as a result included compounds like 
alcohols, aldehydes, ketones, esters, sugars, carboxylic acids, phosphates and 
aliphatic hydrocarbons. 
 
 
Figure  4.3 Pharmacophore with H-bond acceptors pointing from H2O molecules towards 
TYR52 and Asn310 respectively  
 
Search time = 15 minutes 
Maximum limit of Hits = 500 
Number of Hits obtained = 500 
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The type of hits included many compounds other than aldehydes and ketones, 
which made it clear that a two vector pharmacophore with active site exclusion 
volumes was insufficiently selective to obtain a suitable subset of hits.  In 
addition the Catalyst software does not allow restriction of a given hydrogen 
bond acceptor to a subset of chemical groups, namely aldehydes and ketones. As 
a result a significant number of hits were not aldehydes or ketones. While it is 
possible to limit the number of hydrogens for a given acceptor site but the 
ability to restrain the functional groups of the ligands is limited in Catalyst. 
Given the known enzyme action of this class of enzyme this was not sufficient to 
restrict the chemical groups in a suitable way. Therefore, a solution was to make 
a subset of the main library which only contained compounds with aldehyde and 
ketone functional groups. 
 
4.1.2 Pharma xylo 2 
Generation of restructured aldhyde/ketone database 
As we know that XR like other aldo/keto reductases works on either aldehydes or 
ketones it would seem logical to restrict the search to compounds with these 
functional groups. Therefore a database was created containing compounds with 
only aldo and keto functional groups as described in section 3.4.1. The numbers 
of compounds in the new database were reduced to 262 in comparison to the 
naturalism database having 5,492 compounds. The new database was named as 
aldoketocomps.bdb. Re-running pharmacophore search gave the following 
results.  
 
Search time= 31 minutes 
Maximum limit of Hits = 262 
Number of Hits obtained = 71 
 
In the above pharmacophore the radius of the uncertainty spheres around the 
head and tail of the vectors was 0.35 and 0.8Å respectively, meaning that there 
was greater uncertainty in the position of the ligand acceptor position than the 
protein donor atoms.  Out of 71 hits 43 compounds were aldehyde and 3 were 
ketone consistent with their functional group interacting in the anion hole of the 
enzyme. The remaining hits had carboxylic acid or phosphate groups towards this 
position. The hits containing  carboxlic acids and phosphate groups  in the active 
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site and to their justification that they can be accommodated into this position 
in aldo/keto reductases is confirmed by the crystal structures of aldose 
reductase in complex with citrate (PDB: 2ACS) {140} and glucose phosphate 
(PDB:2ACQ) {140} (Figure 4.3) 
 
Figure  4.4 Superimposed X-ray structure of Citrate and Glucose-6-Phosphate in the active 
site of Xylose reductase with carboxyl and phosphate group towards the oxy-anion hole 
(the nicotinamide ring,citrate and glucose-6-phosphate represented as stick model) 
As we have observed before, tighter restrictions on uncertainty spheres around 
the pharmacophore tail (ligand acceptor position) can give better discrimination. 
Therefore the radius of spheres around the head and tail of both the H-bond 
acceptor vectors was reversed i.e; 0.8Å and 0.35Å respectively. This is the 
opposite of what might be expected as the protein positions are well defined but 
the ligand position is more uncertain. However the uncertainty on the protein 
position is required to accommodate certain angular restrictions.   As expected 
the Pharmacophore search gave smaller number of hits as shown below.  
Search time = 22 minutes 
Maximum limit of Hits = 262 
Number of Hits obtained = 54 
 
Out of the 54 hits, 30 compounds were aldehyde and one was ketone with their 
functional groups interacting in the anion hole of the enzyme.  In both search 
results there was a clear preference of aldehyde compounds over ketones given 
the pharmacophore included two hydrogen bond acceptors and exclusion spheres 
within a radius of 10Å.  Analysis of the structure of the active site of XR showed 
that the side chain of Trp24 restricts the space available around the anion hole 
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of the enzyme and the presence of an aliphatic group in this area could cause 
steric hindrance towards Trp24. As a result ketone containing compounds cannot 
satisfy the pharmacophore and thus probably were not selected among the hits. 
The proximity of Trp24 side chain towards the aldehyde of D-Xylose (Figure 4.4) 
shows that presence of ketonic group could cause steric hindrance towards 
Trp24. 
 
 
Figure  4.5 The possible clash of a ketone with the Trp24 (structure highlighted with yellow 
dots) in the active site(in figure the ligand is D-Xylose) 
 
4.1.3 Pharma xylo 3 
By observing the active site of XR along with the H-bond interactions made by 
the hits obtained it appeared that there could be further interactions with in the 
active site other than the specified two H-bond acceptors interactions. A 
thorough examination of the active site revealed for example the key residues 
which have been identified for H-bond interactions include Trp24, Asp51, Tyr52 
and Asn310. This has also been identified in the X-ray structure of XR {136} that 
these residues may facilitate the binding of substrate within the active site. In 
order to further test the capacity of pharmacophore searching in selecting 
suitable ligands as hits an additional Hydrogen bond donor vector was introduced 
from the free carboxyl end of  Asp51 (Figure 4.5). The arrow head of all the 
vectors were set on the grounds of previous hits able to form H-bonds. Further 
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the angle and direction of the vector were optimized. The pharmacophore was 
then subjected to search against aldoketocomps.bdb database.  
 
Figure  4.6 Pharmacophore with additional H-bond donor (in magenta) towards the carboxyl 
oxygen of ASP51, NADP+ is highlighted with yellow dots and H-bond (exclusion spheres are 
removed for clarity). 
 
Search time = 06 minutes 
Maximum Number of Hits = 262 
Number of Hits obtained = 50 
Among the hits 44 compounds were aldehydes 1 was a ketone and the rest were 
carboxylic acids and esters.  As expected the addition of another constraint in 
the form of a hydrogen bond donor reduced the number of hits although not 
excessively and showed that it improved the pharmacophore in the sense of 
getting hits with maximum number of compounds likely to be the 
substrate/ligand.  In addition the orientation of the best hits from the screening 
matched with D-galactose, where the C2 is oriented towards the cofactor 
(NADPH) in such a way, which is consistent with hydride transfer from the 
cofactor NADPH. 
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4.1.4 Pharma xylo 4 
On the basis of previous knowledge available of potential interactions of key 
amino acids {136} within the active site the final optimized pharmacophore was 
generated by  putting  an additional Hydrogen bond donor vector from the ASN 
310 (Figure 4.6). Among the hits one of the convincing hits obtained as a result 
was   D-galactose, which was fitting well in the active site by satisfying 
maximum number of interactions, hydroxyl group of C2 and C3 of D-galactose 
formed hydrogen bonds with the amino nitrogen and carbonyl oxygen of Asn 310 
respectively and its aldehydic functional group was at a reasonable distance 
from the cofactor for hydride transfer. The final pharmacophore seemed to pose 
reasonable interaction, as most of the hits obtained as a result of this 
pharmacophore had their functional group positioned towards the cofactor. This 
could allows the hydride transfer to occur from the cofactor to substrate, 
subsequently leading to the proton transfer from the Tyr52 onto the substrate to 
convert it to its corresponding reduced form as described in detail by {141}. 
(Figure 4.6) 
Searching time = 02 minutes 
Maximum Number of Hits = 262 
Number of Hits obtained = 51 
 
Figure  4.7 Pharmacophore with additional H-bond donor(in magenta) towards the carbonyl 
oxygen of Asn310,D-galactose forming H-bonds with ASN310 and the position of its 
aldhydic group at 2.9Å distance from cofactor NADP+ (highlighted with yellow dots) 
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4.1.5 Manual selection of hits 
Among the hits D-galactose seemed to be a convincing hit as the orientation of 
its aldehydic group towards the cofactor is similar to the suggested mechanism 
for hydride transfer {141}. By keeping the orientation aldehyde group of D-
galactose around the cofactor as standard, the 51 hits from final pharmacophore 
model and some previous pharmacophore were observed manually. Only 25 
compounds were found to have their aldehyde group positioned towards the 
cofactor for the correct transfer of hydride. 
 
Table 4.1 includes the hits conforming to the D-galactose, among the hits some 
have already been tested as a substrate on aldose reductase and have 
demonstrated reasonable activity as a substrate e.g; D-galactose, D-ribose, L-
arabinose, D-xylose and D-glucose. Compounds which are among the hits but 
have not been tested as substrate can be tried invitro to test their catalytic 
activity. On the basis of results obtained, xylose reductase a type of enzyme 
which requires a cofactor for it’s functioning, appears to be an excellent test 
case example for the application of pharmacophore searching method and gives 
the plausible clue of substrate mode of binding and mechanistic details of 
structure-function relationship on molecular level. This example supports the 
purpose of using pharmacophore searching, and shows that this method works. 
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Table  4.1 Results of hits obtained from final pharmacophore search among the hits are 
those compounds which align with D-galactose and those which have already been 
confirmed as substrate for aldose reductases 
S.No Hits Obtained from 
final 
Pharmacophore 
Search 
Hits 
Aligning 
with D-
galactose 
Hits 
previously 
confirmed 
as xylose 
reductase 
substrate 
S.No Hits Obtained from 
final 
Pharmacophore 
Search 
Hits 
Aligning 
with D-
galactose 
Hits 
previously 
confirmed 
as xylose 
reductase 
substrate 
1 D-allose   27 D-altrose   
2 D-galactose   28 D-quinovose   
3 D-galacturonate   29 L-lyxose   
4 D-ribose   30 rutinose   
5 D-fucose   31 D-gulose   
6 L-arabinose   32 D-talose   
7 D-aldohexoses   33 D-rhamnose   
8 D-glucuronic acid   34 D-threose   
9 L-galactose   35 abequose   
10 D-apiose   36 D-idose   
11 D-fructuronate   37 isomaltose   
12 (4S,5S)-4,5-
dihydroxy-2,6-
dioxohexanoic acid 
  38 L-iduronic acid   
13 D-lyxose   39 L-guluronic acid   
14 D-xylose   40 digitalose   
15 L-xylulose 5-
phosphate 
  41 D-glucuronate   
16 D-arabinose 5-
phosphate 
  42 2-N,6-O-disulfo-D-
glucosamine 
  
17 D-mannose   43 digitoxose   
18 D-allose 6-phosphate   44 ascarylose   
19 D-glucose 1,6-
bisphosphate 
  45 tyvelose   
20 5-dehydro-4-deoxy-
D-glucuronic acid 
  46 D-mannuronate   
21 L-fucose   47 boivinose   
22 D-glucose   48 melibiose   
23 D-galacturonic acid   49 5-dehydro-4-deoxy-
D-glucuronate 
  
24 L-xylose   50 L-iduronate   
25 L-threose   51 L-guluronate   
26 colitose       
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4.2 Conclusions based on search models and hits 
1) The enzymatic assays previously carried out by Neuhauser et al {138} 
gives a comparative account of activity of the enzyme against various 
substrate compounds belonging to aldehyde (Table 4.2). The hits such as 
D-aldohexoses are generic and represent a flexible subset of C6-aldehydes 
and so can be looked at further. 
Aldehyde  Relative activity (relative catalytic efficiency) 
D,L-Glyceraldehyde (20 mM)   0.9 (37) 
D-Erythrose (20 mM)       1.8 (100) 
D-Xylose (300 mM)          1 (1) 
L-Arabinose (300 m)       0.7 (2) 
D-Ribose (300 mM)  0.3 (0.2) 
D-Glucose (300 mM) 0.2 (<0.1) 
D-Galactose (300 mM) 0.7 (0.3) 
D-Mannoheptose (240 mM) <0.1 (<0.1) 
D-Xylosone (25 mM)  1.1 (20) 
D-Glucosone (25 mM) 1.1 (22) 
Methylglyoxal (50 mM) 1.4 (20) 
Phenylglyoxal (12 mM) 0.6 (17) 
Valeraldehyde (50 mM) 0.8 (13) 
Pyridine-2-aldehyde (10 mM)  1.0 (7) 
Table  4.2 List of compounds belonging to aldehyde group Identified as substrates 
with comparison of their relative activity, reactions in aldehyde reduction performed 
with 17.4 nM ALR at 25 °C in 300 mM sodium phosphate buffer, pH 7.0, with 
saturating (relative activities) and non-saturating substrate concentrations (1 mM; 
relative catalytic efficiencies). The constant coenzyme concentration was 250 µM 
NADH, table reproduced from {138} 
2)  Some of the substrates like D-Xylosone and D-Glucosone have not been 
search out as hits from the database because in the catalyst software the 
stereochemistry is not defined, resulting in more degrees of freedom 
which leads to a potential possibility that the conformational sampling of 
the compounds is compromised, and thus penalizing the outcome of 
search at the cost of missing potential hits. When the stereochemistry of 
the D-aldohexoses was specified by using the Catalyst software and then 
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subjecting it to search through the naturalism database to search for 
compounds with the same stereochemistry as D-aldohexoses the search 
only gave D-galactose as a hit. Thereby further narrowing down the search 
in terms of specific stereochemistry. 
3) Compounds like methyl glyoxal, D-xylosone and D-Glucosone  which are 
identified as true substrates {138}  and are also present in the database 
but are not detected among hits. This could be because in the database 
there are only two conformations possible for the aldo-keto group (Figure 
4.7). The bond length between C2-C3 is 1.54Å, which is a single bond 
length which means that no partial double bond lies there. The software 
logic statement may presume it to be a partial double bond and thus 
searching for the corresponding conformations or on the other side there 
could be a bug in the program which rules out the possibility of methyl 
glyoxal and  its derivative aldo-keto compounds to be potential hits. 
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Figure  4.8 Two potential conformations of methyl glyoxal found in the database 
 
4) Comparison of the orientation of the hits (the orientation of the aldehyde 
group and the configuration of hydroxyl group at C2 position, forming two 
H-bond interactions with the Asn310 obtained from the final 
pharmacophore and the X-ray structure modeled {136} with the D-Xylose, 
demonstrates close congruence between the two. This further assures the 
sensibility of the pharmacophore and verifies that such mode of 
orientation is important for the substrate recognition purposes within the 
active site. 
 
5) Although short chain aldose compounds like D,L-Glyceraldehyde and D,L-
Erythrose which have been identified as true substrates {138} were among 
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the hits in the initial pharmacophore models in which the number of 
constraints to be satisfied were less but as the number of constraints 
increased the short chain aldo compounds were unable to satisfy all the 
constraints and that’s why they were not included in the  hits from the 
final pharmacophore search. This clearly shows that having more 
constraints means that short chain aldehydes will be omitted from the 
result. One of the other reasons that some of the potential substrates 
have not been identified by the search as potential hits despite present in 
the database is because of the mode of sampling of different 
conformations of the same compound in terms of conformational energy 
of the individual conformation e.g the D-aldohexose has 100 
conformations in the database and the range of the conformational 
energy of these conformations is 0-5.73 Kcal/mole. Similarly in case of D-
galactose there are 100 possible conformations in the database and their 
energy range is 0-11.04Kcal/mol, therefore during the sampling of 
compounds with various conformations there is a probability that some of 
the compounds are compromised with respect to other compounds based 
on conformational energy sampling and thus losing them as a hit during 
search and resulting in missing some potential hits. 
6) By visualizing hits from the final pharmacophore (Figure 4.9) it is observed 
that most of the hits have their aldehydic functional group oriented in 
such a manner, which brings both the carbonyl oxygen and carbonyl 
carbon at a close H-bond distance from the respective protein atoms. 
Further the carbon of the carbonyl carbon is able to get the hydride 
transfer from the Co-factor and thus making it plausible for the carbonyl 
oxygen to get the proton transfer from Tyr52 of the enzyme (Figure 4.8).   
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Figure  4.9 Orientation of the D-galactose towards the co-factor NADP and Tyr52 in 
active site from pharmacophore searching model (image created by using 
DSV,certain residues are removed for clarity purposes) 
 
7) A part from the alignment of the key aldehydic functional group there 
seems to be a specific trend among the hits for the hydroxyl group at C2 
and C3 positions. For instance all the hydroxyl groups in D-galacturonate 
have exactly the same configuration as D-galactose (C2 up and C3 down 
for hydroxyl group), similarly in case of D-Ribose the hydroxyl groups at 
C2 and C3 are in agreement with D-galactose. Interestingly there is a 
visible preference of hydroxyl group in up configuration at C2 position in 
majority of the hits by making two H-bond interactions with the Asn310 of 
the enzyme (Figure 4.9). This has previously been reported in the 
modeled structure of XR with xylose {136}. 
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Figure  4.10 Configuration of  Hydroxyl groups on C2 and C3 of the majority of hits in 
the active site of XR(H-bond interactions are highlighted through yellow dots 
between hydroxyls of C2,C3 and N and O of Asn310, certain amino acid residues are 
removed for clarity,image created by using DSV) 
 
8) The hits obtained including certain aldo-pentoses such as D-Adipose and 
aldo-hexoses such as D-Allose, D-Fucose and D-Quinovose showing the 
same alignment as D-galactose and can be the potential substrate of the 
enzyme. This can be confirmed through the establish enzyme assay. From 
the work by neuhauser et al {138} which describes the relative activity of 
certain substrates e.g; that XR prefers glyceraldehyde, D-erythrose and 
even some aliphatic and aromatic aldehydes on pentose sugars such as D-
xylose and L-Arabinose. The higher activity of the enzyme against 3-C and 
4-C sugars is further supported by the fact that as there are more chances 
of hydration of 3-C and 4-C open chain sugars in comparison to the 
pentoses and hexoses (which tend to cyclise and have lesser chances to 
get hydrated, and thus the relative concentration of the open form is 
reduced). The lower activity of the enzyme against pentoses and hexoses 
can also be due to the absence of any mechanism by which the ring form 
of the compound goes to the active site and then converted to open chain 
form and further converted to product. This further shows that why the 
enzyme may have slow activity against these compounds. The higher 
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activity for small chain sugars could be due to the provision of higher 
number of H-bond interactions and thereby increasing their stability and 
recognition in the active site of the enzyme. From the specific orientation 
of majority of  hits in the active site obtained through pharmacophore 
seraching,  it may not be wrong to suggest that the binding mode  and 
activity of the substrates towards the enzyme active site is driven by the 
concentration of free aldehyde-form (open chain form) along with the 
activity of the chemicals (chemical features of the compound: H-bond 
donor & acceptor interactions). 
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5. Shikimate kinase form Mycobacterium 
tuberculosis 
Shikimate kinase (SK; EC 2.7.1.71) is the fifth enzyme in the chorismate and 
shikimate biosynthetic pathway and catalyses the specific phosphorylation of the 
3-hydroxyl group of shikimate to 3-phospho shikimate (Figure 5.1) in the 
presence of ATP as a co-substrate {96, 142}. In shikimate pathway, initially 
erythrose-4-phosphate is converted to chorismic acid in seven steps. Further 
chorismic acid is subsequently utilized for the biosynthesis of aromatic 
compounds such as  p-amino benzoic acid, folate, ubiquinone and  aromatic 
amino acids i.e.; tryptophan, phenyl alanine and tyrosine {143}. The shikimate 
pathway is of crucial significance in the metabolism of algae, fungi, bacteria and 
higher plants, but it absent in mammals. Among humans, Infectious diseases are 
the leading cause of deaths in the world and it has been learned that 90% of 
these deaths are connected with microorganisms. Among them Mycobacterium 
tuberculosis has the highest death ratio in comparison to other infectious agents 
{144} and this makes  M.Tuberculosis SK (SK) a promising target for the 
development of non toxic novel anti-M.Tuberculosis drugs. 
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Figure  5.1 Conversion of shikimate to 3-phosphoshikimate by SK with ATP as cosubstrate 
 
High resolution X-ray structures of SK with ADP and shikimate bound (PDB 
code:1U8A) {78} and one without shikimate (PDB:1LY4) {143} have been 
determined. The comparison of the two structures shows that the structure 
undergoes induced fit movement on substrate binding and conformational 
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changes occur particularly in the binding and lid domain of the structure after 
substrate binding. 
5.1 Pharmacophore searching for SK 
The SK was chosen for pharmacophore searching method based on the following 
points. 
1. Availability of high resolution structures 
2. Availability of both ligand bound and unbound structures 
3. Flexibility/modification in the structure especially in the active site 
4. Single substrate specificity 
So we were interested in seeing whether the pharmacophore searching method 
could identify the substrate based on interactions within the active site from the 
substrate bound structure and ultimately the substrate free case. 
5.2 Aims and objectives  
The aims of this test case included the following points 
1. To find out the optimum number of interactions needed to be used to 
reduce the number of hits to a manageable level 
2. To compare the pharmacophore interactions and hits obtained among 
the substrate bound  and unbound structures 
3. To differentiate the vital  interactions in the active site in the absence 
and presence of  substrate 
4. To identify  parameters and interactions that need to be optimized to 
retain shikimate among the hits 
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5.3 Generation of Pharmacophore 
Different operations were carried out for the generation and optimization of 
pharmacophore by using Accelrys Discovery Studio Visualizer® and Accelrys 
Catalyst® for database search. Naturalism database was used through out the 
search. The pharmacophore models were generated by using the DSV, Vector 
method as described in section 3.5.2. The H-bond donor and acceptor vectors 
were interconverted at various stages during the generation of pharmacophore 
models by editing the details of the .chm file in a text editor. In brief different 
approaches were used to explore the outcomes in the form of hits. These 
approaches included introduction of hydrogen bond donor and acceptor vectors, 
decrease and increase in the size of uncertainty location spheres around the 
head and tail of the hydrogen bond vectors and changing the radius around the 
active site for the introduction of exclusion sphere. Further details of 
subsequent steps and their outcomes are given in table 5.1. Figure 5.2 shows the 
solid ribbon diagram of SK (PDB: 1U8A) along with the co-factor ADP and product 
DHS forming important H-bonds with the active site residues. 
 
Figure  5.2 Solid ribbon diagram for SK along with ADP and DHS in the active site, forming 
Hydrogen bonds with the active site residues of the enzyme. 
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5.4 Pharmacophore generation via holo-enzyme  
In the initial stages the holo-form of the enzyme structure (PDB code: 1U8A) was 
used for the generation of pharmacophore. All the pharmacophores produced 
through this structure were totally from the ligand (substrate) perspective. H-
bond donor and H-bond acceptor vectors were introduced on the basis of 
possible interactions between the ligand and protein. The resultant 
pharmacophores were then subjected to database search. The step wise details 
for each pharmacophore are given below: 
5.4.1 Pharma Holo 1 
The first pharmacophore was generated by defining all the possible interaction 
in terms of the H-bond interactions provided by the shikimate. In total 4 H-bond 
acceptor vectors were introduced, 2 from the carboxylate group of C7 of 
shikimate towards the guanidinium group of ARG136 and 2 from hydroxyl groups 
of C3 and C5 of shikimate towards the amino end of GLY80 and water molecule 
respectively. An additional single H-bond donor vector was introduced from 
hydroxyl group of C4 of shikimate towards the carboxylate of ASP34. 
Most of the hits obtained as a result of this pharmacophore were correct. The 
hits included both the reactants (shikimate) and products (shikimate phosphate) 
of the actual shikimate kinase reaction (Figure 5.2). 5 of the hits were phoso-
shikimate compounds (which is the product in the actual reaction). Some of the 
carbohydrates were also included in the hits possibly because of their flexibility 
to fit in and satisfy the pharmacophore. Among hits, some of the carbohydrates 
had their phosphate group oriented toward the carboxylate of the shikimate. 
This highlighted the need to define a chemical group such as a carboxylate at 
this position in the pharmacophore to avoid the false hits. 
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Figure  5.3 The hits obtained include both the shikimate and shikimate phosphate and their 
derivatives in the same orientation as described in the X-ray structure of holo-form of SK 
(Greeen Vector = Hydrogen bond Acceptor, Purple Vector =  Hydrogen bond donor) 
 
5.4.2 Pharma Holo 2 
In order to avoid the steric clash of the hits with the water molecule, an 
exclusion sphere was introduced around the water molecule providing H-bond 
acceptor interaction from the hydroxyl group of C5 of shikimate (Figure 5.2). 
The resultant search gave hits which did not include carbohydrates like D-
fuconic acid, D-galactonate, D-galactonic acid. The mentioned compounds were 
not selected possibly due to the clash between the hydroxyl group of these 
compounds with the exclusion sphere around the water molecule (Figure 5.3). 
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Figure  5.4 the introduction of exclusion sphere around the water molecule leads to lose 
some hits due to possible steric clash (the compounds shown were not selected among the 
hits). 
 
5.4.3 Pharma Holo 3 
In order to further avoid the false hits an additional constraint was added by 
introducing an exclusion sphere around a water molecule lying between 
shikimate and GLU61. This resulted in reducing the number of hits from 14 to 10. 
It appeared that the compounds like L-idonic acid and L-idonate were not 
selected because their hydroxyl groups at C3 position was in direct clash with 
the exclusion sphere of the water molecule (Figure 5.4). 
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Figure  5.5 The hydroxyl group of the hit (L-idonic acid) in direct clash with the exclusion 
sphere of the water molecule close to GLU61, the image position has been re-oriented for 
viewing purposes (the image has been reoriented for viewing purposes). 
 
5.4.4 Pharma Holo 4-5 
To explore the critical interactions and their effects in the form of different hits 
the H-bond acceptor vector pointing from C3 hydroxyl group of shikimate 
towards GLY80 was changed to H-bond donor vector. As a result the donor vector 
now pointed towards the carboxylate group of ASP34. The resulting hits were 
reduced to 4, including shikimic acid, shikimate, D-erythritol 4-phosphate and D-
arabinose 5-phosphate. The phosphate groups of the two compounds were 
oriented towards the carboxylate group of shikimate. However, the product 
shikimate phosphate was lost. The results from the pharmacophore indicated 
that the constraints were too strict in some ways. Further the size of uncertainty 
location spheres for the atomic positions was far too small to be practically 
useful which needed to be relaxed. However, the pharmacophore exhibited the 
type of H-bond interaction vectors required to get the minimum number of hits 
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along with the true substrate. The H-bond donor interaction from the hydroxyl 
group of C3 of shikimate was not very fruitful therefore in Pharma Holo 5 the 
pharmacophore model was reverted back to Pharma Holo 3 model. The angle 
and direction of the H-bond vectors were optimized to point exactly toward the 
target atom. 
5.4.5 Pharma Holo 6 
In order to explore the critical interactions in the active site of the shikimate 
kinase, H-bond interactions were removed from the hydroxyl groups of C3 and 
C4 of the shikimate. Further the H-bond acceptor interaction from the 
carboxylate group of C1 of shikimate was changed to a H-bond donor, thus 
pointing towards guanidinium group of ARG58 instead of ARG136. The 
orientation of H-bond acceptor vector originating from the hydroxyl groups of C5 
of shikimate was optimized, so that it pointed towards carboxylate group of 
ASP34 instead of a water molecule. The radius of the uncertainty locations 
spheres around the blobs of tails and heads of the H-bond vectors was changed 
to 0.6Å and 0.3Å respectively (Figure 5.5). The numbers of hits obtained were 
suddenly increased to 290, showing that a lower number of constraints leads to a 
higher number of hits from the database search. 
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Figure  5.6 Three H-bond interactions, one donor and one acceptor from the shikimate 
carboxylic group toward Arg136 and Arg58, and one acceptor from C4 hydroxyl group 
toward Asp34 (the image has been reoriented for viewing purposes). 
 
5.4.6 Pharma Holo 7 
Further optimization of the pharmacophore was carried out by changing H-bond 
acceptor vector to H-bond donor vector pointing from C5 hydroxyl group of 
shikimate towards the carboxylate group of ASP34. Along with it the H-bond 
donor vector was converted to H-bond acceptor vector pointing from carboxylate 
group of shikimate towards the guanidinium group of ARG58. The 
pharmacophore hits were further increased to 437, demonstrating that fewer 
interactions to act as constraints result in more hits which can satisfy them. 
5.4.7 Pharma Holo 8 
In order to reduce the number of hits without losing the true substrate, the 
pharmacophore model was reverted back to Pharma Holo 6 model. The 
pharmacophore was edited by the introduction of H-bond acceptor vector from 
the C4 hydroxyl group of shikimate towards the carboxyl end of ASP34. Radius of 
uncertainty location sphere around the vector tail and head were set to 0.3Å and 
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0.6Å respectively. Though the numbers of hits were reasonably reduced to 87 
but the hits did not include shikimate, showing that the inclusion of exclusion 
sphere around the water molecule and/or the inclusion of new H-bond acceptor 
vector in the pharmacophore are not suitable for selection of shikimate as a hit. 
5.4.8 Pharma Holo 9-10 
The whole model was kept the same as Pharma Holo 8 model, except the radius 
of uncertainty location spheres around the blobs of tails and heads of H-bond 
vectors (both acceptors and donors) was changed from 0.6Å to 0.3Å (Figure 
5.6A). The pharmacophore resulted in 4 hits without shikimate, showing that not 
one but two H-bond acceptor vectors pointing towards the guanidinium group of 
Arg136 are vital for recognition of true substrate  (as shown in Pharma Holo 3). 
Later on in Pharma Holo 10 the radius of uncertainty location spheres around the 
blobs of heads and tails of H-bond vectors (both acceptors and donors) was 
changed back to 0.6Å (Figure 5.6B). 
 
Figure  5.6 The radius of the uncertainty location spheres both around the head and tail of 
the H-bond vectors is 0.3Å in A and 0.6Å in B 
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5.4.9 Pharma Holo 11-14 
Further optimization of the pharmacophore was carried out by changing the 
radius of the uncertainty location sphere for H bond vectors (both acceptors and 
donors). The radius around the blobs head pointing towards the amino acid end 
were fixed to 0.6Å and for the blob tail originating from the ligand end were 
changed from 0.6Å to 0.3Å (Pharma Holo 11). Later on in Pharma Holo 12 the 
radius was further changed from 0.6Å to 0.8Å for the blob head and in Pharma 
Holo 13 the radius around the blob tail of H-bond vectors was changed from 0.3Å 
to 0.35Å. The relaxation in the radius caused significant increase in the number 
of hits as shown in table 5.1. The pharmacophore models from Pharma Holo 7 to 
Pharma Holo 13 had a H-bond acceptor interaction pointing from the carboxylate 
of shikimate towards the guanidinium group of Arg58 and none of these 
pharmacophores were able to pull out shikimate as a hit from the database, but 
as soon as in Pharma Holo 14 model this H-bond acceptor interaction is directed 
toward the guanidinium group of Arg136 instead of Arg58, the pharmacophore 
readily selects shikimate as a hit. This showed that interactions provided by the 
Arg136 in the pharmacophore search model are vital for the recognition of true 
substrate among the hits via database search. 
 
5.4.10 Pharma Holo 15-16 
Keeping in all the constraints same as in Pharma Holo 14 model, only the radius 
of uncertainty location spheres around the blob head of  both H-bond acceptor 
and donor vectors was  changed from 0.8Å to 0.6Å. This change still kept the 
shikimate among the hits, thus exhibiting the validity of the pharmacophore. To 
check the requirement of the optimum radius for uncertainty location spheres 
around the blob head of H-bond vectors (both acceptors and donors) the radius 
was further reduced to 0.4Å in Pharma Holo 16. This resulted in losing shikimate 
as a hit, demonstrating that higher stringency in constraints in terms of smaller 
radius of the uncertainty location sphere would lose the true substrate through 
the database search. 
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5.5 Apo-enzyme for pharmacophore generation 
By going through various optimization stages of generating pharmacophore by 
using the holo-enzyme structure, it became obvious that certain optimized 
constraints are crucial and need to be in the pharmacophore model for selection 
of true substrate among the hits. Keeping in view these constraints the 
pharmacophore was generated by using the apo-structure of the enzyme (PDB 
code: 1L4Y). The pharmacophore models were generated by using the DSV, 
Vector method as described in section 3.5.2. During the course of optimization 
various pharmacophore models were generated by using the apo-structure of the 
enzyme, further details are given below. 
5.5.1 Pharma Apo 1 
Keeping in view the vital interactions offered by certain amino acids in the 
active site, in the initial pharmacophore 2-H bond acceptor vectors were 
introduced towards the guanidinium group of ARG136 and 1 H-bond donor vector 
pointing from a water molecule towards the carboxylate group of ASP34 (Figure 
5.7). The hits (≥300) included shikimate showing that the H-bond interactions 
from Arg136 and Asp34 are vital for substrate recognition. 
 
Figure  5.7 The generation of pharmacophore by using the apo-structure (PDB code: 1L4Y) 
Arg136 and Asp34 are shown as stick models with the corresponding H-bond acceptor 
(green arrows) and donor (purple arrows) vectors respectively. 
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5.5.2 Pharma Apo 2 
Further to the Pharma Apo 1 model, the radius of the uncertainty location 
spheres around the blob of tail of the vectors originating from the potential 
ligand side were changed from 0.6Å to 0.35Å. This stringency in the constraint 
still held the true substrate (shikimate) among the hits (≥300).  
5.5.3 Pharma Apo 3 
To further probe the important interaction provided by the active site of the 
enzyme, an additional H-bond acceptor vector was added from the carboxylate 
end of Asp34 (Figure 5.8). This additional interaction fitted well in the 
pharmacophore and reduced the number of hits (123) without losing the true 
substrate (shikimate). 
 
Figure  5.8 Pharmacophore generated by using the apo-structure (PDB code: 1L4Y) with the 
additional H-bond acceptor interaction (green arrow) originating from the carboxylic group 
of Asp34. 
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Table  5.1 Total number of constraints used in each pharmacophore model, along with 
quantity of hits in each case and time taken for database search (table shows the presence 
of the true substarte (shikimate) among the hits in each pharmacophore model search). 
 
Pharmacophore 
model 
Total 
number of 
constraints 
Number 
of hits 
obtained 
Database 
search time 
(minutes) 
Shikimate 
among the hits 
(Yes/No) 
Pharma Holo1 6 18 35 Yes 
Pharma Holo 2 7 14 25 Yes 
Pharma Holo 3 8 10 50 Yes 
Pharma Holo 4 8 4 20 Yes 
Pharma Holo 5 6 18 35 Yes 
Pharma Holo 6 4 290 20 Yes 
Pharma Holo 7 4 437 10 Yes 
Pharma Holo 8 6 83 18 No 
Pharma Holo 9 6 4 13 No 
Pharma Holo 10 6 209 47 No 
Pharma Holo 11 6 38 20 No 
Pharma Holo 12 6 53 28 No 
Pharma Holo 13 6 89 36 No 
Pharma Holo 14 6 110 28 Yes 
Pharma Holo 15 6 75 19 Yes 
Pharma Holo 16 6 25 20 No 
Pharma Apo 1 4 ≥300 55 Yes 
Pharma Apo 2 4 ≥300 10 Yes 
Pharma Apo 3 5 123 45 Yes 
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5.6 Conclusions 
The course of optimization of pharmacophores for SK structure both with and 
without the substrate bound form demonstrates that certain interactions are 
vital for the selection of shikimate to come out as a hit. Based on the results 
obtained through optimization of various pharmacophore the following 
conclusions can be drawn:  
1) In case of the pharmacophore generation, when using the substrate bound 
structure the Pharma Holo 4 demonstrates the minimum required number 
of constraints for the limitation of hits to a minimum number with 
shikimate present as a hit. It appears that the vital interactions include 
the two H-bond donor vectors pointing towards the ASP34 and 3 H-bond 
acceptor vectors, 2 pointing towards the guanidinium group of ARG136 
and one towards the water molecule (Figure 5.9).  
    
Figure  5.9 Crucial interactions required for the selection of shikimate as a hit from 
the database, when using the substrate bound structure for the generation of 
pharmacophore, two H-bond donor interactions(in magenta) towards the 
carboxylate of ASP34,and three H-bond acceptor interactions(in green),two towards 
the guanidinium group of ARG136 and one pointing towards the water 
molecule,shikimate structure is highlighted with yellow dots(exclusion and 
uncertainty  spheres are removed for clarity purposes)  
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2) In case of using the apo structure of the enzyme, the crucial interactions 
required for the selection of shikimate among the hits include the H-bond 
donor interaction pointing towards the carboxylate group of the ASP34 
and 2 H-bond acceptor interactions pointing towards the guanidinium 
group of ARG136. This can be noticed in the course of optimization of the 
pharmacophore models in Pharma Apo 1,2 and 3 and  also depicted in 
figure 5.10 
   
Figure  5.10 Crucial interactions required for the selection of shikimate as a hit from 
the database, H-bond donor interaction(in magenta) towards the carboxylate of 
ASP34,and two H-bond acceptor interactions(in green)towards the guanidinium 
group of ARG136(exclusion and uncertainty  spheres are removed for clarity 
purposes)  
3) By comparing the two pharmacophores generated separately from the 
substrate bound structure and the apo form of the enzyme, it seems 
obvious that the ARG136 and ASP34 are crucial in providing the H-bond 
interactions for the recognition and stabilization of the shikimate within 
the active site and for the transfer of phosphate group to it. 
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4) It appears from the optimization of the pharmacophore searching that the 
size of the uncertainty location spheres around the H-bond head and tail 
is important in the selection of the true substrate as a hit. The 
optimization of pharmacophore during Pharma holo 15 & 16 indicates that 
the optimum radius of the uncertainty location spheres should be 0.6Å 
towards the blob head end and 0.3Å towards the blob tail end to avoid 
losing the true substrate (shikimate). 
5) It appeared that the problem with shikimate kinase apo structure was 
that, key main chain interactions are not evident without knowledge of 
the ligand bound structures and therefore restricting the number of hits 
was a problem. The inability at this stage in the project to define 
chemical groups also resulted in obvious false miss hits that polluted the 
solution results.  
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6. The Escherica coli protein TdcF, Pdb code: 2UYN  
6.1 Introduction 
The E. coli protein TdcF is a member of the highly conserved     
YjgF/YER057c/UK114 family of proteins, found in euarchea, higher plants and 
prokaryotes. The protein is widespread in nature but as yet has no clear 
biological function. The tdc operon shows the presence of tdcF gene among 
other genes like tdcC whose product is L-threonine/L-serine permease. On the 
basis of binding interactions of some of the analogues of TdcF with keto acids 
and the co-crystallized structure of TdcF with 2-ketobutyrate (Figure 6.1), its 
novel role in the metobilism of 2-ketobutyrate and in turn L-Ile biosynthesis has 
been suggested {145}. To date no binding data is available for TdcF to show 
weak or tight binding against different ligands. 
 
Figure  6.1 Representation  of the sequence of genes on the   tdc operon on the  E-coli 
chromosome and the function of the corresponding gene products,  along with the 
pathways for degradation of L-threonine and L-serine, (A) tdc operon, (B) L-threonine 
anaerobic degradation pathway, and (C) L-serine degradation pathway, Ack = acetate 
kinase; PFL= pyruvate formate-lyase; PTA = phosphotransacetylase. Image adapted from 
{145}. 
 
 The crystal structure of TdcF alone and in complex with a number of ligands has 
been solved by Lawson and co workers {145}. This confirms that the protein has 
a chorismate mutase like fold and exists as a homotrimer (Figure 6.2). There are 
large intersubunit clefts in which the ligands are bound within a well defined 
cavity. No catalytic activity has been ascribed to any member of this protein 
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family. It has been suggested on the basis of structural genomics and structural 
characteristics that 2-ketobutyrate is the best binder to the active site among 
other low molecular weight compounds {145}. 
 
Figure  6.2 Line ribbon diagram/model of TdcF protein, showing the binding site in zoom, 
image adapted from {145}. 
 
All the ligands in the x-ray structure leave a large empty part in the cavity of the 
active site with most of it occupied by water molecules (Figure 6.3). Therefore 
the protein was chosen as a test candidate to find out the potential ligands by 
using pharmacophore searching. This might reveal other potential ligands which 
could occupy more fully the binding cleft, and which could answer certain 
questions like  
1)  If there is a possibility of binding of a larger ligand? 
2)  If a second potential ligand/cofactor can fit in?  
3)  If the binding site confers potential capability of protein-protein 
interactions?  
All these queries make 2UYN a good test case and the availability of ligand 
binders means that the binding of potential ligands using different biophysical 
techniques can be evaluated. Finally the presence of different ligands structures 
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can significantly help to describe the potential ligand binding interactions for 
pharmacophore modeling. 
 
Figure  6.3 Binding site of the protein showing the interactions with 2-ketobutyrate. (A large 
part of the binding pocket is occupied by water molecules), W = Water molecules, image 
adapted from {145}.   
 
6.2  Generation and Optimization of pharmacophore for 
TdcF 
A number of different pharmacophore models were developed as we learned 
what would make an effective pharmacophore given the limitations of the 
methods available. The different models and steps taken are given below: 
6.2.1  Pharma TdcF 1 
First pharmacophore was designed by using Cerius 2 and Weblab Viewer Pro 
programs as described in section 3.5.1. By using the TdcF X-ray structure water 
molecules and the ligand were removed from the active site. Hydrogens were 
generated for all the atoms within a radius of 14.0Å around the binding site by 
using the program Cerius2 {69}. Exclusion spheres were generated for all the non 
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hydrogen atoms and an interaction map was calculated. From this interaction 
map, individual interactions were chosen to represent hydrogen bond donors and 
acceptors which were consistent with the main interactions seen in the protein-
ligand structure {145}. Initially three hydrogen bond acceptor vectors (green) 
and 1 hydrogen bond donor vector (purple) were introduced (Figure 6.4). Out of 
3 hydrogen bond acceptor vectors, 2 were introduced from the basic 
guanidinium group of the Arg105 and 1 hydrogen bond acceptor vector was 
introduced from the peptide nitrogen of the GLN32 and ILE 33 peptide bond. The 
only H-bond donor vector was introduced from the carboxyl oxygen of the GLY31 
(Figure 6.4). The exclusion spheres were introduced around 10Å radius of the 
binding site to prevent the direct space clash between the protein and potential 
hits. The size of uncertainty spheres around H-bond vectors was kept 2.2Å 
towards the protein end and 0.6Å towards the ligand end.  
 
Figure  6.4 Pharamcophore with 3 H-bond acceptors and 1 H-bond donor vector  pointing 
towards the amino acid residues(yellow dotted structure) in the binding site with some of 
the hits obtained from the database search (exclusion spheres are removed for clarity) 
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Figure  6.5 The initial pharmacophore generated, with hydrogen bond acceptors (green) and 
a hydrogen bond donor (magenta), exclusion spheres are shown as gray spheres.  
 
The generated pharmacophore was searched against a multi-conformational 
library of metabolites (Naturalism database with 5492 small ligands) by using the 
Catalyst program (Accelrys). The search resulted in 178 potential ligands which 
satisfied the restraints and H-bond features as defined in the pharmacophore 
model.  The ligands could be compared not only to the pharmacophore but also 
to the original crystal coordinates. This allowed further refinement and 
optimization of the pharmacophore positions using WebLab Viewer Pro 
(Accelrys). The numbers of hits obtained from the naturalism data base were 178 
and search time was 123 minutes 
 
6.2.2  Pharma TdcF 2 
The hits obtained from first pharmacophore showed that most of the hits with 
their side chains were at H-bond distance from the carboxyl oxygen of the 
ARG105. Among the hits least H-bond interactions were seen for GLY31 .Two 
changes were carried out, first the size of the uncertainty spheres around the H-
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bond vectors towards the protein end was changed from 2.2Å to 1.2Å, and 
secondly the position of H-bond donor was changed from GLY31 to the carboxyl 
oxygen of the ARG105. The naturalism database search gave 65 hits in 27 
minutes. 
6.2.3 Pharma TdcF 3 
Most of the hits obtained from the previous model were a bit short of H-bond 
distance and in some cases the atoms of the hits were not exactly pointing 
towards the tail of hydrogen bond vector (Figure 6.6). Therefore for the two 
hydrogen bond acceptors pointing towards ARG105, the x,y,z co-ordinates were 
optimized as described in section 3.5.1. The length of the H-bond acceptor 
vectors towards ARG105 was changed from 2.3Å to 3.0Å. The length of the H-
bond acceptor pointing towards the ILE33 was changed from 2.4Å to3.1Å. For H-
bond donor vector the length was changed from 2.4Å to 2.8Å. 88 hits were 
obtained from the database search in 77 minutes. 
 
Figure  6.6 showing the active site of the protein in web lab preview, with Gluconic acid as 
the ligand attached,with unoptimized  position of the left hand hydrogen bond acceptor 
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6.2.4 Pharma TdcF 4 
Based on the orientation of hits obtained, slight changes were carried out in this 
pharmacophore. The position of H-bond acceptor vector was moved forward so 
that the blob of the vector arrow head touched the peptide nitrogen of the ILE33 
and GLN32 (Figure 6.8). Additional constraint was added in the form of H-bond 
donor vector towads the carboxyl oxygen of the GLY31. Positions of the rest of 
the vectors were kept the same (Figure 6.7).Database search gave 53 hits in 
exactly 53 minutes. 
 
Figure  6.7 Pharmacophore with additional additional H-bond donor (labelled new) towards 
the carboxyl oxygen of GLY31, the position of H-bond acceptor (highlighted in yellow) 
moved more towards the peptide nitrogen of ILE33 and GLN32 (uncertainty spheres are 
removed for clarity viewing). 
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Figure  6.8 view of Protein binding site in web lab preview, showing Neuraminic acid with 
optimized position of the  hydrogen bond acceptor vector (green) towards the left hand side 
6.2.5 Pharma TdcF 5 
The hits obtained from previous pharmacophore were not satisfying the 
pharmacophore constraints, therefore the two H-bond donor and one H-bond 
acceptor (towards ILE33 and GLN32) were removed. By looking at the binding 
mode in the co-crystallized structure {145} and the 3D structure of the protein a 
new constraint in the form of  H-bond acceptor vector was introduced towards 
the CYS107 residue.  
6.2.6 Pharma TdcF 6 
On the basis of orientation of maximum hits obtained from previous 
pharmacophore, an H-bond donor vector was placed pointing towards the 
carboxyl oxygen of GLY31. H-bond acceptor vector towards the CYS107 was 
removed. Another H-bond acceptor vector pointing from the nearby crystallized 
water molecule towards the peptide nitrogen of ILE33 and GLN32 was 
introduced. 
6.2.7 Pharma TdcF 7 
Hits from previous pharmacophore showed that the H-bond acceptor vector 
pointing towards the ILE33 and GLN32 is not of critical importance therefore was 
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removed. H-bond acceptor vector was introduced towards the peptide nitrogen 
of the CYS107. The two H-bond acceptor vectors towards the guanidinium group 
of ARG105 were kept at the same position. 
6.2.8 Pharma TdcF 8 
This time instead of using Cerius 2 and weblab viewer pro the pharmacophore 
was generated by using the DSV, Vector method as described in section 3.5.2. A 
total of 3 constraints were introduced in this pharmacophore. To increase the 
stringency on the constraints the radius of uncertainty/location spheres was 
decreased from 1.2Å to 0.8Å for the H-bond vector arrow heads and from 0.4Å to 
0.35Å for H-bond vector arrow tail. H-bond acceptor pointing towards the 
CYS107 was removed and an H-bond donor vector was introduced pointing 
towards the carboxyl oxygen of the CYS107.  
6.2.9 Pharma TdcF 9 
This pharmacophore comprised of 4 constraints, 3 constraints were the same as 
in the previous pharmacophore. An additional constraint in the form of 
hydrophobic point was introduced in the hydrophobic pocket of the binding site 
which is mostly occupied by the crystallized water molecules (Figure 6.9).  
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Figure  6.9 Pharmacophore with additional Hydrophobic point (blue blob) in the hydrophobic 
pocket mostly occupied by water molecules(red stars) , the amino acid residues ILE33,ILE14 
and PRO11 can be seen(highlighted with yellow dots) (exclusion spheres are removed for 
clarity). 
 
Initial screening of TdcF as a search model gave a number of convincing hits 
which fit the active site cleft. In comparison to other ligands Neuraminic acid 
seemed to make interactions with the best geometry and filled the active site 
cleft.  This compound with other known ligands was tested experimentally for 
binding studies. 
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Table  6.1 Various pharmacophore optimization stages, the corresponding number of hits, 
and the database search time in minutes for TdcF (For optimization stage 1-8 Naturalism 
database was used, while for optimization stage 9-13 Che EBI database was used, similarly 
from optimization stage 1-7 Cerius 2 and Weblab viewer pro softwares were used, while for 
optimization stage 8-13 DSV® was used. 
 
Optimiza
tion stage 
Operation parameters Number 
of hits  
search time 
(minutes) 
1 3 hydrogen bond acceptor vectors, 1 
hydrogen bond donor vector  
178 123 
2 Change in size of uncertainty spheres, 
Change in position of H-bond donor  
65 27 
3 Change in position and length of H-bond 
vectors  
88 77 
4 Addition of H-bond donor vector and slight 
change in position of one of H-bond acceptor 
53 53 
5 Removal of two H-bond donors and one H-
bond acceptor along with the addition of a 
H-bond acceptor at a new point 
300 12 
6 H-bond donor towards GLY31 and H-bond 
acceptor towards GLN32 and ILE33 
1 1 
7 Removal of H-bond acceptor from GLN32 and 
introducing towards CYS107 
300 2 
8 Removal of H-bond acceptor and addition of 
H-bond donor towards CYS107, along with 
decrease in radius of the uncertainty spheres 
around the head and tail of the vectors 
300 26 
9 Addition of constraint in the form of 
hydrophobic point 
50 77 
10 Introduction of query feature ligand with 
multiple atoms assigned to the same query 
atom 
234 4 
11 Specifying  C2-O3 contact as double bond in 
the query 
95 3 
12 specifying  C2-C3 contact as double bond 
and C2-O3 contact as single bond along with 
the addition of H-atom to O1 and O3,  
6 3 
13 Changing C2-C3 contact as single bond and 
removal of H-atoms from O1 and O3  
240 3 
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6.3 Expression and Purification of TdcF: 
At the same time as we performed the in-silico screening of TdcF, we requested 
the plasmid for the protein from Prof.Dr.Gary Sawers, Martin-Luther University 
Halle, Germany. The requested plasmid of the protein was received later on. 
This allowed the purification of the protein to permit the assessment of a 
number of biophysical techniques for measuring the ligand binding.  
 
The pET-FG plasmid for the protein was transformed in to BL21 (DE3) cells and 
expressed in auto induction media (for co-crystallization purposes) and in 15N 
labelled M9 media (for NMR experiments). The N-terminal His tagged protein was 
purified by using Nickel affinity chromatography (Figure 6.10). By using Amicon® 
concentrator (with a MWCO of 5KDa) the protein was simultaneously 
concentrated and buffer exchange in to cleavage buffer (20mM Tris-HCl, 150mM 
NaCl pH: 7.5) to get rid of imidazole. To remove the Histidine tag thrombin 
cleavage was carried out by adding thrombin to the protein as per manual 
(Thrombin kits, User protocol TB188, Novagen). The protein was then purified by 
passing through benzamidine sepharose column to get rid of thrombin. Thrombin 
cleavage was confirmed by running SDS-PAGE on pre and post cleaved samples 
(Figure 6.11). The final purification step was attained by loading the protein 
onto sephadex 75 gel filtration column using AKTA® (Figure 6.12) 
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Figure  6.12 Chromatogram image for TdcF after passing through Sephadex 75 gel filtration 
column. 
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Figure  6.11 SDS gel image for 
TdcF after thrombin cleavage Key: 
1 = Marker, 2 = Protein with His 
Tag, 3 = Protein without His Tag   
4 = Marker 
 
Figure  6.10 SDS gel image for 
TdcF after passing through Nickel 
column. Key: 1 = Marker, 2 = Flow 
through, 3 = Wash1, 4 = Wash2, 5 
= Elute    
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Figure  6.13 SDS gel image for TdcF fractions obtained from gel filtration chromatography (1 
= marker, 2-13 = TdcF eluted fractions) 
6.4 Ligand binding experiments against known ligands  
6.4.1 DSC Experiments 
Differential Scanning Calorimetry (DSC) experiments were carried out for TdcF 
against different ligands to detect binding. Normally binding can be measured 
using Isothermal titration calorimetry (ITC) but for weak binding (Kd, dissociation 
constant values in the micromolar to millimolar range) the ITC method is not 
particularly sensitive and requires significant amounts of protein to obtain any 
results. DSC experiments were carried out with the expectation that ligand 
binding will stabilize the thermal unfolding of the protein and thus resulting in 
an increase in Tm (transition mid point temperature).  
 
The protein and ligand samples were degassed prior to loading. The rate of 
increase of temperature was 1°C/minute, with a temperature range from 15°C-
100°C.  The concentration of protein used was 71.4µM (1mg/mL) and the 
concentration of ligands used was 1mM. The ligands used were Pyruvate and 
Lactate. As TdcF structure contains two cysteine residues per monomer, one 
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partially buried and the 2nd one surface exposed therefore Dithiothreitol (DTT) 
was added to the buffer to prevent the formation of disulphide bonds between 
the cysteine residues. Protein aggregation problems were encountered when 
performing the experiments with the presence of a reducing agent in the buffer. 
In the beginning the presence of DTT in the buffer (20mM Tris, 0.5mM DTT, pH: 
7.8) caused aggregation problems. The resultant DSC scans for the protein, both 
with and without ligand were irregular (Figure 6.14) 
  
Figure  6.14 Abnormal DSC graph in the presence of DTT in the buffer, the irregular pattern 
of 2UYN (TdcF) can be observed both with and without ligands  
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Later on with the removal of DTT from the buffer normal DSC scans were 
obtained. The DSC scans of protein with and without DTT showed that the Tm of 
the protein in the presence of DTT is around 85°C, while in the absence of DTT 
the Tm goes down to around 65°C which might be because of the binding of DTT 
to the protein and stabilizing the native fold. In case of ligands, the addition of 
both pyruvate and lactate, no significant change in the Tm of the protein was 
observed (Figure 6.15). The DSC results suggested that either there is no binding 
at all or very weak to be observed through DSC experiments.  
                
Figure  6.15 Normal DSC scans for 2UYN (TdcF) in the absence of DTT in the buffer, no 
significant changes in Tm are visible after the addition of different ligands (Pyruvate, 
Lactate). 
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6.5 Circular Dichroism (CD) Experiments 
The results obtained from DSC were not helpful in identifying the binders 
therefore CD experiments were carried out in the near and far UV region. The 
CD spectrum for the native protein gave clear sharp peaks in the near UV region 
(250nm-300nm). The near UV spectrum (Figure 6.16) showed the secondary 
structure of the protein corresponding to the aromatic amino acids like 
tryptophans (285nm-295nm), tyrosines (275nm-285nm) and phenylalanine 
(265nm-275nm). The CD experiments were carried out to test if the addition of 
various ligands causes any significant changes in the secondary structure of the 
protein. The ligands used were N-acetlyl neuraminic acid, threonine, lactate, 
alanine, pyruvate and serine. No significant shifts were observed in the near UV 
spectra of protein upon the addition of the ligand (Figure 6.17) except pyruvate 
which conferred a slight shift in the spectra (Figure 6.18). The subtle change in 
the near UV spectrum (250-280nm) brought about by the addition of pyruvate 
might suggest a plausible change in the aromatic environment of the protein. 
The concentration of protein used in near UV and far UV CD experiments was 
96µM and 24µM respectively. The path length of the cell used for near UV and 
far UV experiments was 0.5cm and 0.02cm respectively. 20mM Tris, 0.5mM DTT 
pH: 8.0 buffer was used through out the experiments. The ligands stock solutions 
were prepared in the same buffer and the pH was adjusted to 8.0 
 
Figure  6.16 Near UV CD spectrum for TdcF alone 
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Figure  6.17 Overlaid near UV CD spectra of TdcF in the absence (blue) and presence of N-
acetyl neuraminic acid (green), DL-Threonine (black), L-lactate (pink) and DL-alanine (red)  
 
 
Figure  6.18 Overlaid near UV CD spectra for TdcF in the absence (blue) and presence of N-
acetyl neuraminic acid (red), Pyruvate (green) and DL-Serine (black), slight shift with 
pyruvate can be observed in the 250-280nm range of the spectrum  
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The Far UV spectra for the protein gave clear double minima around 208nm-
225nm corresponding to the α-helices in the protein. The addition of ligands 
caused no significant change in the far UV spectra (Figure 6.19 & 6.20)  
 
Figure  6.19 Overlaid far UV CD spectra for TdcF in the absence (blue) and presence of N-
acetyl neuraminic acid (green), DL-threonine (black), L-lactate (pink) and DL-alanine (red) 
 
 
Figure  6.20 Overlaid far UV CD spectra for TdcF in the absence (blue) and presence of L- 
lactate (green), L-serine (pink) and pyruvate (red), Protein = 24uM, ligand = 454µM). 
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6.6 NMR experiments 
The CD experiment results were not very encouraging to put light on the ligand 
addition effect therefore protein was further used for NMR (Nuclear Magnetic 
Resonance) studies. The protein ligand binding data was gathered by carrying 
out NMR titrations via HSQC (Hetero Nuclear Single Quantum Correlation) 
experiments. Kd values were determined for different ligands based on 
difference in the chemical shift values.  
 
6.6.1 NMR titrations 
Samples of pure 15N-labelled protein with a concentration of 25mg/ml in 20mM 
sodium phosphate buffer pH 7.5 were used for NMR titrations. A Bruker Advance 
600 MHz spectrometer equipped with triple resonance cryoprobe and gradient 
channel was used to record a series of 15N-HSQC spectra.  NMR sample for 
loading onto the spectrometer was prepared in the NMR tube by the following 
ratio: 
570µL (protein) + 30µLD2O+1µLdDTT (1M) = 601µL 
The extent of binding of ligands to TdcF was determined by monitoring the 
change in chemical shifts of HSQC cross-peaks as a function of the ligand 
concentration. To do this, a 0.71 mM solution of 15N-labelled TdcF in 20 mM 
sodium phosphate, 150 mM NaCl, and 1 mM DTT pH 7.5 buffer was titrated 
against the same sample containing ligand. Ligand addition was carried out by 
mixing pure protein sample with sample containing protein and maximum ligand 
The formula used to calculate the exchange volume is given below. 
 
The concentration of protein was confirmed through UV/Vis spectroscopy. The 
ligand solution was prepared in the same buffer as for the protein and the pH 
was adjusted. 
 
 
  (desired ratio — low ratio) 
(high ratio — low ratio) 
Volume to exchange =    total volume 
Chapter  6   145 
 
6.6.2 HSQC Spectra and Kd determination 
In a protein structure different Protons (H) attached to Nitrogen (N) in different 
amino acid residues have different chemical environment in the protein. They 
may be in close proximity to a hydrophobic residue or to a hydrophilic residue. 
Due to this specific chemical environment around each amide nitrogen and 
amide proton (corresponding to a specific amino acid residue) they acquire a 
specific chemical shift value which in turns leads to the appearance of individual 
peaks in a HSQC spectrum. The chemical shift values for specific amino acids can 
change due to the change in chemical environment around these residues. The 
change in chemical environment can be due to pH changes (causing protonation 
or deprotonation of certain amino acid residues) or due to the addition of ligand 
(causing change in the chemical environment or by direct contact). The spectra 
were processed by picking the cross peaks for amide nitrogen and amide proton 
of individual amino acid residues and then assigning chemical shift values to 
them. The changes in position of individual cross peaks were followed upon 
addition of ligand by using the CcpNmr Analysis v.2. program {146}. The changes 
were measured in the form of chemical shift differences. The values obtained 
from chemical shift differences were then entered in to a nonlinear fit (Eq: 1). 
The equation related the resonances in fast exchange between free and bound 
protein. The quadratic equation in terms of non-linear fit {147} used to calculate 
the Kd values for individual ligands is given below  
 
 
Where [ET] and [LT] are total concentrations of enzyme and ligand added, dΩi 
and dΩ are the chemical-shift differences between the observed and initial and 
final and initial resonances, respectively. The more simpler mathematical form 
of Eq:1 can be given in the form of Eq:2 as: 
 
Where Y= Chemicals shift change, A = maximum Chemicals shift change/2          
B= 1+Kd / [protein], X= Ligand/Protein 
Kd + [LT] + [ET] — √ {(Kd + [LT] + [ET]) 2 — 4 [LT] [ET]} 
∆Ωi = 
2[ET] 
∆Ω { Eq: 1 } 
Y = A { (B+X) — √ { (B+X)2 — 4X } } { Eq: 2 } 
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6.6.2.1 Tdcf  with 2-Ketobutyrate 
In the crystal structure of the protein it can be observed that the enol form 
(double bond between C2 and C3 and hydroxyl group at C2) of 2-Ketobutyrate 
binds in the binding site of the protein {145}. This indicates that 2-ketobutyrate 
fits in a more well defined manner within the binding site by satisfying all the H-
bond interactions including the hydrophilic and hydrophobic interactions. The Kd 
value calculated for 2-ketobutyrate was 204µM which is the lowest among all the 
other ligands. The tighter binding of 2-ketobutyrate indicates that the protein 
prefers the enol form on the keto form of the potential ligands. 
  
 
Figure  6.21 A series of overlaid 15N-HSQC spectra for TdcF with increasing 2-ketobutyrate 
concentration (Pink spectra is for protein alone, blue, red, orange and green spectra are at 
4, 8, 17 and 25mM ligand Concentration respectively). 
 
By observing the crystallization conditions for TdcF it appeared that the protein 
was crystallized at pH 8.0 {145}. It has been experimentally demonstrated that 
the pH is a major factor in altering the keto/enol equilibrium of pyruvate. The 
ratio of keto/“enol” becomes unity at pH 5.8 and decreases with increase in pH 
and vice versa; e. g., the keto form is approximately 10 at PH 4.8 and 0.1 at pH 
6.8 there fore it can be estimated that at pH 8 the keto form will be 0.01 {148}.  
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The pH crystallization conditions {145} and the pH dependant keto/enol 
equilibrium experiments {148} indicate that their is a higher proportion of enol 
form than the keto form at pH 8.0. Thus it gives a plausible explanation of 
tighter binding of 2-ketobutyrate (enol form) (Figure 6.21). 
O
O-O
2-ketobutyrate
O
O-HO
2-hydroxy butyrate
+H+
-H+
(Keto form) (Enol form)  
Figure  6.22 Equilibrium tautomers of the 2-ketobutyrate in keto and enol form 
 
6.6.2.2 Tdcf  with pyruvate  
The Kd value calculated for pyruvate was 7000µM. This indicated a 35 times 
weaker binding than 2-ketobutyrate (Kd = 204µM). It has been experimentally 
determined that both keto and enol forms of pyruvate can exist at equilibrium 
and at a pH of 5.8 the ratio is unity and with increase in pH the enol form 
dominates {148}. The weak binding of pyruvate in comparison to 2-ketobutyrate 
can be associated with the protein preference to bind to the keto form of 
pyruvate instead of the enol form and thus shifting the equilibrium towards the 
keto form at pH 8.0. 
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Figure  6.23 A series of overlaid 15N-HSQC spectra for TdcF with increasing Pyruvate 
concentration (Green spectra is for protein alone, blue, red, orange and Pink spectra are at 
3, 5, 7.5 and 12.5mM ligand Concentration respectively). 
 
 
6.6.2.3 Tdcf  with L-Lactate 
The Kd value calculated for L-Lactate was >25.0mM. The reason for not getting 
an exact value for L-Lactate was unsaturation of the binding curve. With the 
corresponding addition of 2-Ketobutyrate the shift distances for certain residues 
change and a point is reached at maximum ligand concentration when no change 
in shift distance is observed this is called the saturation point. In case of L-
Lactate at the highest concentration the binding curve did not show the 
saturation stage (Figure 6.24). Thus the calculated Kd value was > 25.0mM.   
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Figure  6.24 Biniding curve for a single amino acid residue representing change in the 
chemical shift distance of a single amide cross peak due to the addition of ligand (A = L-
Lactate, B =  2-ketobutyrate), the saturation stage is absent in A but visible in B, red curve = 
function fit, blue curve = data fit. 
 
Figure  6.25 A series of overlaid 15N-HSQC spectra for TdcF with increasing L-lactate 
concentration (Green spectra is for protein alone, blue, orange, pink and red spectra are at 
10, 15, 20 and 25mM ligand Concentration respectively). 
6.6.2.4 Tdcf  with L-serine  
The crystal structure of TdcF with L-Serine indicates additional H-bond 
interactions between the amino group of L-Serine and carbonyl oxygen of 
ARG105 {145}. The Kd value calculated for L-Serine was 8.4mM. The Kd value for 
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L-Serine indicated that it has about the same binding affinity for the protein as 
Pyruvate (Kd = 7.0mM) but binds more tightly than L-Lactate (Kd = > 25.0mM ).  
 
Figure  6.26 A series of overlaid 15N-HSQC spectra for TdcF with increasing L-Serine 
concentration (Green spectra is for protein alone, red, blue, pink and  orange spectra are at 
4, 8, 10 and 12mM igand Concentration respectively) 
6.6.2.5 Tdcf  with N-acetyl Neuraminic acid 
The pharmacophore hit Neuraminic acid (tried in the form of N-acetyl 
neuraminic acid) did not show any binding at all .There was no change in 
chemical shift, and the HSQC spectra for both the samples with and without the 
ligand appeared the same. There can be various possibilities of not binding, one 
of them could be the open and closed form of neuraminic acid.  It depends upon 
the ratio of open form to close form at equilibrium stage and then on the likely 
form to bind to the protein. If for instance open form is preferred for binding, 
but at equilibrium point the concentration of open form is much less than the 
closed form (1:200), then there are very less chances of binding of open form to 
the protein. Another reason which might suggest why no binding took place at 
all, could be because of using the acetylated form of neuraminic acid while the 
hit obtained from pharmacophore searching was neuraminic acid. Figure 6.27 
shows the chemical difference between Neuraminic acid and N-acetyl 
neuraminic acid. 
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Figure  6.27 Image showing chemical structure difference between Neuraminic acid and N-
acetyl neuraminic acid. 
6.6.3 Kd values of different ligands for TdcF 
Kd values for different ligands in terms of weak and tight binding can be 
explained in the form of simple equation given below 
Kd = [P] [L] / [C] 
Where P = protein, L = ligand and C = protein-ligand complex. If at a given 
equilibrium stage [C] is bigger than [P] and [L], it gives a low Kd value. A low Kd 
value accounts for tight binding while a high Kd value corresponds to weak 
binding. A total of 5 ligands (N-acetyl neuraminic acid, 2 ketobutyrate, 
pyruvate, L-lactate and L-serine) were titrated against TdcF to calculate their Kd 
values. Table 6.2 gives a comparative account of ligand binding in terms of Kd 
values. NMR titrations revealed that some of the ligands bind very tightly to the 
protein and some very weakly. The binding affinity of different ligands for the 
protein in descending order is given as 
 
2-ketobutyrate> Pyruvate> L-Serine> L-Lactate 
 
S.# Ligand Ligand concentration range (mM) Kd  value (mM) 
1. 2-Keto-butyrate 0-12.5 0.204 ± 0.01 
4. Pyruvate 0-12.5 7.3 ± 0.03 
2. L-Serine 0-25 8.4 ± 0.05 
3. L-Lactate 0-25 >25.0 
Table  6.2 Different ligands   and their concentration range along with calculated Kd values 
for TdcF  
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6.6.4 Pharma TdcF 10 (Generation of Query ligand) 
The Kd values obtained from NMR titrations and the co-crystallized structures 
demonstrated that the presence of carboxylate group on the ligand is important 
for recognition purpose with in the binding site. With the privilege of having the 
X-ray structure of the protein with bound ligands and the Accelrys DSV® 
software with the feature of converting the ligand structure in to query form. By 
using the Query atom method as described in section 3.5.3 a more sophisticated 
form of pharmacophore was generated. The Accelrys DSV® provided the option 
of flexibility in assigning multiple atoms to the same query atom along with 
attributing formal charge, partial charge and oxidation state to the query atoms. 
This assisted in the freedom of search through the data base. Different 
parameters for the query like bond type, charge on atoms and hydrogen count 
on each atom were specified by using Catalyst®. Initial search on the query was 
carried out by using the Catalyst® fast flexible results option. This showed 
whether the query gives hits or not. If in case the query did not give any hits 
then the query was further modified by optimizing different parameters until it 
gave hits. The final query was then subjected to database search. The 
location/size of uncertainty spheres around query atoms was set to 0.4Å. To 
avoid the steric clash between the ligand and the amino acid residues of the 
protien, exclusion spheres were introduced within a radius of 10.0Å around the 
center of the binding pocket (Figure 6.26). The query when searched against the 
naturalism database, provided 234 hits in just 4 minutes. 
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Figure  6.28 Query feature pharmacophore generated through Accelrys DSV® with query 
ligand comprising of multiple atoms for the same query atoms (green spheres), surrounded 
by uncertainty/location spheres (small grey and red spheres), exclusion spheres are around 
the query pharmacophore (large grey spheres) 
 
6.6.5 Pharma TdcF 11 
To explore further the binding site and the type of hits, the query atoms were 
specified individually for each atomic position in the query and the bond 
between C2 and O3 was specified to be double (Figure 6.27). The number of hits 
obtained as a result decreased from 234 to 95. This showed that specifying the 
double bond at this position leads to significant loss of hits. 
 
Figure  6.29 Representation of query pharmacophore with individual atoms specified for 
each atomic position in the query ligand (the uncertainty spheres around atoms and 
exclusion spheres around the query ligand have been removed for clarity) 
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6.6.6 Pharma TdcF 12 
As most of the hits obtained showed specific bonding between C2-C3 and C2-O3, 
therefore the query pharmacophore was modified by changing C2-C3 bond type 
from single to double and C2-O3 from double to single. The number of hits 
obtained as a result of this operation were only six and 2-hydroxy butyrate was 
absent among the hits. 
 
Figure  6.30 Representation of query pharmacophore with change in bond type from single 
to double between C2-C3 and from double to single between C2-O3. 
 
6.6.7 Pharma TdcF 13 
Addition of hydrogen atom on O1 and O3 and specifying the C2-C3 contact as a 
double bond in the last query pharmacophore caused losing of the 2-hydroxy 
butyric acid as a hit. Therefore in this pharmacophore model the hydrogen count 
on these atoms was set to free (any number) (Figure 6.29). This resulted in 
significant increase in number of hits and also regained the 2-hydroxy butyric 
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acid as a hit. The enol form of the 2-keto butyrate whose co-crystallized 
structure has been determined {145} was not in the database; instead the 
hydroxyl form was present which came up as a hit.  
 
Figure  6.31 Representation of pharmacophore in the form of query ligand in Accelrys DSV® 
with hydrogen atoms removed from O1 and O3. the exclusion and uncertainty location 
spheres have been removed for clarity. 
 
6.7 Co-Crystallizations for TdcF 
 
To determine the binding mode of a given ligand the glycerol stock of the 
protein was dialyzed overnight in 50mM Tris pH 7.5. The Protein was 
concentrated to 25mg/ml by using Amicon® concentrator. Crystallization trials 
were carried out using conditions around those known to yield crystals from the 
work of Lawson et al {149}. The protein was used at a concentration of 
10mg/ml. PEG (Polyethylene glycol) of Mr 1500, 2000, 3350 and 8000 were used 
as a precipitant in the 4%, 6%,8%,10%,12%,14% and 16% concentration range. 
Crystalline precipitates were seen at PEG 1500 in the concentration range of 4%, 
6%, 8% and 10%. The above crystallization conditions were further optimized to 
get individual crystals. Most of the optimized conditions resulted in crystalline 
precipitates. 
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6.8 Conclusions and Future work 
The Kd values obtained (Table 6.2) give good indications to the features required 
for tight binding. Namely compounds with carboxylate and a keto group at C2 
position e.g; 2-ketobutyrate and pyruvate bind better than the ligands having 
tetrahedral geometry at C2 such as lactate. Serine has been shown to bind in a 
quite different conformation which accounts for its modest binding affinity.  
 
1) Ligands having keto group at C2 bind preferentially to the protein.  
 
2) 2-keto butyrate appears to be the best binder and could be a ligand at 
physiological concentrations (Table 6.2) 
3) N-acetyl neuraminic acid does not bind to the protein but neuraminic acid 
should be tried to exclude this as a possibility.  
 
To test if the ligand effect could be measured by CD, higher concentrations of 
ligands would need to be tried. NMR titrations showed the advantage of 
measuring weak and tight binding. TdcF was used as an initial test case for 
checking the compatability of pharmacophore searching for identification of 
suitable ligands. Hits obtained through pharmacophore searching included 
compounds like pyruvate and Lactate. Serine was also among the hit which has 
already been co-crystallized. The Kd values obtained for different ligands showed 
that 2-ketobutyrate is the best binder and could be the potential ligand of the 
protein at physiological concentration. The pharmacophore hit Neuraminic acid 
satisfies all the constraints in the pharmacophore and needs to be tested in its 
native form for binding purposes. The results from pharmacophore searching and 
the binding data in the form of Kd values suggests TdcF to be a binding protein 
which may be performing a regulatory role by binding to 2-ketobutyrate and 
preventing its accumulation. The results obtained by using Pharmacophore 
searching on TdcF are promising and further encourage its use on other unknown 
proteins to findout potential ligands for them. The potential ligands can be 
tested by using NMR for detecting binding in terms of Kd values. 
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7. HutD, a protein of unknown function from 
Pseudomonas aeruginosa PAO1  
HutD (PA5104/PAD) is a conserved hypothetical protein of unknown function 
from Pseudomonas aeruginosa PAO1. Its gene is associated with the histidine 
utilization (Hut II) pathway operon. The hut genes are located in Hut operon 
with hutD located downstream of hutC in an overlapped manner (Figure 7.1).  
HutD encodes a protein of 200 amino acids with a Mr of 21.74 kDa that belongs 
to a group of uncharacterized proteins Pfam0596 that are highly conserved in 
bacteria. The crystal structure of HutD from P.aeruginosa PAO1 has been 
determined in our group and by others (PDB: 1YLL). The asymmetric unit 
contains four chains that are folded into four domains.  
 
Figure  7.1 Structure of the P. fluorescens SBW25 hut locus, the metabolic hut genes and the 
hut regulators are shown by open and solid arrows respectively, image adopted from {150} 
 
 HutD is a broadly conserved but functionally unknown component of the 
histidine utilization pathway in P. auroginosa. Recently, the hutD gene in a 
related organism P. fluorescens SBW25 has been genetically characterized and 
its involvement in histidine and urocanate utilization has been suggested by gene 
deletion studies {150}. In the study the growth of deletion mutants relative to 
wild type at different media composition was determined. It was observed that 
the hutD deletion mutant grows slowly on histidine or urocanate compared with 
the wild-type. ∆hutC mutant and ∆hutCD mutant showing that hutD functions 
independently of hutC (Figure 7.2).  
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On the basis of  this data hutD  has been suggested to be governing the 
activation of hut operon .The biological need for a regulator may relate to the 
potentially harmful effects of high rate of histidine catabolism, as one of the 
consequences resulting from the high levels of hut activity is the build-up of 
intracellular ammonium {150}. Although the structure of HutD is available it has 
proved little information into its function and the molecular mechanisms of HutD 
action remains unknown. 
 
Figure  7.2  Growth kinetics of the hutCD deletion mutants in different growth media 
compositions.  wild-type SBW25 = open circles, mutant ∆hutC = solid triangles, mutant 
∆hutD = open triangles, mutant ∆hutCD = open squares, (A) = M9 salts plus glucose and 
ammonia, (B) = M9 salts plus urocanate and (C) = M9 salts plus histidine, ∆=deleted gene, 
image adopted from {150} 
 
 
Chapter  7   159 
7.1 Histidine utilization (Hut) pathway 
In bacteria, histidine is degraded in nature through one of four pathways but in 
bacteria this is normally by (Hut pathway I) or a five-step enzymatic pathway 
(Hut pathway II) with glutamate as the mutual end product. The two pathways 
have the first three steps in common from histidine to urocanate, urocanate to 
imidazolone propionate (IPA), and IPA to formiminoglutamate (FIGLU), catalyzed 
by histidase (HutH), urocanase (HutU) and imidazolone propionase (HutI), 
respectively (Figure 7.3). 
In Hut pathway I breakdown of formimino glutamate (FIGLU) to glutamate and 
formamide is mediated by a single enzyme but in Hut pathway II FIGLU is 
converted to N-formyl L-glutamate (NFGLU) and ammonia by FIGLU 
iminohydrolase (HutF) encoded by hutF and then NFGLU is converted to 
glutamate and formate by formyl glutamase (HutG, also known as NFGase) 
encoded by hutG, an additional ammonium is produced in Hut pathway II. Excess 
ammonium is a stress for bacteria as it sends a nitrogen-replete signal causing 
the cessation of many catabolic enzymes including the hut enzymes. It has been 
established that some enteric bacteria, such as Salmonella typhimurium, 
Klebsiella aerogenes  and the Gram positive bacterium Bacillus subtilis use the 
four step histidine degradation pathway (Hut I), whereas Pseudomonas putida, 
Pseudomonas auroginosa and Streptomyces coelicolor use the five-step(Hut II)  
pathway {150}. 
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Figure  7.3 (A) The histidine degradation pathway (II), the five-step histidine degradation 
pathway (Hut II) of Pseudomonas is shown with the enzyme involved in each reaction, image 
adopted from Karp et al. [151} 
 
7.2 Putative role of HutD  
A number of hypotheses have been put forward in relation to the function of 
HutD. Different studies have been carried out in order to prove the hypothesis, 
yet none have been fully conclusive. 
1) If HutD (PAD) acts via protein-protein interaction with HutC as predicated 
by their genetic organization, the double deletion mutant ∆hutCD would 
display the same phenotype as ∆hutC mutant, but the ∆hutCD mutant 
expressed an intermediate phenotype compared to ∆hutC and ∆hutD 
thereby indicating that HutC is not required for HutD function and 
functions independently of HutC {150}.  
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2)  It has been proposed that HutD may be involved in the regulation of   hut 
operon. Growth and fitness assays by using laboratory media suggest that 
HutD may function to govern the upper level of hut transcription by 
controlling the intracellular concentration of the hut inducer (urocanate), 
and thus may play a regulatory role in expression of hut enzymes {150}. 
3)  HutD may bind to the weak promoter region of hutG and thereby 
repressing expression of hut enzymes {150}.  
Based on above hypothesis and studies it is not unreasonable to expect that HutD 
may bind another metabolite which is not in the Hut pathway to regulate 
ammonium and glutamate production. This provides a difficult case for 
pharmacophore searching as there is no active site residues, no enzyme activity 
that can be assayed and potentially a significant number of ligands that could 
interact with it. We aim to identify a subset of chemicals which we could assess 
for binding and thereby identify a ligand and potentially a function to HutD. 
7.3 Aims and objectives  
The pharmacophore searching and the ligand binding studies may provide 
insights into the molecular mechanism of HutD action. The objectives of this 
study were: 
1) To express and purify HutD from P. auroginosa 
2) To perform pharmacophore searching on the protein and obtain a 
small subset of potential ligands 
3) To obtain the chemicals to test binding between HutD and 
potential   ligands  
7.4 Over-expression and purification of HutD 
Transformations were carried out to introduce the pTBL2:PAD1 plasmid into an 
expression strain BL21 DE3 cells. A large numbers of colonies were obtained as a 
result on tetracycline plates. Over expression of HutD was carried out using LB, 
auto induction and M9 media. A SDS-PAGE analysis showed that about 50% of the 
protein was in the insoluble fraction when using LB media (Figure 7.4). In order 
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to increase the expression levels, different strategies were adopted, which are 
mentioned below. For all the SDS-PAGE analysis the NuPAGE Novex (Invitrogen®) 
Bis-Tris 4-12% gel was run in 4-12% Bis-Tris MES buffer. 
 
Figure  7.4 SDS-PAGE analysis for  test of expression of HutD in LB media: 1= molecular 
weight marker in Kda (Bio labs, NEW ENGLAND cat# P7708S), 2=pre-induced soluble sample, 
3= 1hour induced soluble sample, 4= 2hours induced soluble sample, 5=3hour induced 
soluble sample, 6= 4hour induced total sample, 7= 4 hour induced insoluble sample. 
7.4.1 Using Auto induction media 
In order to increase the expression levels of the protein, auto induction media 
was used, and cultures were grown at 37°C for 24 hours. The use of auto 
induction media slightly increased the expression levels. The protein yield from 
1L cultures was 12mg in total while from LB media it was 10mg in total.  
7.4.2 Using M9 media 
 M9 media was used for growing cultures. The use of M9 media helped in 
increasing the expression levels (Figure 7.5). The protein yield form 1L culture 
was raised to 15mg in total.  
  1             2            3            4            5            6             7 
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Figure  7.5 SDS-PAGE analysis for  test of expression of HutD in M9 media: 1= molecular 
weight marker in Kda (Bio labs, NEW ENGLAND cat# P7708S), 2=total pre-induced sample, 3= 
2hour induced total sample, 4= 4hours induced total sample, 5=overnight induced total 
sample, 6= soluble pre-induced sample, 7= 2hour induced soluble sample, 8= 4hour induced 
soluble sample, 9=overnight induced soluble sample, 10=pre-induced insoluble sample, 
11=2hour induced insoluble sample, 12=4hour induced insoluble sample, 13=overnight 
induced insoluble sample, 14=molecular weight marker in Kda 
7.4.3 Changing temperature and IPTG concentration of the 
cultures 
At higher temperatures the bacterial cultures grow faster but protein cannot 
fold properly and lead to the formation of misfolded protein which gets 
packaged into inclusion bodies and thus most of the protein remains in the 
insoluble fraction. On the other hand the decrease in temperature results in 
slow expression but low final cell density, but allows the protein to fold 
properly. To get around  this problem large cultures (in M9 media) were grown 
initially at 37°C and as the O.D600 reached to 0.6, the cultures were put in 
slushy ice box for 5 minutes and then induced with 0.1, 0.4 and 1.0mM IPTG and 
left for overnight induction at 15°C. The change in temperature decreased the 
amount of protein in the insoluble fraction with increase in amount of protein in 
the soluble fraction. The varying amount of IPTG did not affect the expression 
level (Figure 7.6). 
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Figure  7.6 SDS-PAGE analysis for  test of expression of HutD in M9 media: 1= molecular 
weight marker in Kda (Bio labs, NEW ENGLAND cat# P7708S), 2= pre-induced total sample, 
3=pre- induced soluble sample, 4= pre-induced insoluble sample, 5,8,11=overnight induced 
total sample, 6,9,12= overnight induced soluble sample, 7,10,13= overnight induced 
insoluble sample,14=molecular weight marker in Kda, 5-7= samples with 0.1mM IPTG,8-10= 
samples with 0.4mM IPTG,11-13= samples with 1.0mM IPTG 
7.4.4 The effect of temperature on HutD growth 
The protein expression in host cells is usually influenced by various growth 
factors such as temperature, inducer concentration, induction time and duration 
{152}. The effect of growth temperature on HutD solubility was examined and 
the results showed significant effect of growing temperature on protein 
solubility: when HutD was induced at 15ºC instead of 37ºC, a large proportion of 
HutD was soluble. The protein yield reached to 25mg from 1L culture as a result 
of inducing the protein at low temperature. The effect can be explained by the 
possibility that high temperatures could enhance interaction of hydrophobic 
regions of protein folding intermediates and promoting the formation of 
inclusion bodies whereas lower growth temperatures may reduce the expression 
rate of unfolded proteins and thereby decreasing the kinetics of protein 
intermediate interaction, and thus limiting the aggregate formation and 
enhancing the protein solubility {153} . 
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7.4.5  Harvesting and Purification of HutD 
The cells were harvested and further nickel purification was carried out as 
described in section 2.13. Different fractions obtained from Ni-column were 
loaded on a SDS PAGE gel (Figure 7.7). The target protein was found in the 
elution fraction (Elution buffer: 300mM Imidazole 50mM Tris, 300mM NaCl pH: 
7.5). To get rid of high imidazole content the elution fraction was subjected to 
dialysis for 4 hours  in 20mM Na-phosphate, pH:7.5 dialysis buffer and later on 
concentrated down at 3000xg by using Vivaspin® and then passed through the 
gel filtration column as a final purification step.  
 
Figure  7.7 SDS-PAGE analysis for HutD after Ni-purification: 1= molecular weight marker in 
Kda (Bio labs, NEW ENGLAND cat# P7708S), 2=flow through, 3= 75mM Imidazole wash, 4= 
300mM Imidazole elute 
7.4.6 Size exclusion chromatography (Gel Filtration) 
The concentrated sample was then subjected to size exclusion chromatography 
as described in section 2.13.2. During Gel filtration it was observed that the 
protein gave a single sharp peak when at a concentration of 1mg/ml (Figure 
7.8).  While at a higher concentration (15mg/ml) an additional shoulder peak 
also appeared attached to the main peak (Figure 7.9). This indicated that 
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protein tends to oligomerize at a higher concentration and has both the 
monomer and dimer (higher content) forms while at lower concentration only 
monomer form exists. This was confirmed by running a SDS PAGE gel on eluted 
fractions in which the bands for fractions corresponding to the shoulder peak 
appeared at the same location as for the main peak (Figure 7.10). The evidence  
from size-exclusion chromatography suggests that HutD forms a dimer in the 
elution buffer at higher concentrations, is in agreement with the dimerization of 
HutD reported in P. fluorescens SBW25 {154}. The pure fractions obtained after 
gel filtration were pooled and concentrated down to the desired concentration 
by centrifuging at 4000xg in a viva spin. The absorption co-efficient for the 
protein  was calculated by submitting the amino acid sequence of the protein in 
Expasy ProtaParam tool (http://web.expasy.org/protparam/),which was 1.76 for 
1mg/mL. The final concentration of protein was calculated by measuring the 
absorbance at 280nm by using JASCO-550 UV spectrophotometer. 
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Figure  7.8 Chromatogram for HutD after size exclusion chromatography with individual 
fractions eluted on molecular size basis (at 1mg/ml the protein elutes after 12ml, suggestive 
of the monomer form) 
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Figure  7.9 Chromatogram for HutD after size exclusion chromatography with individual 
fractions eluted on molecular size basis (at 15mg/ml the protein elutes at 9ml (dimer 
form)with a shoulder peak at 12ml,suggestive of the monomer form) 
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Figure  7.10 SDS-PAGE analysis for HutD after gel filtration: M= molecular weight marker in 
Kda (Bio labs, NEW ENGLAND cat# P7708S), D5-D11 = pure elution fractions containing HutD 
7.5 Pharmacophore searching for HutD 
Pharmacophores had been run previously with the hydrogen bond vector method 
with little or no success. With improvements in the pharmacophore methodology 
described in this thesis, future pharmacophores for HutD were generated by 
using the query atom method as described in section 3.5.3. All the preliminary 
searches were carried out in catalyst by using the “fast flexible search” option 
prior to the actual pharmacophore search through the ChEBi database. If the 
search gave hits then the actual search was carried out against naturalism 
database by using Accelrys catalyst®. Figure 7.11 shows the solid ribbon diagram 
of HutD along with the Sulfate group and glycerol molecule in the putative 
binding site, forming important H-bonds with the active site residues. 
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Figure  7.11 Solid ribbon diagram for HutD along with Sulfate and glycerol molecule in the 
putative binding site, forming Hydrogen bonds with the active site residues of the protein. 
 
7.5.1 Pharma HutD 1 
As a SO4
2- ion and a glycerol molecule were found in D chain of the protein in one 
of our unpublished HutD crystal structure (Lokhamp Bernhard PhD thesis 2003, 
University of Glasgow). The first pharmacophore for HutD was generated for D 
chain of the protein and the query ligand was generated by using it as a 
template (Figure 7.11). The hydrogen count on oxygens of the query ligand was 
set to 1 and the radius of the uncertainty location sphere for query atoms was 
set to 0.4Å. The pharmacophore was then subjected to search against the 
naturalism database. We presumed that a sugar phosphate would be a suitable 
ligand. 
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Figure  7.12 Query ligand in the active site of HutD with surrounding key amino acid residues 
the fragment type, query ligand generated by using SO4 and hydroxyl group of the glycerol 
as template (all exclusion spheres, some amino acid residues and water molecules have been 
removed for clarity viewing) 
 
All the hits contained a phosphate group aligned with the query atoms 
(generated via sulphate ion). Maximum hits had their hydroxyl group satisfying 
the query atom of the pharmacophore (generated via hydroxyl group of 
glycerol). Majority of the hits included phospho sugars like beta-D-fructose 6-
phosphate, D-xylulose 5-phosphate, D-ribulose 5-phosphate, erythrulose 1-
phosphate. some hits had phosphate groups attached to glycerol like glycerol 1-
phosphate, 3-phospho-D-glyceroyl dihydrogen phosphate, 2,3-bisphosphoglyceric 
acid, 3-phosphoglyceric acid, 3-phospho-D-glyceric acid while few phospho 
amines like serine phospho ethanolamine, glycero-3-phospho ethanolamine were 
among the hits as well. 
Number of hits obtained = 71 
Time taken = 40 minutes 
7.5.2 Pharma HutD 2 
The hits obtained through first pharmacophore had short contacts with the 
surrounding amino acids, which ruled out the possibility of H-bonding and some 
hits were having hydrophobic clash with certain residues and thus unlikely to be 
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the ligands. In order to avoid this, the pharmacophore was modified by 
increasing the uncertainty location sphere around query atoms to 0.6Å. With the 
hypothesis that the ligand may have H-bond interactions with the conserved 
arginine (Arg41) of the protein, the query ligand sulphate fragment was modified 
to carboxylate group, with its 2 oxygens pointing towards the Arg41 of the 
protein. Further in the crystal structure the binding site has glycerol, forming 
good H-bonds with ASP108 and ASN110 therefore carbon was added to OH group 
of glycerol in the pharmacophore (Figure 7.12). The database search just took 1 
minute.    
 
Figure  7.13 Modified pharmacophore with oxygens of the query ligand carboxylate group 
pointing towards ARG41 and SER43 at H-bond distance, carbon atom added to the hydroxyl 
group query ligand towards the ASP108 (all exclusion spheres, certain amino acid residues 
and water molecules have been removed for clarity viewing) 
This time the hits were not in clash with the active site residues and formed 
good H-bonds with residues like ASP108, ASN110 towards the glycerol query end 
and with ARG41 towards the carboxylate query end. The hits included sugars like 
D-galacturonate, D-arabinonate and 5-dehydro-2-deoxy-D-gluconate. The hits 
also included some dicarboxylate compounds like 5-hydroxypentanoate, 3, 4-
dicarboxy-3-hydroxybutanoate and glutarate. 
Number of hits obtained = 12 
Time taken = 1 minute 
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7.5.3 Pharma HutD 3 
In order to check the possibility of different types of ligands, the oxygen atom 
attached to carbon (towards the ASP108 residue) was changed to Nitrogen and 
the hydrogen count on Nitrogen was set to free. The bond between carbon and 
nitrogen was optimized to single/double (Figure 7.13). The final pharmacophore 
was then searched through the naturalism database. 
 
Figure  7.14 Final pharmacophore with oxygen atom of the query fragment towards ASP108 
replaced with Nitrogen, FIGLU is shown as line model satisfying the query and making H-
bond interactions with ASP108 and ARG41 (all exclusion spheres, certain amino acid 
residues and water molecules have been hidden for clarity viewing) 
The hits from the final pharmacophore included mostly amino acid and their 
derivatives like D-arginine, L-arginine, argininate, N-formimidoyl-L-glutamate 
(FIGLU) and some guanidine compounds like 3-guanidinopropanoic acid, 4-
guanidinobutanoic acid and 5-guanidino-2-oxopentanoate. The database search 
interestingly gave Formimino glutamate (FIGLU) among the hits (important 
metabolite in the Hut pathway). The formimino group of FIGLU formed H-bond 
with the carboxyl group of ASP108. In addition the carboxylate of FIGLU which 
was not searched for did not make any clashes but rather was in the proximity of 
residues with which it could make hydrogen bonds. Bases on pharmacophore 
model it was considered that FIGLU could be the most likely ligand to bind to 
this protein.  
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Number of hits obtained = 9 
Time taken = 1 minute 
 
7.6 Ligand selection and synthesis 
The selection and synthesis of ligands was based on the hits obtained from 
pharmacophore searching and metabolites involved in Hut II pathway. FIGLU an 
important metabolite of the Hut pathway was the most convincing hit that came 
out from pharmacophore search. NFGLU and glutamate are the penultimate and 
last metabolites respectively in the Hut II pathway, their structural similarity to 
the predicted hit FIGLU made them obvious choices for comparison. Urocanate 
was included for binding studies as it has been predicted {154} to bind to the 
protein through ITC studies but not by pharmacophore searching. Based on 
growth studies {150} and pharmacophore searching histidine has been suggested 
not to be a ligand therefore was included as a negative control. 
7.6.1  Synthesis of N-Forminino L-Glutamate (FIGLU) 
N-Formimino L-Glutamate (FIGLU) was synthesised by the procedure used for the 
preparation of N-formimino L-aspartic acid by Hayaishi {155}. The method 
involved the condensation of formamidine and L-Glutamate in the presence of 
Ag2CO3 and formamide. To prepare FIGLU, 1.06g (20mmol) of formamidine 
hydrochloride, 2.0g (11mmol) of Ag2CO3, 1.12g (10mmol) of L-glutamic acid, and 
5mL of formamide were vigorously stirred for 36 hours at room temperature in 
50mL round bottom flask, stoppered with a CaCl2 tube. The mixture was then 
subjected to rotary evaporation for 30 minutes to remove most of the dissolved 
CO2, treated with 100mL of 0.06N HCl and then filtered. The filtered solution 
was then subjected to rotary evaporation. The final fraction obtained after 
rotary evaporation was treated with ethanol to remove excess of formamide (as 
formamide is soluble in ethanol). The insoluble fraction obtained after 
treatment with ethanol was subjected to freeze drying to get pure form of FIGLU 
as described in biochemical preparations {156}.    
1H NMR and 13C spectra were recorded on a Bruker DPX-400 spectrometer with 
chemical shift values in ppm relative to TMS (δH 0.00 and δC 0.0) as standard 
with D2O as a solvent at room temperature. Spectroscopic data was in 
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accordance with the literature. δH (400 MHz, D2O) 2.00 (2H, q, J 7.9 Hz, 3-CH2), 
2.26 (2H, t, J 4.1 Hz, 4-H2), 4.1 (1H, t, J 6.2 Hz, 2-H), 7.78 (1H, s, 5-COOH), 
7.80 (1H, s, 1-COOH); δC (100MHz, D2O) 27.53, 32.70, 57.43, 153.67, 175.05 and 
180.83. 
7.7 CD results for HutD 
To see the effect of potential ligands on the secondary structure of the protein, 
particularly on the aromatic regions of the protein the selected potential ligands 
were added to the protein and their near and far UV spectra were recorded. All 
the CD spectra were recorded at a protein concentration of 1.82mg/mL (for 
Near UV) and 0.92 mg/mL (for Far UV). Cell path length was 0.2cm and 0.01cm 
for Near and Far UV analysis respectively. The CD experiments were carried out 
in buffer solution of 20mM Na-phosphate, 50mM NaCl pH: 7.8 at 20°C.  
Significant changes were observed in the Near UV CD spectra as a result of 
addition of FIGLU and NFGLU (Figure 7.14). Though the shifts were much bigger 
in case of NFGLU, the changing pattern in the near UV region (particularly in 
290-300nm range) for NFGLU and FIGLU was pretty similar. 
 
Figure  7.15 Near UV (250-320nm) CD spectra for (A) HutD (blue) and HutD with 5mM FIGLU 
(red), (B) HutD (blue) and HutD with 5mM NFGlu (red) 
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The bigger shifts in the near UV region due to the addition of NFGLU suggest 
some changes in the secondary structure of the protein. Further the similarity in 
the Near UV CD spectra might indicate that these ligands are causing the same 
effect in or around the binding site of the protein. This indicates that the ligand 
may have caused some change in the arrangement of the aromatic amino acid 
residues as a result of direct or indirect interaction. No significant changes were 
observed in the far UV region of the CD spectra due to addition of NFGLU and 
FIGLU (Figure 7.15) 
                      
Figure  7.16 Far UV (190-260nm) CD spectra of HutD  (blue) with 2.5mM FIGLU (red) and 
2.5mM NFGLU (green). 
 
 
The spectral changes brought by the addition of L-glutamate and L-Histidine 
were not observable. The pattern observed for both these ligands was same in 
the Near UV and Far UV region (Figure 7.16-17). The overall composition of α-
helices and β-strands nearly remained the same in case of these ligands. 
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Figure  7.17 (A) Near UV (250-320nm) and (B) Far UV (190-260nm) CD spectra for HutD (blue) 
and HutD with 310µM L-glutamate (red) 
 
 
 
Figure  7.18 (A) Near UV (250-320nm) and (B) Far UV (190-260nm) CD spectra for HutD (blue) 
and HutD with 310µM L-Histidine (red) 
 
 
In case of urocanate the experimental studies were hampered due to the fact 
that urocanate absorbs very strongly in the Near UV and Far UV region. In order 
to test and confirm that urocanate absorbs the UV very strongly, the 
fluorescence experiments were carried out. 
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7.8 Fluorescence spectroscopy on HutD 
When a molecule is transformed from ground state to excited state through 
electromagnetic radiation, the energy of absorbed photon is equal to the energy 
difference between two levels, the molecule can return to its ground state by 
emitting a photon of energy difference to that of the excited state, this emission 
is known as fluorescence. The electromagnetic radiation is typically absorbed by 
a tryptophan in a protein {157}.  As there are 6 tryptophans in HutD structure, 
fluorescence experiments were performed to monitor conformational changes in 
protein structure as a result of interaction with ligands. The concentration of 
HutD in all samples was 0.1mg/mL and concentration of all ligands was 0.27mM. 
The buffer used was 20mM Na-phosphate pH: 7.8. All the fluorescence 
experiments were performed on Perkin Elmer LS508 spectrofluorimeter. 
Only a little increase in intensity of fluorescence was observed when FIGLU and 
NFGLU were added to the protein (Figure 7.18). In case of urocanate a big 
decrease in fluorescence was observed which could be due to the quenching 
effect of urocanate. 
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Figure  7.19 Overlayed flourscence spectra for HutD with potential ligands (the quenching 
effect is prominent due to the addition of urocanate to HutD) 
 
In order to confirm the quenching effect, a control experiment was performed. 
N-acetyl-tryptophan-amide (NATA) solution (0.025mg/mL) was prepared in the 
same buffer and the ligands were added one by one to see the effect. Here also 
when urocanate was added to NATA, the huge quenching effect was observed 
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(Figure 7.19). No spectra was obtained showing any binding of ligand causing 
major structural change in the protein. 
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Figure  7.20 Overlayed flourscence spectra for N-acetyl-tryptophan-amide (Nata) with 
different ligands (the quenching effect is prominent due to the addition of urocanate to 
Nata) 
 
7.9 NMR results for HutD 
NMR had been shown to be successful for testing the ligand binding for TdcF 
(Chapter: 6), therefore HSQC spectra were carried out by using the 15N-labelled 
protein. However, the spectra were not clean as might have been predicted 
from the crystal structures. It was therefore necessary to optimize the 
conditions for getting better and cleaner spectra. Initially the spectra were 
recorded at a range of temperature with varying buffer composition (salt and 
pH). Throughout the optimization it was observed that some of the peaks in the 
spectra were smeared, which could be because of the dimerization of the 
protein, and thus causing a change in the structure at the dimer interface. The 
dimerization of the protein has previously been indicated during the purification 
of the protein at gel filtration step, but not in earlier studies (Bernhard Lokhamp 
PhD thesis 2003, University of Glasgow). The protein samples for NMR both with 
and without the ligand were prepared as described in section 6.6.1. After 
optimization of the conditions all the HSQC spectra for the protein were 
recorded in 20mM Na-phosphate, pH:7.2 buffer at 43°C.The ligands were 
prepared in the same buffer solution as of the protein and further the pH of the 
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ligand solution was adjusted prior to their addition to the protein. The 
concentration of protein was 300µM in all the experiments. 
Figure  7.21 NMR-HSQC spectra for 15N-labelled HutD without any ligand 
 
7.9.1 HutD with FIGLU 
The overlayed spectra of protein with successive additions of ligand showed 
some marked changes. A total of 15 peaks changed their position. It was 
observed that certain peaks slightly changed their positions while few peaks 
travelled larger distances (Figure 7.21). Certain peaks moved a lot with 
increasing concentration of the ligand, as represented by open square boxes 
around the peaks. The range of ligand concentration was used between 0-15mM. 
At 15mM ligand concentration certain peaks disappeared and some new peaks 
appeared which might suggest some conformational change in the structure of 
the protein as a result of ligand binding. In native protein spectrum some 
smeared peaks (corresponding to two peaks) appeared which could be attributed 
to two conformations of protein as a result of dimer formation. In the 
subsequent spectra with the addition of FIGLU certain portion of the smeared 
peaks appeared stronger with increase in intensity which suggested preference 
of one conformation over the other as a result of ligand binding. The protein 
Chapter  7   181 
seemed to be saturated at 10mM ligand concentration with the ligand as at 
15mM ligand concentration the peaks did not shifted any further 
 
Figure  7.22 Overlayed HSQC spectra of HutD with FIGLU, empty square boxes= peaks 
bigger shift due to the addition of the ligand, empty circles= peaks with no change due to 
the addition of ligand, rounded rectangles= peaks with smaller shifts (green spectra is for 
protein alone, blue orange and red spectra are at 3,5 and 10mM ligand Concentration) 
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7.9.2 HutD with NFGLU 
The comparison of spectra between the protein alone and protein with NFGLU 
showed marked changes with change in position of 10 peaks. It was observed 
that certain peaks slightly changed their positions and few peaks disappeared 
due to the addition of the ligand (Figure 7.22). Some new peaks also appeared at 
the start of ligand addition and further kept on moving with successive addition 
of ligand. For some peaks the pattern of movement was similar as to FIGLU. The 
protein was saturated at 10mM ligand concentration as further addition of ligand 
did not cause any change in the peak positions.  
 
Figure  7.23 Overlayed HSQC spectra of HutD with NFGLU, empty square boxes= peaks 
bigger shift due to the addition of the ligand, empty circles= peaks with no change due to 
the addition of ligand, rounded rectangles= peaks with smaller shifts(green spectra is for 
protein alone, blue orange and red spectra are at 1,3 and 10mM ligand concentration) 
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7.9.3 HutD with Urocanate 
By seeing the overlayed spectra after the addition of urocanate, it was observed 
that 5 peaks shifted their position, among which only one peak travelled a big 
distance and the rest shifted slightly. By comparing the spectral changes brought 
by Urocanate it appeared that the specific peaks which changed their position 
due to Urocanate also shifted in case of NFGLU and FIGLU but the shift distance 
travelled due to the former was fairly small in comparison to latter one. The 
protein appeared to be saturated at 10mM ligand concentration as further 
addition of ligand did not cause any significant changes in the position of the 
peaks (Figure 7.23).  
 
Figure  7.24 Overlayed HSQC spectra of HutD with Urocanate, empty square boxes= peaks 
bigger shift due to the addition of the ligand, empty circles= peaks with no change due to 
the addition of ligand, rounded rectangles= peaks with smaller shifts(green spectra is for 
protein alone, blue and red spectra are at 5 and 10mM ligand concentration) 
By comparing the shift changes in peaks due to the addition of FIGLU, NFGLU 
and Urocanate were more or less of the same pattern. The changing effect 
observed due to NFGLU was more obvious (peaks travelling bigger distances) 
than by FIGLU and Urocanate for the same peaks. 
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7.9.4  HutD with L-Glutamate 
The changes observed as a result of addition of L-Glutamate to the protein were 
fewer than with FIGLU and NFGLU. Only 4 peaks appeared to shift due to ligand 
addition while rest remained static (Figure 7.24). The specific peaks which 
changed their position due to L-glutamate also appeared to be shifting in case of 
NFGLU and FIGLU but the shift distance travelled due to the former was fairly 
small in comparison to latter one. The ligand was used in the concentration 
range of 0—20mM.  
 
Figure  7.25 Overlayed HSQC spectra of HutD with L-glutamate, empty square boxes= peaks 
bigger shift due to the addition of the ligand, empty circles= peaks with no change due to 
the addition of ligand, (green spectra is for protein alone, blue and red spectra are at 10and 
20mM ligand concentration) 
 
Chapter  7   185 
7.9.5 HutD with L-Histidine 
In case of L-histidine, the spectra showed no change in the peak positions except 
slight shift in only one peak (Figure 7.25). Interestingly the addition of all the 
other ligands did not change the position of this peak. A logical explanation for 
this could be the charge state of Histidine, as Histidine has a pKa value of 6.5 
and small increase in pH can cause it to be deprotonated. The pH of the buffer 
solution was 7.2 which means that Histidine can cause protonation of some 
protein residues. This suggests that L-histidine either does not bind to the 
protein or binds very weakly even at a concentration of 20mM. 
 
Figure  7.26 Overlayed HSQC spectra of HutD with L-Histidine, empty square boxes= peaks 
bigger shift due to the addition of the ligand, empty circles= peaks with no change due to 
the addition of ligand (green spectra is for protein alone, blue and red spectra are at 10 and 
20mM ligand concentration) 
 
7.9.6 Determination of Kd values 
The Kd values for different ligands were calculated (Table 7.1) by using the same 
fitting function as described in section 6.6.2. In terms of Kd values NFGLU 
appeared to be a tighter binder than FIGLU.  For Urocanate and L-glutamate Kd 
values were in the mM range, which shows weak binding. The Kd value for L-
Histidine could not be determined due to insufficient data points to fit the curve 
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however the HSQC spectra for histidine indicates that it does not bind to the 
protein.  
S.# Ligand Ligand concentration range (mM) Kd  for HutD  
1 FIGLU 0-15 500µM±0.58 
2 NFGLU 0-15 92µM±0.25 
3 L-glutamate 0-20 >30mM 
4 Urocanate 0-10 >1.5mM 
5 L-Histidine 0-20 N.D 
Table  7.1 The range of different ligands added to HutD along with their calculated Kd values  
 
7.10 Conclusions and future work 
1. The pharmacophore search extracted FIGLU as a potential ligand form the 
database, and predicted a discrete binding mode for this ligand (Figure 
7.26). 
 
Figure  7.27 Graphical representation of FIGLU (stick model) in the binding site of 
HutD, green broken lines show FIGLU forming H-bonds with THR24, ARG41, SER43 
and ASP108 
Chapter  7   187 
 
2.  The availability of pseudo ligands in the form of crystallization chemicals 
was important as it allowed the use of the query atom method. However, 
it did not predict NFGLU as a ligand because we had no evidence that Asp 
108 could be protonated and so to act as a proton donor for the carbonyl 
oxygen of NFGLU. 
3. From CD and NMR experiments it can be deduced that HutD does not 
significantly interact with histidine, urocanate or glutamate. There is 
strong evidence of binding to NFGLU and FIGLU with NFGLU having a Kd in 
the physiological range for ligand.  
4. From the NMR results it appears that NFGLU causes more shifts in the 
spectra than FIGLU which need to be characterized more to confirm which 
is the preferred ligand. 
5. The outcome of the NMR and CD experiments was in agreement for 
ligands like NFGLU, FIGLU and L-Histidine. The results helped to 
differentiate between true binders and non-binders. Both the techniques 
suggest L-Histidine to be a non-binder.  
6. This work shows that HutD binding to the ligands in descending order is  
NFGLU> FIGLU >Urocanate 
This further supports the hypothesis that HutD may function as a binding 
protein, to play a regulatory role in the Hut pathway. 
7. The favorable ability of HutD to crystallize means that either soaking of 
native crystals or co-crystallisation with ligands should permit a detailed 
look at the binding of both FIGLU and NFGLU and whether they elicit the 
same conformation in the protein.  Obtaining a clear idea of the ligand 
that binds to HutD should allow a better understanding of the function of 
this protein and how it performs a regulatory role in histidine utilization 
pathway. 
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8.  Ralstonia eutropha N-formylglutamate amido-
hydrolase like protein (PARI) 
As part of an ongoing project, studying the structure and mechanism of 
Pseudomonas auroginosa amidohydrolase (PAA), a N-formyl glutamate amido 
hydrolase (NFGase) from the histidine utilization pathway. A crystal structure of 
a related protein (PDB code: 2Q7S) from Ralstonia eutropha, annotated as 
NFGase (PARI) and deposited in protein databank under the JCSG project. The 
sequence alignment (Figure 8.1) carried out between PARI and NFGases from 
different microorganisms demonstrates significant sequence similarity over the 
whole protein sequence, suggesting a common fold and function. The x-ray 
structure of PARI has been determined at a resolution of 2.0Å, and is annotated 
as NFGase, solely on the basis of sequence similarity and over presumed fold 
similarity to the actual NFGases. The protein comprises of 290 amino acids with 
a molecular weight of 32.6 Kda and exists in the monomer form.  
 
Figure  8.1 Amino acid sequence comparison of PARI with other NFGases, residues 
highlighted with red bars indicate the position and location of identical residues in the 
structure, the sequences were aligned using MultAlin {158} 
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As co-crystallization experiments were unsuccessful with PAA while enzyme 
inhibition assays demonstrated nano molar inhibition with certain inhibitors (as 
described in section 9.4). It was decided to study R. eutropha enzyme (PARI) 
which could be more suitable for structural characterization. For this purpose 
the plasmid of PARI was purchased from the Protein Structure Initiative Material 
Repository (PSI-MR, ref: PMC2808882). 
 
8.1 Over-expression and purification of PARI 
The PARI plasmid came as a small cell culture. The cell cultures were streaked 
on agar plates containing kanamycin (30µg/mL). Some overnight cultures were 
also setup from the same cell cultures. 
The plasmid was isolated from the overnight liquid cultures by using the 
QIAGEN® Miniprep kit. The concentration of the plasmid DNA (70ng/µL) was 
checked by using nano drop spectrophotometer. Transformations were carried 
out to introduce the plasmid into an expression strain BL21 DE3 cells. Large 
numbers of colonies were obtained as a result on kanamycin plates. 
Over expression of PARI was carried out by using LB, auto induction and M9 
media. The His-tagged protein was purified by using nickel affinity 
chromatography. The yield of protein from LB media was only 1—1.5mg protein 
from 1L culture. This was significantly less than the reported value mentioned 
on the web link of JCSG website. A SDS-PAGE analysis was carried out which 
showed that most of the protein was in the insoluble fraction, while only a small 
amount was present in the soluble fraction of the protein (Figure 8.2). For all 
the SDS-PAGE analysis the NuPAGE Novex (Invitrogen®) Bis-Tris 4-12% gel was 
run in 4-12% Bis-Tris (MES) buffer and for reference the molecular weight marker 
from Bio labs, NEW ENGLAND cat# P7708S was used. In order to increase the 
expression levels of the protein, different strategies were adopted which are 
mentioned below. 
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Figure  8.2 SDS-PAGE analysis for  test of expression of PARI in LB media at 37°C: 1 = 
molecular weight marker in Kda, 2 = pre-induced soluble sample, 3= 1hour induced soluble 
sample, 4 = 2hours induced soluble sample, 5 = 3hour induced soluble sample, 6 = 4hour 
induced soluble sample, 7 = 4 hour induced total sample, 8 = 4hour induced insoluble 
sample,9 = molecular weight marker in Kda (numerals in vertical column represents 
different molecular weights for individual bands) 
 
8.1.1 Lowering temperature of cultures in auto induction media. 
In order to increase the expression levels of the protein, cultures were grown in 
auto induction media at 20°C and 30°C. The lower temperature should help by 
reducing the rate of over expression and give more time for the bacteria to 
attempt to refold incorrectly folded protein. At higher temperature the mis 
folded protein is targeted to inclusion bodies to keep it from interfering with the 
functioning of the cell. The usage of auto induction media at lower temperature 
did not increase the expression levels significantly. 
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Figure  8.3 SDS-PAGE analysis for  test of expression of PARI in auto induction media after 
over night induction at lower temperatures: 1 = molecular weight marker in Kda, 2, 3&4 = 
total, soluble and insoluble samples grown at 20°C in bowelled flasks, 5, 6&7 = total, soluble 
and insoluble samples grown at 20°C in non-bowelled flasks, 8, 9&10 = total, soluble and 
insoluble samples grown at 30°C in bowelled flasks,11, 12&13 = total, soluble and insoluble 
samples grown at 30°C in non-bowelled flasks, 14=molecular weight marker in Kda. 
 
8.1.1.1 Using RosettaTM 2 DE3 cells 
The presence of some rare codons in the plasmid of PARI, could lead to stalling 
of translation of the mRNA during protein synthesis and hence leading to 
insoluble protein. In order to prevent this transformations were carried out in 
RosettaTM 2 (DE3) competent cells (Novagen material number: 71397-4, Kit batch 
number: D00111972, Antibiotic resistance: chloramphenicol) which provides 
sufficient supply of rare codons. The usage of Rosetta cells did not increase the 
expression levels significantly. 
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8.1.2 Using M9 media (supplemented with zinc sulphate) 
The choice of growth media and using different cell types can have an effect on 
the over expression of proteins. This is due to a difference in the metabolites 
and proteins present in the cell that might help or hinder correct folding of the 
protein. As by using auto induction media the expression levels were too low, M9 
media (minimal media) was used for growing cultures. The use of M9 media 
helped in increasing the expression levels and the protein yield form 1L cultures 
reached to 4-5mg in total. As the active site of the protein has Zn2+  and to rule 
out the possibility of Zn2+  as a limiting factor, ZnSO4 was added to some batches 
as a source of Zn2+  at a final concentration of  10µM. The addition of zinc to the 
cultures did not significantly increase the expression levels, therefore was 
discontinued later on. 
 
Figure  8.4 SDS-PAGE analysis for  test of expression of PARI in M9 media: 1 = molecular 
weight marker in Kda, 2 = total pre-induced sample, 3 = 2hour induced total sample, 4 = 
3hours induced total sample, 5 = overnight induced total sample, 6 = soluble pre-induced 
sample, 7 = 2hour induced soluble sample, 8 = 3hour induced soluble sample, 9 = overnight 
induced soluble sample, 10 = pre-induced insoluble sample, 11 = 2hour induced insoluble 
sample, 12 = 4hour induced insoluble sample, 13 = overnight induced insoluble sample, 14 = 
molecular weight marker in Kda. 
 
8.1.2.1 Lowering temperature of M9 cultures 
One of the possible reasons for low expression levels could be the misfolding of 
the expressed protein due to high temperature conditions of the growing 
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cultures, as at higher temperature the protein grows faster but cannot fold 
properly and some times this misfolded protein culminates in the form of 
inclusion bodies, leaving the protein in the insoluble fraction. To prevent these 
possibilities large cultures (in M9 media) were grown initially at 37°C and as the 
O.D600 reached 0.6, the cultures were put in slushy ice box for 5 minutes and 
then induced with 1mM IPTG and further left for overnight growth at 15°C. The 
change in temperature slightly increased the expression levels and the resulting 
protein yield was 4-6mg in total from 1L cultures. Poor expression levels can also 
be attributed to any gene which becomes toxic to the plasmid and thus 
damaging the T7 RNA polymerase, leading to very low yields of protein.  
 
8.1.3 Purification of PARI 
The cells were harvested and further nickel purification was carried. Different 
fractions obtained from Ni-column were loaded on a SDS PAGE gel (Figure 8.5). 
The protein was found in the elution fraction. The purified protein obtained 
after nickel purification had significant contamination of DNA as demonstrated 
by a peak at 260 nm from UV spectrum. In order to remove the high imidazole 
content and DNA content the elution fraction was subjected to over night 
dialysis in 2L of 20mM Na-phosphate buffer, pH: 7.5 at 4°C. The UV spectrum of 
protein sample after dialysis showed the removal of DNA with no peak at 260nm. 
The protein was then concentrated by using Vivaspin® at 3000xg to the desired 
concentration and then passed through the gel filtration column. 
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Figure  8.5 SDS-PAGE analysis for PARI after Ni-purification: 1 = molecular weight marker in 
Kda, 2 = flow through, 3 = 20mM Imidazole wash, 4 = 300mM Imidazole elute 
8.1.3.1 Size exclusion chromatography (Gel Filtration) 
The concentrated sample was subjected to size exclusion chromatography. The 
pure fractions obtained from gel filtration (Figure 8.6) were pooled and 
concentrated down by using the Vivaspin® at 3000xg. To check the purity of the 
protein the fractions obtained from gel filration chromatography were then 
loaded on to SDS-PAGE (Figure 8.7). The concentration of the protein was 
measured by using the molar absorption value. The molar absorption value (A280 
= 1.24 for 1g/L) was obtained from the amino acid sequence of the protein by 
using the expasy prota param resource (http://web.expasy.org/proparam). It 
was observed that the protein concentrated more quickly at 20°C rather than at 
4°C. During purification of different batches it was observed that the protein is 
purified better in buffer solution of 20mM Na-Phosphate, 50mM NaCl pH: 7.8. 
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Figure  8.6 Chromatogram for PARI after size exclusion chromatography with individual 
fractions eluted on molecular size basis 
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Figure  8.7 SDS-PAGE analysis for PARI after Ni-purification: M = molecular weight marker in 
Kda, A5-A7 = elution fraction with impurities, A8-A12 = pure elution fractions containing 
PARI. 
 
8.2 Protein aggregation problems 
During the purification, the protein appeared to be prone to precipitation, 
presumably because of the high Imidazole or NaCl concentration in the elution 
buffer. Each time when the protein was purified by using Ni-column, the elution 
fraction went cloudy, and when further subjected to buffer exchange, 
precipitates started to form; these precipitates were then removed by 
centrifuging the samples at 3000xg. In order to avoid the precipitation of PARI 
during its purification different parameters were altered such as  
1. Change in pH of purification buffers 
2. Varying NaCl concentration in the purification buffers 
3. Changing  the Tris-HCl concentration in purification buffers  
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The pH of the buffers was changed as it is possible that if the iso-electric point 
of the protein coincides with the pH of the solution then the protein will have no 
overall charge and will precipitate out of solution. Equally the concentration of 
NaCl, which screens protein charges in solution is known to be able to either 
increase or decrease solubility which is the basis of salting in or salting out in 
protein crystallization. Though a slight improvement was observed, but none of 
the parameters changed were able to completely fix the protein aggregation 
problem. 
A test experiment was carried out to observe the effect of increase in 
temperature on the aggregation rate of the purified protein. The experiment 
was carried out by using a 90 well Biometra PCR® machine. The starting 
temperature was set to 15°C and final temperature to 40°C. The starting 
concentration of the protein was 3mg/ml in 20mM Na phosphate, 50mM NaCl pH: 
7.8 buffer. Each of the 100µL protein sample were put in small eppendorfs and 
then in respective wells with temperatures of 15°C, 20°C, 24°C,  31.2°C, 35.9°C 
and 40.0°C The running time for the experiment was set to 40 minutes and the 
top lid of the instrument was closed to maintain the temperature. It was 
observed that after 40 minutes the samples at higher temperature went cloudy 
and when centrifuged at 12000xg for 10 minutes, precipitates were visible in the 
bottom of the eppendorfs. Further the supernatant was taken and the 
concentration of the protein sample was measured. The concentration (mg/mL) 
of individual protein samples after 40 minutes of experiment was measured. 
After 40 minutes at the following temperatures in the wells 15°C, 20°C, 24°C,  
31.2°C, 35.9°C and 40.0°C, the concentration of protein was 3, 2.75, 2.5, 2.3, 
2.03 and 1.95 mg/mL respectively. A gradual decrease in the concentration of 
protein samples was observed with the increase in temperature (Figure 8.8). The 
experiment indicated that the protein tends to form precipitates as the 
temperature is increased. 
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Figure  8.8 Effect of increase in temperature on the rate of aggregation of PARI, the protein 
concentration difference before and after the experiment is more visible at higher 
temperatures (as represented through vertical connected lines) 
 
To see the effect of temperature for continuously longer period of times on the 
rate of protein aggregation, the experiment was carried out at 20°C and 40°C 
and the change in protein concentration was measured after each hour for a 
maximum of 3 hours. The precipitates formed after each hour were removed by 
centrifuging at 12000xg for 5 minutes, rest of the conditions for the experiment 
were kept the same as set in previous experiment. The experimental results 
indicated that the rate of protein aggregation was higher at 40°C than at 20°C 
(Figure 8.9). 
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Figure  8.9 Aggregation rate of PARI at 20°C and 40°C for a period of 3 hours (protein 
concentration was measured after each hour following centrifugation of individual samples, 
protein concentration at the start of the experiment was 2.24 mg/mL) 
 
From both the experiments it was concluded that  
1. The protein is heat labile 
2.  Unstable at higher temperatures 
3. The rate of irreversible aggregation is fastest at higher temperatures 
8.3 NFGase activity of PARI 
PARI NFGase activity was tested by using the established enzyme assay which 
had been developed for the PAA protein, where hydrolysis of the amide bond is 
followed at A210nm as described in section 2.19.2. The results of the enzyme 
assays were very surprising as no activity was detected at all. The assays were 
repeated with varying concentrations of protein and the integrity of the protein 
was validated by CD and NMR. All possibilities were considered such as 
misfolding of the protein, proteolysis, inhibition, absence of zinc etc. If PARI was 
indeed an NFGase or related enzyme, all the possible events would be expected 
to reduce but not completely eliminate the activity. The sequence of PARI was 
searched against all protein sequences for the Ralstonia eutropha genome 
sequence at the CMR (Comprehensive Microbial Resource) website. The search 
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revealed that PARI (2Q7S) is one of a number of genes (HutG1, HutG2 & HutG3)  
with an NFGase like sequence, including one sequence (HutG1) which is located 
in the histidine utilization pathway operon and has high sequence similarity to 
PAA (Figure 8.10). The enzyme assay and analysis of the genome sequences lead 
to the conclusion that PARI is not a true NFGase and is a different enzyme with 
different substrate specificity. This was then used as a test case for 
pharmacophore searching. 
  
Figure  8.10 Sequence similarity of amino acids between PARI (2Q7S), PAA and some other 
structural analogues, PAA is the top sequence followed by 4 other NFGase related 
sequences from R. eutropha including PARI (2Q7S), HUTG1 HUTG2 and HUTG3, HUTG1 
shows high  sequence similarity to PAA while sequences of 2Q7S, HUTG2 and HUTG3 show 
higher similarity within their structures and form a related but different sub group of 
proteins,  sequences were aligned by using MultAlin {158}. 
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8.3.1 Spasm search 
As the PARI and NFGase like proteins have not been characterized with respect 
to their ligand binding or enzyme mechanism, the enzyme fold does not help in 
understanding the function by analogy with related proteins.  The active site of 
PARI is reasonably open and contains a zinc binding motif (Figure 8.11). 
 
Figure  8.11 The structural fold of protein PARI from R.Eutropha, the active site Zn2+ is 
represented as a grey sphere surrounded by the coordinating residues 
 
 In order to search for protein structures with similar arrangement of amino acid 
residues in the active site, the SPASM {159-161} software was used. This could 
provide an insight into function as the active site may be conserved while the 
fold is not e.g. serine protease catalytic triad is found in a number of unrelated 
protein families.  
Initially five amino acid residues, three zinc coordinating residues (HIS31, ASP54 
and HIS171) and two conserved residues (ARG78 and GLU249) were selected from 
the active site of PARI, copied and pasted in to a new window of DSV and then 
file saved with a .pdb extension. This file was then search against a recent 
database based on proteins from the PDB by using SPASM software on a local 
computer as the Web server was no longer available. Certain constraints in 
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search parameters were optimized by using the available options in the Spasm 
software, namely:  
1. Residue substitution options possible 
2. sequence directionality not considered and  
3. The side chain group would be considered and not the main chain 
positions. 
 The above parameters were necessary to optimize as we already knew that 
there was no protein with a similar fold so the order of the residues and their 
main chain positions were expected to be different. As a result of SPASM search 
the numbers of hits obtained were 25 (Table 8.1). Majority of hits were 
carboxypeptidases while deaminases, oxido reductases and amidases were also 
included among the hits. 
Table  8.1 Hits obtained from SPASM search along with their PDB codes, type of protein and 
source of origin, most of the hits were carboxypeptidases  
S.No PDB Code Type of protein Organism Atoms 
matched 
RMSD 
(Å)  
1 1UWY CARBOXYPEPTIDASE M Homo sapiens  37 0.61 
2 1PCA PROCARBOXYPEPTIDASE A Sus scofra 37 0.63 
3 2CTC CARBOXYPEPTIDASE A  Bos taurus    37 0.63 
4 2BO9 CARBOXYPEPTIDASE A4 Homo sapiens  37 0.66 
5 1H8L CARBOXYPEPTIDASE GP180  Lophonetta specularioides  37 0.67 
6 1ZLI Carboxypeptidase B  Homo sapiens   37 0.67 
7 1M4L CARBOXYPEPTIDASE A  Bos taurus    37 0.69 
8 2NSM Carboxypeptidase N catalytic chain Homo sapiens  37 0.69 
9 1CBX CARBOXYPEPTIDASE A  Bos taurus    37 0.7 
10 1JQG CARBOXYPEPTIDASE A  Helicoverpa armigera   37 0.7 
11 5CPA CARBOXYPEPTIDASE A  Bos taurus    37 0.7 
12 1DTD CARBOXYPEPTIDASE A2 Homo sapiens  37 0.71 
13 1Z5R procarboxypeptidase B  Sus scrofa  37 0.71 
14 1NSA PROCARBOXYPEPTIDASE B  Sus scrofa  37 0.72 
15 1OBR CARBOXYPEPTIDASE T  Thermoactinomyces 
vulgaris   
37 0.73 
16 1YW4 Succinylglutamate desuccinylase  Chromobacterium violaceum 37 0.78 
17 2O4H Aspartoacylase  Homo sapiens  37 0.8 
18 1KWM Procarboxypeptidase B  Homo sapiens  37 0.85 
19 2BCO Succinylglutamate desuccinylase  Vibrio parahaemolyticus   37 0.85 
20 3B2Y Metallopeptidase containing co-
catalytic metalloactive site 
 Shewanella denitrificans 
os217 
37 0.86 
21 2QVQ Cellular tumor antigen p53  Homo sapiens   37 0.87 
22 2Q4Z Aspartoacylase  Rattus norvegicus  37 0.94 
23 2G9D Succinylglutamate desuccinylase  Vibrio cholerae   37 1.05 
24 1JWQ N-ACETYLMURAMOYL-L-ALANINE 
AMIDASE 
 Paenibacillus polymyxa 37 1.37 
25 1XOV 
 Ply protein  Bacteriophage psa  37 1.49 
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The hits could be transformed onto the coordinates of PARI using a 
transformation matrix which was applied using Coot {95}. However, due to 
differences in convention the Spasm rotation matrix is the inverse of that used 
by coot so the matrix had to be transposed.  Good agreement between the 
residues involved in the zinc binding were seen between carboxypeptidase and 
PARI, also other residues were found in common which could be included in the 
alignment of the proteins. Among other carboxypeptidases structures that had 
an active site architecture similar to PARI, 1CBX was found to be the best hit 
(Figure 8.12). The 1CBX structure was determined with a ligand in the active site 
and this could provide very useful starting point for pharmacophore searching.  
 
Figure  8.12 Superimposed folded structure of PARI (blue) with 1CBX CarboxypeptidaseA 
(orange). The superimposed structures demonstrate the overall fold similarity and identical 
orientation of the active site residues (the active site residues around the zinc atom are 
shown as stick model) 
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8.4 Pharmacophore searching for PARI 
All the pharmacophores were generated by using the query atom method as 
described in detail in section 3.5.3. 
8.4.1 Generation of pharmacophore for PARI 
All the hits obtained through SPASM search were visualized in COOT®. 1CBX was 
selected as a template model on the bases of close resemblance of active site 
residues to PARI. The structures of 1CBX and PARI were visualized simultaneously 
in COOT® by using the superimposing feature. The x, y and z co-ordinates of the 
hits were transformed with reference to PARI by using the operator function 
(through the route of calculate, scripting) and python command: 
transform_molecule_by (molecule number) m11 m12 m13 m21 m22 m23 m31 
m32 m33 x y z 
The transformed coordinates were then saved with a .pdb extension and further 
visualized in DSV®. Both the PARI and 1CBX structures were optimised by using 
the structure superimpose and add selecting pairs of atoms to act as tethers 
option. This way an optimal alignment was made possible. 
8.4.1.1 Pharma PARI 1 
Clearly, the inhibitor for 1CBX would not be a suitable inhibitor of the enzyme as 
the benzyl group is not present exactly in active site pocket near the zinc atom, 
however the key aspects of the ligand recognition, i.e; the carboxylate group 
interactions with the zinc ion could be utilized. Alignment of 1CBX with PARI 
enabled to take the key conserved features of the inhibitor L-benzyl succinate 
found in the active site of 1CBX and transfer them to the PARI active site. The 
pharmacophore with a simple minimal description along with exclusion spheres 
was generated. The generated pharmacophore was searched through the 
ChEBI.bdb database.  The search gave 76 hits in just 40 minutes time. The hits 
included notably benzyl succinic acid, succinic acid, L-aspartic acid and N-
carbamoyl-L-aspartic acid (Figure 8.13). 
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Figure  8.13 Superimposed structures of ICBX (line models) and PARI (stick model) along 
with the pharmacophore containing N-carbamoyl L-Aspartic acid as a hit in the active site 
surrounding by conserved residues, green dashed line shows crucial H-bonds between 
ARG (highlighted in yellow which is slightly disordered in PARI) and carboxy terminus of 
the ligand all exclusion spheres, some amino acid residues and water molecules have been 
removed for clarity viewing 
 
8.4.1.2 Pharma PARI 2 
All the hits obtained through first pharmacophore had only carbon atoms 
specified for position 1, 2 and 3 in the query ligand. In order to see the effect on 
the chemical features of the hits, multi atoms were specified on these positions 
including C, N and O. The radius of uncertainty location sphere around positions 
1, 2 & 3 was changed from 0.4Å to 0.8Å (Figure 8.14). Further the H-count for 
position A and C was changed to 0 and bond order between A-B and C-D was set 
to single/double. The pharmacophore was then searched through the ChEBI.bdb 
database. The search gave 126 hits, in which some of the hits had nitrogen atom 
at position 2 (which is important for catalytic activity of a Carboxypeptidase, in 
terms of cleaving the peptide bond). The type of hits obtained demonstrated the 
benefit of relaxing/optimization of the above mentioned constraints, thus 
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getting more potential ligands. The hits also included 5 dipeptides, 
geometrically positioned in a favorable manner (for peptide cleavage) preferred 
in the active site of a Carboxypeptidase. The hits in particular included N-
carbamoyl-L-aspartic acid, N-carbamoyl-L-valine, benzyl succinic acid, 
glycylglycine, L-cysteinylglycine and L-prolylglycine 
  
Figure  8.14 Pharmacophore with the size of the uncertainty location sphere at position 1, 2 
& 3 changed from 0.4Å to 0.8Å, among the hits glycylglycine (a dipeptide) is represented as 
a stick model superimposed on query ligand in the active site of the protein, the presence of 
nitrogen atom at position2 favours the possible cleavage of peptide bond. (All exclusion 
spheres, certain amino acid residues and water molecules have been hidden for clarity 
viewing) 
 
To check the number of peptides in the database a chemical searching of the 
database with an alanyl group gave only 47 hits which included only Ala-Glu as a 
dipeptide. It became clear that very few peptides (di/tri) were found in the 
database. In order to fulfil this gap a peptide database was generated (as 
described in section 3.4.2). The generated database had all possible 
combinations of di and tri-peptides i.e. 8,400 compounds and was used in later 
pharmacophore searches.  
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8.4.1.3 Pharma PARI 3 (sub-structure fragment based search) 
In order to avoid a biased search via a ligand model, the position 2 was removed 
from the previous pharmacophore and the location of the Cα carbon was not 
defined. A minimal pharmacophore was specified which contained: 
1. Position C along with the carbonyl oxygen at position D towards the 
zinc metal ion. 
2. Carboxyl carbon at position A and its corresponding two oxygens 
towards the ARG78 of the protein. 
The modification left a fragment type sub structure pharmacophore in place 
(Figure 8.15). The resultant pharmacophore was then searched against the 
dipeptide and tripeptide database.  
  
Figure  8.15 Position_2 removed from the pharmacophore, leading to a substructure 
fragment style pharmacophore. Asp-Gly-Ser a tripeptide among the hits is represented as 
stick model (All exclusion spheres, certain amino acid residues and water molecules have 
been removed for clarity viewing) 
Interestingly 200 hits were obtained through the search, majority of the 
dipeptides and tripeptides had their C-terminal positioned towards the GLU249 
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as per proposed mechanism for a carboxypeptidase (Figure 8.16) except some 
peptides with aspartate which had the R-group oriented towards the carboxyl 
binding site. The hits included 101 dipeptides like Ala-Gln, Ala-Gly, Ala-Ile, Ala-
Pro, Ala-Ser and 99 tripeptides like Asn-Ala-Asn, Asn-Ala-Pro, Asn-Ala-Thr, Asn-
Gly-Asp, Asn-Gly-Gly. Due to the absence of well defined hydrophobic pocket, 
peptides (di/tri) with bulky hydrophobic residues were absent amongst the hits. 
 
Figure  8.16 Schematic representation of possible nucleophilic mechanism for 
Carboxypeptidase A, R= peptide chain, adapted from{162}. 
8.4.1.4 Pharma PARI 4 
In a proposed mechanism of carboxypeptidases {163}, tyrosine residue has a 
significant role in the stabilization of the substrate. Upon the introduction of the 
substrate tyrosine closes in to the active site (S1^) forming H-bonds with the 
carbonyl oxygen of the peptide (Figure 8.17) and thus creating a pocket (S1) to 
fit in the whole substrate (either a di or tripeptide). In order to identify 
potential residues that could bind in the S1 binding site the previous 
pharmacophore was modified by changing the position of the TYR227 (by using 
the Torsion feature of the DSV®). The resultant distance between the carbonyl 
oxygen of the query ligand and TYR227 (previously 6.158Å) was optimized to a 
good H-bond distance of 2.836Å (Figure 8.17). The resultant pocket on top of 
TYR227 was visualized by using the solvent surface feature of DSV®, which was 
mostly hydrophobic in nature , comprising of MET173, PRO226, ARG251, ASN175, 
LEU189 (towards the bottom of the pocket) and LEU181 (towards the top of the 
pocket). The exclusion spheres were introduced around the optimized active site 
and the resultant pharmacophore was searched through the di and tri peptide 
database. The search gave 26 hits which included 8 dipeptides like Cys-Gly,   
Glu-Gly, Gly-Gly, Pro-Gly and 18 tripeptides like Ala-Gln-Gly, Ala-Thr-Gly, Arg-
Ser-Gly, Asp-Gly-Gly, Asp-His-Ser. All the hits demonstrated the formation of H-
bond between their carbonyl oxygen and TYR227 of the enzyme.  
Chapter  8   209 
 
Figure  8.17 Representation of the change in position of the TYR227 at a H-bond distance 
from POS_D, the final position of TYR227 is shown as stick model while the previous 
position is in line model, Val-Gly a dipeptide among the hits is represented as stick model 
(all exclusion spheres, certain amino acid residues and water molecules have been removed 
for clarity viewing) 
 
8.4.1.5 Pharma PARI 5 
The orientation of hits towards the hydrophobic pocket (S1)  was not as desired, 
in order to get hits  fitting well within the hydrophobic pocket, the size of the 
uncertainty location sphere around the carboxyl carbon (Pos_1/C) was changed 
from 0.8Å to 0.6Å, the rest of the pharmacophore was kept the same. The 
search gave 11 hits from the dipeptide/tripeptide database, but still the R-
groups of the hits were not fitting in the hydrophobic pocket (Figure 8.18). 
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Figure  8.18 Graphical representation of the hits (in line model) in the active site of the 
protein, the hydrophobic pocket (labelled as S1) is empty while the R groups of the hits are 
located outside the hydrophobic pocket. 
 
8.5 Ligand selection and synthesis 
 Given the difficulty in assigning specific amino acid groups to the S1 site and 
the potential variation in possible peptides, it was decided to try and identify 
binding ligand to the active site (S1^, C-terminal carboxylate binding site). 
Simple amino acids as products are likely to have weak affinity. Therefore N-
carbamoyl amino acid derivatives would seem to be suitable candidates as they 
cannot be hydrolysed by the enzyme and should give insight regarding affinity of 
the protein for different amino acid derivatives. 
Carbamoyl derivatives of different amino acids like carbamoyl cysteine, 
carbamoyl lysine, carbamoyl glutamate, carbamoyl glutamine, carbamoyl 
phenylalanine, carbamoyl methionine, carbamoyl valine, carbamoyl threonine, 
carbamoyl leucine,   and carbamoyl-histidine were synthesized by using the 
microwave method as used by Verado et a l{164}. All the reactions were carried 
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out in a domestic microwave oven (Panasonic NN-SD466M) at 1000W. Mass 
spectra were obtained by using a JEOL JMS-700 spectrometer. 1H NMR and 13C 
spectra were recorded on a Bruker DPX-400 spectrometer with chemical shift 
values in ppm relative to TMS (δH 0.00 and δC 0.0) as standard with D2O as a 
solvent at room temperature. Specific optical rotations of the compounds were 
determined in 0.25M NaOH solution in methanol at 20°C (compound 
concentration 15mg/mL) by using Automatic polarimeter APV-6W, RUDOLPH 
RESEARCH ANALYTICAL, NJ, USA. All the experimental data(optical rotation, 
mass spectrometry, 1H NMR and 13C) was consistent with the already published 
data {164}.  The details of the microwave procedure for carbamoyl glutamate 
synthesis are given below. 
8.5.1 Synthesis of Carbamoyl Glutamate: 
Carbamoyl glutamate was synthesized by the Microwave-assisted method {164}. 
L-glutamic acid (6.0 mmol) was added in to a 50 mL beaker containing a stirred 
solution of NaOH (0.24g, 6.0mmol) in water (1.8mL). When a clear solution was 
obtained, urea (0.62g, 10.30mmol) was added, and the reaction mixture was 
made homogenous by well mixing with the help of a glass rod. The reaction 
vessel was covered with a watch glass and placed into an unmodified domestic 
microwave oven, together with a 500mL beaker containing water (300—400mL), 
and irradiated for 4 minutes at 1000W. The reaction mixture was then cooled at 
0°C, and 6M HCl (1.0mL, 6.0mmol) was added while stirring. The obtained solid 
was filtered and washed with water (6.0mL) to eliminate excess urea and NaCl, 
yielding carbamoyl glutamate in a spectroscopically pure form. The % yield of 
the synthesized compounds was 75.2%. 
Spectroscopic data was in accordance with the literature. {α}D +4.2; (m/z) (CI) 
191.25 (95%), 164.23 (35%), 120.22 (15%), 97.22 (20%), 71.15 (45%); δH (400 MHz, 
D2O) 1.81—1.92 (m, 2H, 3-CH2) 2.03—2.13 (2H, m, 2-CH2), 4.09 (q, j 5.0, 4-CH); 
δC (100MHz, D2O) 29.15, 34.16, 55.70, 161.0, 180.20 and 182.55. 
Brenda enzyme database (http://www.brenda-enzymes.info/) was used as a 
reference to add a sensible concentration of potential ligands to the protein. 
The affinity values for different ligands in case of carboxypeptidases were in the 
range of 1—2mM. 
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8.6 CD results for PARI 
To see the effect of potential ligands on the secondary structure of the protein, 
particularly on the aromatic regions of the protein the selected potential ligands 
were added to the protein and their near and far UV spectra were recorded. All 
the CD spectra were recorded at a protein concentration of 1.7mg/mL; cell path 
length was 0.01cm and 0.2cm for Far and Near UV analysis respectively. The CD 
experiments were carried out in buffer solution of 20mM Na-phosphate, 50mM 
NaCl pH: 7.8 at 20°C.  
The near CD spectrum for PARI with carbamoyl cysteine (Figure 8.19) 
demonstrated subtle changes in the 270-290nm range, which may suggest some 
slight structural rearrangements in the binding site. 
 
Figure  8.19 Near UV (250-320nm) and Far UV (190-260nm) CD spectra for PARI (blue) and 
PARI with 20mM Carbamoyl cysteine (red).  
The spectral changes brought by the addition of carbamoyl lysine, carbamoyl 
glutamate and L-Histidine (Figure 8.20-22) were very subtle and the pattern 
observed for these ligands was more or less the same in the Near UV region. This 
similarity in CD spectra might indicate that these ligands are causing the same 
effect in or around the binding site of the protein. Pertaining to the fact that 
the ligands are small and thus are unlikely to cause a big shift in the near UV or 
far UV spectra, the overall composition of α-helices and β-strands nearly 
remained the same in case of these ligands. 
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Figure  8.20 Near UV (250-320nm) and Far UV (190-260nm) CD spectra for PARI (blue) and 
PARI with 20mM Carbamoyl lysine (red).  
 
 
Figure  8.21 Near UV (250-320nm) and Far UV (190-260nm) CD spectra for PARI (blue) and 
PARI with 20mM Carbamoyl glutamate (red).  
 
 
Figure  8.22 Near UV (250-320nm) and Far UV (190-260nm) CD spectra for PARI (blue) and 
PARI with 20mM L-Histidine (red).  
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The spectral changes observed for L-glutamate and N-formyl L-glutamate were 
more significant than the rest of the ligands (Figure 8.23-24). The changing 
pattern in the near UV region (particularly in 255-310nm range) for L-glutamate 
and N-formyl L-glutamate was pretty similar, though the shifts were much bigger 
in case of N-formyl L-glutamate. In the far UV region changes were observed for 
N-formyl L-glutamate (particularly in 190-220nm range). The bigger shifts both 
in the near UV and far UV region due to the addition of N-formyl L-glutamate 
suggests some changes in the secondary structure of the protein.  
 
Figure  8.23 Near UV (250-320nm) and Far UV (190-260nm) CD spectra for PARI (blue) and 
PARI with 20mM L-glutamate (red).  
 
Figure  8.24 Near UV (250-320nm) and Far UV (190-260nm) CD spectra for PARI (blue) and 
PARI with 20mM N-formyl L-glutamate (red).  
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By comparing all the CD spectra both in the near UV and far UV region, it 
appears that N-formyl L-glutamate brings more significant changes than any 
other ligand. The effect of different ligands on the protein in descending order 
can be given as 
N-formyl L-glutamate > L-glutamate > carbamoyl cysteine > carbamoyl 
histidine = carbamoyl lysine = carbamoyl glutamate 
8.7 NMR experiments on PARI 
In order to see the effect in terms of ligand binding, HSQC spectra were carried 
out by using the 15N-labelled protein. The protein was over expressed in M9 
media supplemented with15N-labelled NH4Cl. The protein samples for HSQC 
spectra both with and without the ligand were prepared in the same way as 
described in section 6.6.1. The ligands were prepared in the same buffer 
solution as of the protein and further the pH of the ligand solution was adjusted 
to the protein solution To get a cleaner spectra, and better signal to noise ratio, 
the experiments were carried out at different temperatures. The spectra were 
recorded with 5°C increase in temperature, starting from 20°C up to 40°C.  
The increase in temperature with the aim to get higher signal to noise ratio 
resulted in sharp signals for the protein. Initially the HSQC spectra for the 
protein were recorded in buffer solution of 20mM Na-phosphate, 150mM NaCl 
pH: 7.5. The appearance of the HSQC spectra was not very clear, therefore to 
increase the signal to noise ratio the salt concentration was decreased to 50mM 
in the buffer solution which resulted in sharp peaks for individual residues. All 
the experiments were carried out at 35°C in buffer solution of 20mM Na-
phosphate, 50mM NaCl pH: 7.8. The final concentration of protein and different 
ligands was 100µM and 20mM respectively. 
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Figure  8.25 NMR-HSQC spectra for 15N-labelled PARI without any ligand 
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8.7.1 N-formyl L-glutamate with PARI 
The overlayed HSQC spectra for the protein along with N-formyl L-glutamate 
showed some marked changes. It was observed that certain peaks significantly 
changed their positions while few peaks disappeared and some new peaks 
appeared as well (Figure 8.26). The changes brought about by the addition of N-
formyl L-glutamate were more profound and visible than any other ligand. The 
changes can be attributed to a direct interaction between certain amino acid 
residues and N-formyl L-glutamate. 
 
Figure  8.26 Overlaid HSQC spectra for PARI along with 20mM N-formyl L-glutamate, empty 
square boxes around peaks represent the change in position of peaks due to the addition of 
ligand, empty circles around peaks represent no change due to the addition of ligand (green 
spectra = protein alone, blue spectra = protein with ligand) 
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8.7.2 Carbamoyl histidine with PARI 
More marked changes in the peaks positions were observed due to the addition 
of carbmoyl histidine to the protein, it appeared that some peaks travelled a 
longer distance and appeared at a new position while some peaks slightly 
changed their position. The changing pattern occurring due to the addition of 
carbamoyl histidine had some similarities with N-formyl L-glutamate. The bigger 
chemical shift for certain residues was the same as due to addition of N-formyl 
L-glutamate (Figure 8.27). 
 
Figure  8.27 Overlaid HSQC spectra for PARI along with 20mM carbamoyl histidine, empty 
square boxes around peaks represent change in position of peaks due to the addition of the 
ligand,  empty circles around peaks represent no change due to the addition of ligand 
(green spectra = protein alone, blue spectra = protein with ligand) 
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8.7.3 L-glutamate with PARI 
The overlayed HSQC spectra for protein along with L-glutamate indicated 
significant changes. Some peaks completely disappeared due to the addition of 
ligand, few peaks had bigger chemical shifts and some peaks slightly changed 
their position (Figure 8.28). The changing pattern of HSQC spectra due to the 
addition of L-glutamate had similarities with N-formyl glutamate, but it 
appeared that some peaks completely disappeared as a result of addition of L-
glutamate which in case of N-formyl L-glutamate had slightly moved their 
position.  
 
Figure  8.28 Overlaid HSQC spectra for PARI along with 20mM L-glutamate, empty square 
boxes around peaks represent change in position of peaks due to the addition of the ligand,  
empty circles around peaks represent no change due to the addition of ligand (green 
spectra = protein alone, blue spectra = protein with ligand) 
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8.7.4 Carbamoyl glutamate with PARI 
In case of addition of carbamoyl glutamate to the protein, it was observed that 
some of the peaks moved slightly, while few peaks completely disappeared 
which may suggests the change in the conformation of some amino acids of the 
protein (Figure 8.29). By comparing the spectra of the protein alone and in the 
presence of carbamoyl glutamate, the spectral changes indicate that the 
chemical environment of some residues of the protein changed significantly 
which resulted in change in chemical shift values for certain amino acid 
residues.  
               
Figure  8.29 Overlaid HSQC spectra for PARI along with 20mM carbamoyl glutamate, empty 
square boxes around peaks represent change in position of peaks due to the addition of the 
ligand,  empty circles around peaks represent no change due to the addition of ligand 
(green spectra = protein alone, blue spectra = protein with ligand)  
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8.7.5 Carbamoyl lysine with PARI 
Both slight changes and bigger changes were observed in the overlayed HSQC 
spectra for carbamoyl lysine. The changing pattern of HSQC spectra due to the 
addition of carbamoyl lysine had similarities with carbamoyl histidine (Figure 
8.30). The spectra were not clean to a desired level due to poor signal to noise 
ratio and thus caused difficulty in analyzing the spectral changes. 
 Figure  8.30 Overlaid HSQC spectra for PARI along with 20mM carbamoyl lysine, empty 
square boxes around peaks represent the change in position of peaks due to the addition of 
ligand,  empty circles around peaks represent no change due to the addition of ligand 
(green spectra = protein alone, blue spectra = protein with ligand) 
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8.7.6 Carbamoyl cysteine with PARI 
In the event of addition of carbamoyl cysteine to the protein very few changes 
were observed (Figure 8.31). By close observance it appeared that the spectrum 
for the protein with and without carbamoyl cysteine were almost similar. This 
indicates that carbamoyl cysteine does not bind to the protein at all. 
              
Figure  8.31 Overlaid HSQC spectra for PARI along with 20mM carbamoyl cysteine, empty 
square boxes around peaks represent the change in position of peaks due to the addition of 
ligand,  empty circles around peaks represent no change due to the addition of ligand 
(green spectra = protein alone, brown spectra = protein with ligand) 
 
By analyzing all the individual and overlayed HSQC spectra it appeared that 
there were a number of phenomena taking place due to the addition of ligand to 
the protein. The slight change in chemical shift values of certain residues can be 
due to the change in the chemical environment of the residues. The 
disappearance of certain peaks as a result of ligand addition can be attributed to 
a complete conformational change of the amino acid residues. The bigger 
chemical shift changes in certain residues can be due to direct interaction with 
the ligand, which could be occurring in the protein active site. The increase 
/decrease in intensity of some peaks can be ascribed to more exposed/buried 
nature of the individual amino acid residue due to the addition of ligand.It was 
not possible to calculate the Kd value for individual ligands, which requires 
number of points in the form of ligand addition. The outcome of the experiments 
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was helpful in differentiating the ligand in terms of binders and non-binders. As 
explained by the HSQC the individual ligands can be categorized in terms of 
causing overall changes in descending order as: 
N-formyl L-glutamate > carbamoyl histidine > L-glutamate > carbamoyl 
glutamate = carbamoyl lysine > carbamoyl cysteine 
8.8 Effect of ligand addition on aggregation of PARI 
The addition of individual ligands to the protein caused aggregation which could 
be due to high temperature (35°C) and/or the addition of high concentration of 
ligand. During the NMR and CD experiments it appeared that the protein tends to 
precipitate quickly due to the addition of ligands. To find out the effect of 
ligand addition on the rate of aggregation a test experiment was carried out in 
the same manner as previously carried out for native protein (section 8.2). 20mM 
L-glutamate was added as a ligand to the individual protein samples prior to the 
start of the experiment. After a 40 minutes experiment it was observed that 
ligand addition significantly increases the aggregation rate, particularly in the  
20—25°C  and slightly in the 30—40°C temperature range (Figure 8.32). 
               
Figure  8.32 Graphical representation of effect of temperature on aggregation rate of PARI 
due to the addition of ligand at a range of temperature (vertical lines show the relative 
decrease in protein concentration due to the addition of ligand in a 40 minute experiment) 
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To further confirm these results another test experiment was carried out (as 
described in section 8.2) in which the protein samples along with the ligand 
were subjected to 20°C and 40°C temperatures for 3 hours and the protein 
concentration was measured after each hour (Figure 8.33). The comparative 
graphical data demonstrated that the liganded-protein tends to aggregate 
quickly and at higher rates than the unliganded-protein. It was concluded from 
the experimental data that the rate of aggregation is mainly due to the 
temperature factor, but the addition of ligand causes significant increase in it. 
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Figure  8.33 Graphical representation of effect of temperature on aggregation rate of PARI 
(with and without ligand), the protein concentration was measured at 20°C and 40°C after 
each hour for a total of 3 hours 
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8.9 Conclusions and Future work 
The amount of work that could be performed on PARI was limited by significant 
issues which included low yield of protein from large scale cultures, prompt 
aggregation and instability of the protein due to the addition of ligand. By 
carrying out standard enzyme assays on PARI (PDB: 2Q7S) it is confirmed that it 
is not an NFGase. There is strong homology of the active site with 
Carboxypeptidase, not only the residues that coordinate the zinc atom but also 
catalytic residues and those associated with binding the c-terminal carboxylate 
group. Pharmacophore searching identified glutamate among others as possible 
residues to bind in the S1^. However in PARI structure there is no hydrophobic 
pocket S1, which would restrict the substrate specificity of the enzyme. It is 
presumed that upon peptide binding a conformational change accompanying the 
down ward movement of TYR227 side chain is necessary to open the S1 binding 
pocket. The NMR titrations suggest that peptides with a C-terminal glutamate 
may be potential substrates; however more binding experiments would be 
required to confirm this with other N-carbamoyl-amino acids to observe and 
define the specificity. An obvious next step is to synthesize dipeptides with a C-
terminal glutamate and see whether they act as substrates by using the standard 
assay developed for testing carboxypeptidase activity. In the absence of 
peptidase activity, the assignment of this protein as a carboxypeptidase is 
uncertain.  
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The N-formyl glutamate amido hydrolase from pseudomonas auroginosa (PAA) is 
the last enzyme in the Histidine utilization pathway II (Hut II). The enzyme 
hydrolyses N-formyl glutamate to glutamate and formate (Figure 9.1). The 
enzyme comprises of 266 amino acids with a Mr of 29.8Kda. In HUT II glutamate 
and formate are produced in the last step, but dependent on the organism it can 
produce formate or formamide. Formate is potentially toxic to the bacteria as it 
can form formaldehyde and can be simply metabolized to CO2 by formate 
dehydrogenase {165}. Interestingly majority of the formate from this pathway 
gets incorporated as the C2 of purine rings in purine biosynthesis {166}. The 
structural mechanism by which formate is incorporated as C2 in the purine rings 
during purine biosynthesis is unknown.  
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Figure  9.1 PAA catalyzing N-formyl glutamate to formate and glutamate 
 
  Hut I comprises of 4 enzymatic steps while the Hut II pathway has 5 enzymatic 
steps. The initial 3 enzymatic steps are same in both Hut I and Hut II. The two 
pathways differ in their conversion of N-formimino-L-glutamate (FIGLU) to L-
glutamate.  In Hut I pathway the conversion is achieved by a single enzymatic 
step involving formiminoglutamate hydrolase (HutG), which hydrolyses FIGLU to 
yield L-glutamate and formamide.  In Hut II pathway   the same overall process 
is achieved by 2 enzymatic reactions where FIGLU is initially converted to N-
formyl-L-glutamate (NFGLU) by formiminoglutamate deiminase (HutF) and in the 
9. Biochemical characterization of Pseudomonas 
auroginosa Amidohydrolase (PAA) 
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final 5th step NFGLU is hydrolyzed by formylglutamate deformylase (PAA) to yield 
L-glutamate and formate (Figure 9.2). 
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Figure  9.2 Hut II 5 step pathway, PAA catalyzes the 5th step by converting NFGLU to L-
glutamate and formate, image adopted from {151}. 
 
9.1 Aims and objectives 
The aims of the study which could help in understanding the enzyme mechanism 
are given below  
1. Kinetic characterization of the enzyme 
2. Inhibition assays on the protein with potential inhibitors mimicking 
the true substrate of the protein 
3. Co-crystallization of protein with different inhibitors for analysis of 
binding mode. 
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9.2  Expression and purification of PAA 
The plasmid was transformed in to BL21 (DE3) cells, and the protein was over 
expressed in auto induction media (Figure 9.3). The N-terminal His tagged 
protein was then purified through Nickel column. 
 
 
 
Figure  9.3 SDS-PAGE analysis for PAA after Over night induction in autoindution media: 1= 
molecular weight marker in Kda (Precision plus proteinTM BioRad, cat# 161-0373), 2-6= 
overnight induced samples of PAA (vertical column with different molecular weights for 
individual bands) 
 
 
SDS-PAGE analysis showed that the protein is eluted at 75mM Imidazole 
concentration instead of 200 or 300 mM Imidazole concentration, keeping this in 
view in all the future batches the PAA were purified by eluting at 75mM 
Imidazole with a wash at 20mM Imidazole (Figure 9.4). For all the SDS-PAGE 
analysis NuPAGE Novex (Invitrogen®) Bis-Tris 4-12 % gel was used in 4-12 % Bis-
Tris (MES) buffer. The elution fraction was buffer exchanged to get rid of excess 
of Imidazole and subsequently concentrated down to the desired concentration 
by using Vivaspin®. The concentrated protein was then used for co-
crystallizations, Isothermal titration calorimetry (ITC) and inhibition assays. 
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Figure  9.4 SDS-PAGE analysis for PAA after Ni-purification: 1= flow through, 2= 75mM 
Wash1, 3=75mM Imidazole wash2, 4, 5= 200mM Imidazole elute, 6= 300mM Imidazole elute, 
7=molecular weight marker in Kda  
 
9.3 I T C studies on PAA with potential inhibitors 
ITC experiments were carried out on protein, with the potential inhibitors, 
butane tri carboxylic acid (BTCA) and Citrate. 1mM of citrate was used in the 
beginning but the titration curve did not show any change, therefore later on 
the concentration was increased to 10mM. The increase in concentration 
resulted in an observable change in the titration curve (Figure 9.5). 
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Figure  9.5  ITC titration Curve for PAA along with citrate 
For BTCA comparatively tight binding was observed as the initial 0.53mM 
concentration was sufficient to show changes in the titration curve (Figure 9.6). 
The ITC data obtained after titration gave N value of 0.86 for BTCA indicating 
that inhibitor and binding site ratio is about 1:1, K value (Association constant, 
Ka) was 9.6µM, which in terms of Kd(1/Ka)= 0.1µM, the enthalpy value (∆H) was 
negative showing that binding of BTCA to PAA is exothermic in nature.   
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Figure  9.6  ITC titration Curve for PAA along with BTCA 
 
The binding curve for citrate gave N value of 1, showing 1:1 binding of a citrate 
molecule to PAA, the K value was 4366M (Kd = 0.23mM), enthalpy value (∆H) was 
positive (1638), showing that the reaction is endothermic in nature, and the 
entropy value (∆S) was fairly high (22.15) in comparison to BTCA (9.0), showing 
that the reaction between citrate and PAA is more entropy driven then BTCA 
with PAA. ITC results were further supported by the enzyme inhibition assays, 
which gave Ki values of 150nM and 0.54mM for BTCA and citrate respectively. 
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Figure  9.7 Overlaid ITC titration curve for PAA with both BTCA and Citrate 
 
The ITC results demonstrated tight binding of PAA to BTCA while weak binding to 
citrate. The concentration of protein used in the ITC experiments was 28µM 
against Citrate (10mM) and 62µM against BTCA (0.53mM). 
9.4 Inhibition studies on PAA 
Previously enzyme assays have been carried out for PAA in the presence and 
absence of inhibitors (Teresa Morenés Bertrán an Erasmus student). Inhibitors 
which have been tested previously include EDTA (non competitive inhibitor Ki = 
110nM), Citrate (competitive inhibitor, Ki = 0.54mM) and potential transition 
state mimic N-Sulphoglutamate (competitive inhibitor, Ki = 2.36mM). The 
potential inhibitor 1, 2, 4- Butane tricarboxylic acid (BTCA) and carbamoyl 
glutamate (CG) were selected on the basis of structural similarity with citrate 
and the substrate N-formyl glutamate (Figure 9.8). 
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Figure  9.8 Comparison of chemical structures of substrate (N-formyl glutamate) with 
inhibitors (BTCA, Citrate and CG) 
 
 
The enzyme assays were performed by using jasco-550 double beam 
spectrophotometer at a wavelength of 210nm. The hydrolysis of amide bond was 
followed by a decrease in absorbance at 210nm. Both enzyme and inhibition 
assays were carried out in  PBS buffer (1.4M NaCl, 27mM KCl, 100mM Na2HPO4, 
18mM KH2PO4 pH: 7.2).  Final concentration of protein was 1.38µM and 0.46µM in 
the cell for BTCA and CG respectively. The substrate concentration was varied 
between 0.05—1.5mM. Different inhibitor concentrations were used for 
calculating the Ki values. Inhibition assays on both BTCA and CG indicated non 
competitive inhibition with a Ki of 150nM (similar to EDTA) for BTCA and 40µM 
for CG (Figure 9.9-10). The Lineweaver- Burk equation given below was used for 
calculating the Km, Vmax and slope (Km/Vmax) values. 
 
 
 
 
 
 
      1     =     Km        +     1 
      V           Vmax [S]       Vmax  
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Figure  9.9 Line weaver-Burk plot for PAA with and without BTCA (the extrapolated lines 
cross at the same point at negative x-axis to give the same -1/Km value) 
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Figure  9.10 Lineweaver-Burk plot of PAA with and without CG (the extrapolated lines cross 
at the same point at negative x-axis to give the same -1/Km value) 
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9.4.1 Calculation of Ki for BTCA and CG  
The inhibition constant, Ki was calculated by using the appropriate formula for 
noncompetitive inhibition as mentioned in figure 9.11  
 
Figure  9.11 Graphical representation of Lineweaver-Burk plot for Non-competitive inhibition 
 
               
The Ki values calculated for BTCA and CG at individual inhibitor concentrations 
are given in table 9.1.  The average calculated Ki value for BTCA was 190nM, 
which is near to the Ki value for EDTA (117nM, previously determined in the 
group). The average Ki value for CG was calculated to be 34µM. 
Inhibitor Inhibitor concentration (mM) Calculated Ki value (µM) 
0.2 0.240  BTCA 
0.4 0.140  
0.117 53.6  
0.234  40  
0.468  32  
CG 
1.17  40  
Table  9.1 Ki values for PAA against BTCA and CG by using non-linear regression plots. 
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The Km and Vmax values for BTCA and CG were calculated by using both 
Lineweaver-Burk (Table 9.2) and non linear regression plots (Table 9.3). 
Inhibitor Inhibitor concentration  Km (mM ) Vmax (µM/S ) 
0.00 µM 1.19 12.3 
0.2  µM 0.80 5.90 
BTCA 
0.4  µM 0.7611 3.48 
0.00   mM 0.776 4.34 
0.117  mM 0.784 2.53 
0.234  mM 1.31 2.32 
0.468  mM 1.37 1.28 
CG 
1.17    mM 2.12 1.32 
 
Table  9.2 Km and Vmax Values of PAA with BTCA and CG by using Lineweaver-Burk plots. 
The values obtained through Lineweaver-Burk plot are not the most accurate 
way of obtaining these values as the plot and the trend line are overly affected 
by points measured for the lowest substrate concentrations, which have the 
largest error.  A better method is to calculate the values directly by non linear 
regression fit to the Michelis-Menton equation (Table 9.3). 
Inhibitor Inhibitor 
concentration 
Km(mM ) Vmax (µM/S ) 
0.00 µM 0.6124±0.0563 15.33 ± 3.81 
0.2  µM 0.5454±0.1571 8.33 ± 1.33 
BTCA 
0.4  µM 0.3346±0.0719 4.0 ± 0.26 
0.00   mM 0.692±0.158 12.4 ± 2.68 
0.117  mM 0.687±0.180 3.9 ± 0.65 
0.234  mM 0.504±0.05 1.84 ± 0.19 
0.468  mM 0.288±0.06 0.79 ± 0.05 
CG 
1.17    mM 0.441±0.23 0.40± 0.09 
 
Table  9.3 Km and Vmax Values of PAA with BTCA and CG obtained by using Non-linear 
regression plots. 
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Figure  9.12 A typical Non-linear Regression plot for PAA with 0.2µM BTCA (Vmax value is in 
M/min) 
 
For BTCA and CG the individual kinetic inhibition data in terms of Lineweaver-
Burk plot gave the -1/Km values which were close to each other.  Very less 
variation in -1/Km value both in the inhibited and un-inhibited cases indicated a 
Non-competitive inhibition against PAA. The analysis of data from both the plots 
indicated greater changes in Vmax values in comparison to the Km values which 
again assured that the inhibition is non-competitive in nature. 
 
9.4.2 PAA Inhibition studies using Nickel, EDTA, BTCA and Zn 
solution  
To test if active site zinc is being chelated by BTCA in the same way as EDTA. 
The inhibition assays were performed in the presence of Ni2+ solution. In case of 
a chelating effect BTCA would interact with Ni2+ preferentially and therefore 
would result in reduced inhibition. The inhibition assays were carried out at 0.2 
µM BTCA with 1mM solution of NiCl2 in the reaction mixture.  No change in the 
rate of reaction was observed in comparison to the control experiment (0.2µM 
EDTA along with nickel solution). The rate of reaction was faster when EDTA was 
used along with the Nickel solution and was half when only EDTA was used 
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(Table 9.4). The inhibition assays thus confirmed that BTCA is not chelating the 
zinc in the active site. 
 
S.No Amount of 
Enzyme(µM) 
Substrate 
Conc. 
(mM) 
EDTA 
Concentration 
NiCl2 
concentration 
BTCA 
concentration 
RAbs/min 
1 1 0.6 - - - 0.728 
2 1 0.6 - - 0.2µM 0.444 
3 1 0.6 - 1mM - 0.748 
4 1 0.6 - 1mM       +          0.2µM                             
(Pre-incubated) 
0.473 
5 1 0.6 - - - 0.730 
6 1 0.6 0.2µM                             - - 0.340 
7 1 0.6 0.2µM                             1mM - 0.681 
Table  9.4 Enzyme kinetics for PAA in the presence of Ni2+, BTCA and EDTA (- = Not added). 
 
9.4.3  Dialysis of PAA with BTCA and Inhibition Assays 
Non competitive inhibition of the enzyme could be due to the binding of the 
inhibitor at a site away from the substrate binding site.  Alternatively, it could 
be due to the inhibitor binding to the active site covalently. Initially it was 
presumed that BTCA is acting in a similar way as EDTA by chelating zinc in the 
active site.  This hypothesis was tested by adding inhibitor to the protein 
followed by dialysis and subsequent assays.  
 
 
 
 
Status Inhibitor 
concentration 
(µM) 
Enzyme 
concentration 
(µM) 
Substrate 
Concentration 
(mM) 
RAbs/min 
0.00 µM 1 0.6 0.721 Before 
dialysis 
10.00 µM 1 0.6 0.0080 
0.00 µM 1 0.6 0.713 After 
dialysis 
10.0 µM 1 0.6 0.1460 
   Table  9.5 Enzyme inhibition assays for PAA before and after dialysis 
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 Inhibition assays were carried out to calculate the saturating concentration of 
BTCA against PAA. The result showed that 10uM of BTCA was sufficient to 
completely inhibit 1uM of the enzyme. Two (native PAA and PAA with 2mM 
BTCA) 100uL samples of 0.3mM enzyme were dialyzed overnight at 4°C in 10mM 
sodium phosphate buffer pH:7.2. After 18 hours of dialysis, enzyme assays were 
carried out on both the samples (Table 9.5). The reaction rate of the post-
dialyzed enzyme incubated with BTCA was 20 times more than the pre-dialyzed 
enzyme incubated with BTCA. The regain in activity observed could be only if 
the inhibitor has diffused out of the enzyme during dialysis. The significant 
recovery in activity of PAA after dialysis lead to the conclusion that BTCA is 
neither an irreversible inhibitor which chelates the zinc nor it is forming an 
irreversible covalent link to the enzyme. 
 
9.5  Crystallization trials for PAA with BTCA 
The Automated crystallization trials were carried out for PAA with Inhibitor 1, 2, 
4 Butane Tri carboxylic acid (BTCA). The crystallizations were carried out at a 
final concentration of 0.7mM (20mg/mL)   of protein and 4mM concentration of 
inhibitor. The crystallizations were carried out by the robot system using the 
PACT and the JCSG+ suite composition, the M-Screen (M1-M72) was also tried 
manually, crystalline precipitates were observed in M-Screen including M-05, M-
09, M-10, M-20, M-26 and M-72 . In case of PACT ½ screen crystalline type of 
precipitates were seen in E4, E8, E9 and H11 in both native protein and with 
inhibitor. Keeping in view the PACT ½ conditions at which the crystalline 
precipitates were obtained, crystallizations conditions were further optimized. 
Crystalline precipitates were seen at PEG 8K concentration of 4%, 6%, 8% and 
10%, Increase nucleation was causing a shower of small crystals and Nucleation 
rate seemed to be very high due to which the individual crystals were unable to 
grow.  Streak seeding was also carried out by using a cat hair in to a clear drop 
to cause the seeding. The streak seeding resulted in crystalline precipitates but 
not individual crystals suitable for diffraction studies.  
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9.6 Conclusions  
The following conclusions can be drawn from the enzyme inhibition studies. 
1. BTCA is a tight binding noncompetitive inhibitor of PAA. Although the 
inhibitor has a similar Ki to that of EDTA, but it is experimentally 
demonstrated that its effect is not by chelation (as by EDTA) of the active 
site Zn2+, but rather by binding to the enzyme directly.  
2. In case of BTCA, the nature of the inhibition has been investigated and 
indicates that the inhibitor can be dialyzed out of the enzyme over time 
and therefore does not form an irreversible covalent adduct with the 
protein.  
9.7 Future Aims 
In order to characterize the mechanism of enzyme, it would be 
appropriate to obtain co-crystals of the enzyme with the inhibitors 
described here. Methods to obtain crystals include changing the protein 
source from related bacteria, and limited proteolysis, for example. A 
crystal structure would greatly help in understanding the substrate 
specificity of the enzyme and give a structural context to the data 
presented here.  
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10. Probing protein X-ray structures with unknown 
ligands 
10.1 Introduction 
The very nature of the protein data bank (PDB) is the possibility to deposit an X-
ray structure of protein with an unknown ligand or a completely wrong ligand. 
This may be due to an eagerness to publish and secondly perhaps less rigorous 
supervision, which finally may result in errors in the submitted X-ray structure. 
Mostly the errors related to the correct assignment of ligands and co-factors are 
because they may be of little importance to the publishing author. For instance 
a structural biologist may be interested more in the over all fold of the protein, 
but becomes a nightmare for a medicinal chemist who may be interested very 
specifically in the binding site {167}. 
In the past majority of the protein X-ray structures were deposited with the aims 
and interest towards understanding the overall fold of the given protein, and 
thus the bound ligands or co-factors were not given the same consideration as 
the protein backbone. There were program libraries available for fitting the 
residues in geometrical reasonable conformations, but none for the ligands and 
co-factors, as a result they refined into unlikely geometries. In recent years due 
to a huge increase in the use of protein crystallography in structure based drug 
design, the protein-ligand interface has been recognized as important as the 
overall fold of the protein, and  more attention is being paid now in order to 
assure that the ligands and co-factors are treated appropriately {167}. 
Some authors have recently pointed out that some of the deposited structures of 
proteins containing ligands in the PDB database are totally wrong. Some of these 
structures may be wrong due to a mistake by a crystallographer or because of 
misunderstanding of the chemistry that is modeled, perhaps by introducing some 
error in the stereochemistry {168-170}. For instance figure 10.1 shows the 
typical assignment of a wrong ligand in the PDB structure of 2UYG, where the 
electron density fits by a citrate molecule but the structure has been deposited 
with a glycerol molecule as a ligand. 
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Figure  10.1 Wrong identification of a ligand as (A) a glycerol molecule instead of (B) a citrate 
molecule in X-ray structure of 2UYG, the blue electron density is the weighted observed 
electron density and the green density is difference density showing missing components 
of the ligand.  
 
Apart from human errors there are two other reasons for poor ligand geometry. 
First one is the resolution of diffraction pattern obtained from protein structures 
which are so bad that it becomes very difficult to refine them for individual 
atom positions. Second error culminates due to the insufficient search of various 
other viable ligand conformations during the model building phase {167}. 
To address these issues and to propose a reasonable solution, Discovery studio 
visualizer (DSV) and Catalyst® were used in this part of the project. The 
programs were used for pharmacophore model development and then searching 
against the databases. The databases used were naturalism, comprising of 5,422 
small chemicals created from the ChEBI database, or the full database of 14,000 
compounds.  The X-ray structures with unknown ligand(s) were identified with 
code UNL, selected through the RSCB web interface.  
10.2 Aims and Objectives 
The study was carried out with the following aims: 
1. If pharmacophore searching can be utilized to conceive the identity of 
unknown ligands.  
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2. What are the limitations due to low resolution data in correct identification 
of ligands?  
3. How well the pharmacophore hits satisfy the electron density of the 
unknown ligands? 
10.3 Screening of Protein X-ray structures 
The RCSB protein data bank (PDB) (www.rcsb.org) was searched for the 
occurrence of unknown ligands as a starting set of structures to evaluate. It is 
essential to have electron density of the unknown ligands to experimentally 
evaluate them. The coordinates and data were uploaded from the Uppsala 
electron density server (EDS) {171} and visualized by using the graphics software 
Coot version 0.6.2 {95}. Initially all the available protein structures with 
unknown ligands in RCSB protein data bank were visualized by using coot. This 
allowed visual inspection of the electron density to confirm that the unknown 
ligand is in fact a proper ligand and not just a collection of water molecules or a 
polyethylene glycol (PEG) fragment or a single point presumed a metal ion. It 
was clear that there was a real variety of density with some researches labeling 
any non spherical density as unknown ligand, while others represented whole 
ligands in this way. These whole ligands which were the exception were chosen 
for consideration for ligand searching. By studying these unknown ligands in the 
protein binding site, in some cases the ligands were similar to certain 
compounds i.e.  Glycerol, phosphate and citrate and it appeared that some of 
the compounds were co-crystallized with the protein because of their presence 
in the crystallization conditions. The X-ray liganded structures were downloaded 
from the PDB web link (www.rcsb.org). All the X-ray structures were first 
visualized in Coot program (Figure 10.2) to observe and compare the calculated 
and observed electron density map (for the protein structure in general and for 
the unknown ligand in particular).  
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Figure  10.2 Electron density map visualization in coot, unknown ligand atoms with observed 
electron density (blue mesh) around it in the binding site of the protein (1VKM), the dashed 
lines represent the inter atomic distances between the atoms of the unknown ligand and 
surrounding amino acid residues and water molecules 
 
In Catalyst certain features of the pharmacophore model were parameterized by 
optimizing chemical features of the atoms of the unknown ligand i.e. atom type, 
charge on atom, bond type and hydrogen count on certain atoms (Figure 10.3). 
The bond order clearly gave some indication of a potential atom type but it was 
important not to try and first guess atom types. Hydrogen bond interactions with 
the protein gave further restraints to the query. 
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Figure  10.3 Catalyst software with provision of optimizing bond type, multiple atomicity and 
hydrogen count on the atoms of the unknown ligand for final modelling of the 
pharmacophore (exclusion sphere have been hidden for clarity viewing) 
Further details like information about the binding domain, location of unknown 
ligand (either present in the binding site or at the periphery of the protein), 
electron density, selected pharmacophore searches and best hits are 
represented in tabulated form in Appendix 1. During visualization of protein 
structures with unknown ligands it appeared that 
1. Most of the structures had poor and disordered electron density.  
2.  In some cases the bonding electron density between the ligand atoms was 
absent. 
3.  Some ligands were lying in a complete hydrophobic pocket of the protein 
with the possibility of very few interactions. 
Further details relating to electron density and other factors about the protein          
structures in numerals are given below in table 10.1 
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Over all details for PDB structures Number of 
PDB 
structures 
Structures with  ligands having poor and/or disordered  electron density for the 
unknown  
70 
Structures with  ligand having very weak electron density  53 
Structures without X-ray data       33 
structures with disordered and fragmented ligands  19 
Structures with benzamidine like ligand in the binding site  13 
Structures with electron density absent between the atoms of the ligands 12 
Structures with ligands located outside the binding pocket at the periphery of 
the protein  
10 
Structures with ligands in hydrophobic pocket of the protein 3 
Structures subjected to pharmacophore searching  14 
Total number of PDB structures evaluated   227 
Table  10.1 Total number of PDB structures and different attributes of the protein structure 
with respect to the ligand in separate rows with numerals 
The X-ray structures (with more well defined electron density of the unknown 
ligand matching with the position of atoms within in the binding site) were 
selected for pharmacophore searching. DSV was used for generating the 
pharmacophore model for the selected X-ray structures of the protein by using 
the DSV Vector and Query atom methods, as described in section 3.5.2-3. A 
number of factors were taken in to account for the selection of protein 
structures with unknown ligands for pharmacophore searching i.e. availability of 
potential H-bond interactions between the ligand and the protein, availability of 
good electron density for the unknown ligand and location of unknown ligand in 
well defined binding site. The pharmacophore searches which gave interesting 
results in the form of potential hits are mentioned below, while some searches 
which were not very conclusive are mentioned in the Appendix 1. Details of X-
ray structures, their pharmacophore modeling and resulting hits conforming to 
the electron density of the unknown ligands are presented below under the PDB 
code title heading. 
 
 
Chapter  10   247 
10.3.1 1VKM 
1VKM is the Crystal structure of an indigoidine synthase a (idga)-like protein 
(tm1464) from Thermotoga maritima MSB8 diffracted at a resolution of 1.90Å. 
The hits obtained as a result of pharmacophore search model by using the query 
atom method, were fitting well in the binding site. A total of 29 hits were 
obtained from the final pharmacophore search. The majority of the hits were 
phosphate sugars including pentoses, hexoses and some 3C and 4C sugars. 
Assigning multiple atomicities to the atoms resulted in reasonable hits, 
especially in case of phosphate groups, the inclusion of phosphorus atom among 
other atoms (C, N) of the query atom at position 1 helped in finding various 
sugar phosphates, which satisfied the pharmacophore model (Figure 10.4). 
Among the hits D-erythritol 4-phosphate coherently fitted the e-density (Figure 
10.5) and seems a unique hit which further needs to be investigated in 
connection with the mechanism of binding and any activity if present. 
  
Figure  10.4 D-erythritol 4-phosphate shown as stick model, efficiently satisfies all the 
constraints of the pharmacophore model, while few atoms of some other hits (shown as line 
model) violate the pharmacophore model (some of the amino acid residues and exclusion 
spheres are removed for clarity purposes) 
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Figure  10.5 Visualization of D-erythritol 4-phosphate in coot along with environmental 
distances, the hit totally satisfies the electron density of the unknown ligand in the 
structure. 
10.3.2 3P6K 
3P6K is a PLP-dependent aminotransferase (ZP_03625122.1), found in 
Streptococcus suis 89-1591. The X-ray crystal structure of the enzyme has been 
determined at a resolution of 2.07Å and submitted under the JCSG project. The 
enzyme has two chains i.e.; A and B. The unknown ligand with reasonably fair 
electron density resembled a purine ring. The unknown ligand is present in 
binding site of the chain B only. The pharmacophore model for the enzyme was 
created by using the query atom method. In the first pharmacophore only the 
positions of the individual atoms were specified with bonding connection 
between them. The hits (59) obtained as a result mainly comprised of big 
structures like sporines, rifmycin and their derivatives. The hits were clearly and 
significantly over stepping the query atoms of the pharmacophore and would not 
be expected to be disordered or fragmented within the crystal structure (Figure 
10.6).  
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Figure  10.6 Sporines (stick model) as one of the hits clearly violating the limit of the query 
atoms in the pharmacophore (small grey spheres with green bonding stripes) 
As the hits in the initial pharmacophore were crossing the boundaries in terms of 
query atoms of the pharmacophore, therefore in the next pharmacophore 
additional exclusion spheres were introduced around the query atoms (Figure 
10.7). This resulted in limited number of hits (4). The hits in this pharmacophore 
where satisfying the query atoms of the pharmacophore and also were not in 
steric clash with the surrounding residues e.g.; pyridoxilactone and its 
derivatives. 
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Figure  10.7 Pyridoxilactone as a hit (stick model) exhibiting compliance with the query 
atoms of the pharmacophore (small grey spheres with green bonding stripes) the 
surrounding large grey spheres are the exclusion spheres. 
 
 
10.3.3 2AAM 
2AAM is the crystal structure of a putative glycosidase (tm1410) from 
thermotoga maritime diffracted at a resolution of 2.20Å and submitted under 
the JCSG project. The protein has an unknown ligand with disordered electron 
density in the binding pocket, present at the same position in all the A, B, C, D, 
E and F chains of the protein. 
In the initial stages only 11 bonded atoms of the unknown ligand were selected 
for the generation of pharmacophore model by using the query atom method. 
Majority of the resultant hits (9) obtained were not in compliance with the 
model (Figure 10.8).  
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Figure  10.8 Initial pharmacophore consisting of 11 bonded atoms (green and grey spheres) 
based on geometry of the unknown ligand. One of the hit (stick model) shows 
noncompliance with the pharmacophore model (big grey spheres represent the exclusion 
spheres) 
To further optimize the parameters, in the final pharmacophore model, one of 
the atoms of the ring and two of the branch were assigned with multiple atoms 
(C, N, and O) labelled as position 1, 2 and 3 respectively (Figure 10.9). The 
bonding parameter between these positions was set to either single or double 
bond by using the Catalyst® pharmacophore optimization parameters. Two 
additional atoms, bonded to position 4 and 5 were added from the unknown 
ligand to the pharmacophore model. The number of hits was reduced to nearly 
half and included beta-D-galacturonic acid. Among other hits beta-D-
galacturonic acid was found to be the best hit as it completely satisfied the 
overall pharmacophore model. When visualized in coot the hit fitted well to the 
electron density of the unknown ligand. 
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Figure  10.9 Final pharmacophore with multiply assigned atoms at position 1, 2 and 3, along 
with additional bonded atoms connected to position 4 and 5. Beta-D-galacturonic acid (stick 
model) shows complete compliance with the pharmacophore model (certain exclusion 
spheres and amino acid residues are removed for clear viewing purposes) 
 
 
10.3.4 2F6R 
2F6R is the crystal structure of bifunctional coenzyme A synthase (CoA 
synthase): (18044849) from Mus musculus diffracted at a resolution of 1.70Å, 
and published under the JCSG project. Based on query atom method 
pharmacophore model was generated by using the unknown ligand as the 
template. The model comprised of 10 bonded multiply assigned atoms(C, N and 
O), with standard valencies. The database search gave convincing hits (35), with 
majority of them satisfying the maximum pharmacophore parameters. After 
visual inspection L-citramalic acid came out as a valid hit (Figure 10.10) which 
was absent in the crystallization conditions. This further increases its potential 
as a true ligand of the enzyme. Citric acid and citrate were also among the hits, 
which can be the putative ligands.  
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Figure  10.10 L-citramalic acid (stick model) among the hits, fully satisfies the introduced 
constraints in the pharmacophore model. The small green and grey spheres are the multiply 
assigned pharmacophore atoms, the big grey spheres around the ligand are exclusion 
volume spheres. 
By visualizing the hits in coot it appeared that the methyl group of citramalic 
acid fitted well into the partially disordered electron density region (Figure 
10.11). Keeping in view the disordered electron density no further constraints 
were applied as it can cause to loose potential hits. 
 
Figure  10.11 Graphical representation of L-citramalic acid in coot along with environmental 
distances, the hit is in agreement with the electron density of the unknown ligand in the 
structure (the hydrogen atoms have been removed for clarity viewing) 
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10.3.5 1TVF 
1TVF is the crystal structure of penicillin-binding protein 4 (PBP4) from 
Staphylococcus aureus. The unknown ligand has been defined in terms of 
individual non-bonded atoms with good electron density around each atom of 
the unknown ligand. The pharmacophore was generated by using the query atom 
method. The individual atoms of the unknown ligand were assigned as multiple 
atoms (C, N and O) in the model. The majority of the hits (10) obtained through 
database search included citrate and its derivatives. Interestingly in the 
crystallization conditions of the protein citrate is used as a buffer, which implies 
that the unknown ligand most likely to be a citrate molecule, being crystallized 
along with the protein during crystal formation. Figure 10.12-14 show the 
schematic progress of pharmacophore generation and the outcome from the 
database search. In figure 10.12 the individual atoms of the unknown ligand are 
labelled as “unknown ligand atoms”. In figure 10.13 these atoms are specified as 
the query atoms of the pharmacophore in the binding site of the protein. In 
figure 10.14 citric acid satisfies all the constraints of the pharmacophore and fits 
well in the binding site and is most likely to be a true ligand. 
 
Figure  10.12 Selection and labelling of unknown ligand atoms for pharmacophore model 
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Figure  10.13 Query atoms of the pharmacophore along with exclusion spheres in binding 
site 
 
 
Figure  10.14 Citric acid as a hit satisfying all the constraints of pharmacophore model in the 
binding pocket of the protein 
Chapter  10   256 
10.3.6 2PY6 
2PY6 is the crystal structure of methyltransferase FkbM (YP_546752.1) from 
Methylobacillus flagellatus KT diffracted at a resolution of 2.20Å. The structure 
is deposited under the JCSG project. The unknown ligand is situated well inside 
the binding pocket. The pharmacophore model for the protein was generated by 
using query atom method. Most of the hits obtained through pharmacophore 
searching of the database were penetrating beyond the specified query atoms of 
the model and thus violating the provided constraints (Figure 10.15). A possible 
reason for this problem can be the water molecules in the protein structure, 
around which the exclusion spheres are not introduced in the pharmacophore 
model and thus the software logic may consider those spaces as free, thus 
resulting in selection of longer and bigger ligand structures or this can be due to 
a flaw in the catalyst software. Apart from violating the pharmacophore model, 
some of the hits satisfied the model, which included some sugars and amino 
acids like L-homoserine, erythritol, L-erythrulose and L-arabinose. 
 
Figure  10.15 Majority of the hits (line models) clearly violating the atomic constraints of the 
pharmacophore model (highlighted small yellow spheres and green bonding stripes, amino 
acid residues and exclusion spheres are removed for clarity purposes) 
Chapter  10   257 
10.3.7 3EZU 
3EZU is the crystal structure of multidomain protein of unknown function with 
GGDEF-domain (NP_951600.1) from geobacter sulfurreducens diffracted at a 
resolution of 1.95Å. The structure is deposited under the JCSG project. The 
unknown ligand had good electron density and situated well within the binding 
site. The pharmacophore model was generated by using the query atom method. 
The bonded query atoms along with the exclusion spheres were then subjected 
to the database search. The search gave hits, among which many satisfied the 
pharmacophore completely and some violated the pharmacophore. Few hits like 
2-ethylhexan-1-ol, triethanolamine and diethylaminoethanol (Figure 10.16) 
fitted the electron density and are most likely to be potential ligands of the 
protein. 
 
Figure  10.16 Diethyl amino ethanol fits the pharmacophore model and the electron density 
map of the unknown ligand in the binding site of the protein. 
10.3.8 1VK8 
1VK8 is the crystal structure of a putative thiamine biosynthesis/salvage protein 
(tm0486) from hyperthermophilic anaerobe Thermotoga maritima diffracted at a 
resolution of 1.80Å, published in journal of molecular biology {172}. Protein 
belongs to a family of thiamin-binding proteins which are involved in responding 
to the cell oxidative conditions.  The protein has a ferredoxin-like fold and is a 
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homo-tetramer. The unknown ligand was identified in the pocket of each 
monomer, with well defined electron density. Some atoms of the unknown 
ligand are bonded to each other, while some are identified as individual entities, 
lying close to the bonded unknown atoms (Figure 10.17). 
  
Figure  10.17 Bonded atoms (line model in red) of the unknown ligand and non-bonded 
atoms (red stars) of the unknown ligand in the binding site of the protein. 
A number of pharmacophore models were generated for the binding site of the 
protein by using the query atom method. In the first pharmacophore model, all 
the bonded and non bonded atoms of the unknown ligand were used as a 
template for the query atoms. The model was optimized by specifying the bonds 
between the non-bonded atoms and bonds between non-bonded and bonded 
atoms by using the Catalyst software. As the protein is a thiamine binding 
protein, therefore the atom specification (C,N and O) and bond type (single, 
double) were specified in the pharmacophore model in relation to thiamine 
(Figure 10.18). The hits obtained as a result did not have thiamine among them. 
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Figure  10.18 Pharmacophore model comprising of query atoms with respect to the position 
of unknown ligand atoms (both bonded and non-bonded) in the binding site of the protein 
(exclusion spheres are removed for clear viewing) 
 
To further improve the pharmacophore in terms of pulling thiamine as a hit, in 
the new model the query atoms around the non-bonded atoms of the unknown 
ligand were removed. A total of 166 hits were obtained through this model 
which included thiamine and its corresponding aldehyde, carboxylic and 
phosphate forms. This showed that the incorporation of non-bonded atoms of 
the unknown ligand in the model is not helpful for sole selection of true ligand 
of the protein.  
In order to reduce the number of hits without losing the potential ligands, the 
hydrogen count on the nitrogen query atom was set to two in the final model 
(Figure 10.19). This resulted in only 35 hits which included the thiamine and its 
aldehyde, carboxylic and phosphate forms, exhibiting that specifying the 
hydrogen count on the nitrogen atom serves to reduce the hits to a reasonable 
number without losing the potential ligands. 
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Figure  10.19 Final pharmacophore model with non-bonded atoms removed and the 
hydrogen count on nitrogen (solid blue sphere) fixed to two, the thiamine (line model) fits 
well in the pharmacophore without clash with the surrounding exclusion spheres in the 
binding site (exclusion spheres are hidden for clarity purposes) 
 
It will be interesting to mention here that in pharmacophore modeling, exclusion 
spheres are introduced by selecting area of the binding site with certain radius 
(Å). The selection excludes the coordinating water molecules in the protein 
structure. This  provides more 3D space and  flexibility in search for selecting 
comparatively bigger ligands, as in case of  1VK8 (thiamine binding protein) , 
where during the search the availability of bigger 3D space made it possible to 
identify and accommodate comparatively bigger ligand, thus thiamine and its 
derivatives were selected among other hits. 
By visualizing the hits in coot it appeared that the aminopyrimidine ring of 
thiamine fitted well into the electron density while the thiazole ring fitted in 
the partially disordered electron density region (Figure 10.20). Keeping in view 
the disordered electron density no further constraints were applied as it could 
cause to loose the potential hits. 
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Figure  10.20 Graphical representation of thiamine in coot along with environmental 
distances, the hit is mostly in agreement with the electron density of the unknown ligand in 
the structure (the hydrogen atoms have been removed for clarity viewing). 
10.3.9 2FTR 
2FTR is the crystal structure of an ethyl tert-butyl ether d (ethd) family protein 
(bh0200) from bacillus halodurans c-125, diffracted at a high resolution of 
1.40Å. The structure is submitted under the JCSG project. The unknown ligand is 
located well inside the binding pocket of the protein with reasonably good 
electron density. The pharmacophore model for the protein binding site along 
with the unknown ligand as a template was generated by using the query atom 
method. The initial pharmacophore model gave hits, which were not aligning 
properly with the model. Therefore in the final model one of the query atoms at 
position one was removed (Figure 10.21). The modification in the model resulted 
in partial freedom and thus selection of suitable ligands in response. Some the 
convincing hits included compounds like homo-serine, L-leucine, L-homoserine, 
creatine, L-aspartic acid, L-asparagine, oxaloacetic acid, acetylpyruvic acid and 
malic acid. These hits were not pulled out by the previous pharmacophore and 
can be the potential ligands of the protein. 
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Figure  10.21 Pharmacophore model based on unknown ligand in the binding site of the 
protein. Position 1 was removed in the final model, allowing more flexibility in selection, 
among the hits homoserine (stick model) best fitted the model (amino acid residues and 
exclusion spheres are hidden for clarity) 
 
10.3.10 3NNR 
3NNR crystal structure has x-ray data to a resolution of 2.49Å, which belongs to 
TetR-family of protein a transcriptional regulator (Maqu_3571) from 
Marinobacter aquaeolei VT8. The X-ray structure is published under the JCSG 
project. The assigned unknown ligand is kind of a long chain with good electron 
density and situated well within the binding site of the protein. The resolution is 
not particularly high and as such represents a challenging case. 
A number of pharmacophores were generated by using the H-bond vector 
method. In the first model two H-bond acceptor vectors were introduced from 
the hydroxyl group of Tyr59 and Tyr115, majority of the hits (210) obtained 
through this model were mainly oriented and confined in the surrounding area of 
Tyr59 and Tyr115 (Figure 10.22). The hits included various amino acids, short 
chain sugars. However a few hits like lauric acid were able to partially satisfy 
the electron density of the unknown ligand in the form of a long chain fatty 
acid.  
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Figure  10.22 Pharmacophore model with 2 H-bond acceptors from Tyr59 and Tyr115 in the 
active site, majority of the hits shown as line models are confined in the surroundings of 
Tyr59 and Try115. 
Keeping in view the presence of long chain electron density in the binding 
pocket the 2nd pharmacophore model, in addition to the two H-bond acceptor 
interactions, the model was further modified by specifying the individual atoms 
of the unknown ligand as 7 hydrophobic points (Figure 10.23). The hits obtained 
(300) as a result of this model were quite encouraging as maximum hits were 
long chain fatty acids, with their carboxylic groups pointing towards the H-bond 
acceptor vectors of Tyr115 and Tyr59 and the corresponding hydrophobic chains 
were positioned exactly towards the hydrophobic points created in the model. 
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Figure  10.23 Introduction of hydrophobic points (blue spheres) at the designated positions 
of the individual atoms of the unknown ligand specified in X-ray structure. 
 
To further explore the binding site, the numbers of hydrophobic points were 
reduced to 5 in the pharmacophore model (Figure 10.24). The resultant hits 
obtained from the 3rd pharmacophore model were only 8. The hits included 
palmitic acid, linoleic acid and their derivatives. This indicated that the specific 
number and position of hydrophobic points in the model is crucial for the 
number and type of hits. 
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Figure  10.24 2 H-bond acceptor (green arrows) and 5 hydrophobic points (cyan spheres) in 
the pharmacophore model along with palmitic acid as a hit shown in line model in the 
binding site of the protein. 
 
In the 4th pharmacophore model one of the hydrophobic points was removed 
from the very end and instead a hydrophobic point was introduced between the 
1st and 2nd hydrophobic points. The number of hits (17) was doubled as a result 
and included some other fatty acids like mauristic acid and its derivatives while 
palmitic acid was not included in the hits, showing that the removed 
hydrophobic point at the very end is essential for the selection of palmitic acid 
and its derivatives. 
To test whether the presence of hydrophobic points is essential in the 
pharmacophore model for selection of long chain fatty acids as hits, all the 
hydrophobic points were removed and the individual atoms corresponding to the 
unknown ligands were selected for generation of exclusion spheres around them 
(Figure 10.25). The hits (210) obtained included many long chain fatty acids like 
capric acid, decanoic acid and dedecanoic acid and their derivatives, showing 
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that the presence of hydrophobic points is not crucial for selection of long chain 
fatty acids. 
 
Figure  10.25 Pharmacophore model generated with 2 H-bond acceptor interactions along 
with exclusion spheres specified around the designated atoms of the unknown ligand. 
 
The visualization of hits in coot indicated that mostly the hits containing long 
chain fatty acid satisfy the electron density. By close observance it appeared 
that palmitic acid best fits the electron density (Figure 10.26). Therefore, the 
conclusion can be drawn that the most likely ligand is a fatty acid in the form of 
palmitic acid.  
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Figure  10.26 Graphical representation of palmitic acid in coot along with environmental 
distances, the hit is in reasonable agreement with the electron density of the unknown 
ligand in the structure (the hydrogen atoms have been removed for clarity viewing) 
 
10.4 Conclusions 
After evaluating various PDB structures through various stages of visualization 
and modelling search, the following opinions are made 
1. The availability of good electron density for the unknown ligand is a major 
factor in selection for pharmacophore searching and getting sensible hits. 
X-ray resolution of 2.5Å or better was necessary for the placement of 
atomic positions, whilst hydrogen bonding vectors could be used in lower 
resolution and other restraints would be necessary. 
2. The structures with disordered and/or poor electron density of the 
unknown ligand are unlikely for pharmacophore modelling. 
3. Labelling of unknown ligands is varied and random, as in most cases a 
single atom has been labelled as an unknown ligand, which most likely can 
be an ion or a water molecule. 
Chapter  10   268 
4. In case of 1VKM , D-erythritol 4 phosphate which is obtained as a potential 
hit and best fits the electron density, can be used experimentally to 
evaluate ligand binding. 
5. The pharmacophore method works successfully to find the suitable ligand 
even if the bonding electron density is absent between the atoms, as 
observed in case of 1TVF. 
6. The pharmacophore searching works efficiently in finding logical ligand 
for the target protein i.e. palmitic acid in case of 3NNR. 
7. PDB structures can be used to identify and/or suggest potential ligands for 
proteins in some cases but not on the whole because of limiting factors 
like electron density, hydrophobic pocket, ligand at the periphery and 
very small ligand.  
8. To obtain sensible hits certain parameters have to be optimized during 
the course of searching, leading to freedom in selection of hits. DSV and 
Catalyst have the option to parameterize certain features of the 
pharmacophore i.e. type of bond (double or single), Hydrogen count on 
atoms (1, 2 or free) and assigning multiple atomicity (C, N, S, O) to the 
query atoms.  
On the basis of outcome obtained from above examples, it can be concluded 
that pharmacophore searching works in a significant way to find a suitable ligand 
both for a known and unknown protein. The hits obtained from the search could 
indicate the crucial H-bond interactions which are necessary for the ligand 
binding event. The method can be readily used for searching specific classes of 
compounds to be potential ligand for certain proteins. In order to find out the 
protein ligand interaction in detail the hits obtained from pharmacophore 
searching can be subjected to ligplot. Ligplot can give information with regard 
to the hydrogen bond interactions, hydrophobic interactions between the ligand 
and the amino acid residues of the protein active site. For instance in case of 
1VKM, ligplot gives detail interaction map between D-erythritol 4-phosphate and 
the binding site of the protein (Figure 10.27). 
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Figure  10.27 A typical ligplot representing the protein-ligand interactions between D-
erythritol 4-phosphate and amino acid residues in the active site of 1VKM. 
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The following Publications have recently been published from this work 
 
1. Rapid assembly of potent type II dehydroquinase inhibitors 
via "Click" chemistry, Medchemcomm,P 271-275, 
D.O.I:10.1039/c0md00097c, Oct, 2010 {173} 
 
2. Synthesis and evaluation of potent ene-yne inhibitors of 
type II  dehydroquinases as tuberculosis drug leads, 
Chemmedchem,P 262-5, D.O.I:10.1002/cmdc.201000399, 
Feb, 2011 {174} 
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11. Type II DHQases 
The enzyme dehydroquinase (3-dehydroquinate dehydrates; DHQase) catalyses 
the reversible dehydration of  dehydroquinic acid (Figure 12.1) to form 
dehydroshikimic acid {175}. The reaction is part of the two metabolic pathways, 
the biosynthetic shikimate pathway and the catabolic quinate pathway {176, 
177}. The shikimate pathway is an essential biosynthetic pathway involved in the 
biosynthesis of aromatic amino acids in many microorganisms but is absent in 
humans {142}.  The dehydration of dehydroquinate is catalyzed by two distinct 
classes of dehydroquinase (type I and II) by different mechanisms {178} . Both 
types have marked differences in their amino acid sequences, subunit molecular 
weights, secondary tertiary and quaternary structures, thermal stability and 
catalytic mechanisms {179}. The type II DHQase monomer consists of a five-
stranded parallel β-sheet core flanked by four α- helices arranged with a similar 
overall topology to flavodoxin {179} . 
O
OH
HO
O O-
Dehydroshikimate
O
OH
HO
O O-
OH
TypeII DHQase
Dehydroquinate  
Figure  11.1 Conversion of Dehydroquinate to Dehydroshikimate in the presence of TypeII 
DHQase 
 
 
The enzyme is a homododecamer and the subunits are arranged as a tetramer of 
trimers. Each subunit of type II DHQase has a molecular weight of approximately 
16.5 kDa. The position of the active site was suggested by the cluster of 
conserved residues near the C-terminus of the β-strand {180}. The enzyme is 
most studied from the microorganisms Streptomyeces coelicolor, M. tuberculosis 
and Helicobacter pylori. Streptomyeces coelicolor was the first organism shown 
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to possess only a biosynthetic type II dehyroquinase  rather than a type I 
dehydroquinase {181}. Helicobacter pylori is a Gram-negative bacterium and 
lives in stomach and duodenum of Human beings causing chronic gastritis, peptic 
ulcer and gastric adenocarcinoma, the type II dehydroquinase  of H.pylori 
DHQase shows a strong  identity to other members of type II dehydroquinase 
family {182}. Due to the absence of shikimate pathway in humans type II DHQase 
is considered to be an attractive target for the development of selective 
antimicrobial agents {142}.   Several rounds of inhibitor development have been 
carried out leading to nanomolar inhibition levels against the enzyme {183}. One 
of the compounds 1,4,5-trihydroxy-3-(3-nitrophenyl)cyclohex-2-enecaroboxylic 
acid (a 3-nitrophenyl derivative of dehydroquinate) with a Ki of 54.0nM is the 
most potent inhibitor reported against M. tuberculosis type II DHQase {184}. 
However most of them have performed poorly in whole cell tests (unpublished 
data). There is significant need to develop the pharmacokinetic properties of 
these molecules before these inhibitors can seriously be considered as potential 
antimicrobial agents for treating the diseases in humans. 
 
11.1 Aims and objectives 
1. Purification of different DHQases 
2. Comparative characterization of the enzyme  
3. Inhibition studies to be performed in collaboration with Dr Richard Payne, 
University of Sidney.  
 
11.2 Expression and Purification of DHQases 
All the DHQases plasmids were inserted in to the expression host BL21 (DE3) cells 
by using the transformation protocol. The M. tuberculosis DHQase (MTB DHQase) 
was purified by a three step process involving ion exchange chromatography, 
hydrophobic interaction chromatography and size exclusion chromatography as 
described in section 2.14. Fractions obtained after each purification step were 
tested for activity through standard DHQase enzyme assay and the fractions with 
maximum activity were pooled and loaded on to another column for further 
purification. 
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His tagged versions of Streptomyeces coelicolor DHQase (SC DHQase), 
Helicobacter pylori DHQase (HP DHQase), Campylobacter jejuni DHQase (CJ 
DHQase) and Candida albicans DHQase (CA DHQase) were purified by using nickel 
purification method. The successive stages of purification of different DHQases 
in pictorial form are given below (Figure 12.2-7). 
 
Figure  11.2 Chromatogram for MTB DHQase eluted on Q-sepharose Column (ion exchange 
chromatography) 
 
 
Figure  11.3 Chromatogram for different fractions of MTB DHQase eluted on Phenyl 
sepharose column (HIC) 
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Figure  11.4 Chromatogram image showing different fractions of MTB DHQase eluted on 
superdex 200 column 
 
 
Figure  11.5 SDS-PAGE analysis for SC DHQase after Ni-purification: 1= flow through, 
2=70mM Imidazole wash, 3= 300mM Imidazole elute 4=500mM Imidazole elute, 5=700mM 
Imidazole elute, 6= molecular weight marker  
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Figure  11.6 SDS-PAGE analysis for HP DHQase after Ni-purification: 1= molecular weight 
marker in Kda (Bio labs, NEW ENGLAND cat# P7708S), 2= cell pellet, 3= supernatant, 4=flow 
through, 5=70mM Imidazole wash, 6, 7=300mM Imidazole elute, 8= molecular weight marker  
 
 
Figure  11.7 SDS-PAGE analysis for Purified DHQases: 1 = molecular weight marker in Kda 
(BioRad precision plus protein TM catalog no: 161-0373), 2 = Bacillus subtilis DHQase, 3 = 
HP DHQase, 4 = MTB DHQase, 5 = SC DHQase, 6 = CJ DHQase,7 = CA DHQase, 8 = MTB, 9 
= molecular weight marker  
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The purified samples of MTB DHQase, SC DHQase and HP DHQase were 
lyophilized and then sent to Dr. Richard Payne, University of Sidney, for enzyme 
inhibition assays. 
11.3 Kinetic studies on DHQases  
11.3.1 Enzyme Assays 
The Standard assay to measure 3-dehydroquinase activity follows the formation 
of 3-dehydroshikimate. Dehydroquinate is added to the protein sample, and the 
rate of conversion of 3-dehdroquinate to 3-dehdroshikimate is monitored by the 
increase in absorbance at 234nm.  
 
Enzyme kinetics were carried out to 
 
1. Compare the Km and Kcat values of DHQases from different 
microorganisms 
2. Test the activity of the purified enzymes after lyophilization to 
confirm that freeze-drying the sample had caused no appreciable 
effect on the enzyme activity of the samples.  
3. Compare the cacluated values (Km, Kcat) with previously reported 
values for different DHQases 
 
All enzyme assays were carried out using Jasco V-550 dual beam 
spectrophotometer as described in section 2.19.1. Typically a 1mL path length 
quartz cell was used. Dehydroquinate was used as a substrate. Molar extinction 
coefficient for 3-dehydroquinate was measured to be 12000 M-1cm-1.  All the 
assay measurements were made in triplicate by using 100mM Tris pH: 7.0 
buffers. The assay data was used to calculate the Km and Kcat values by using the 
Michelis-Menten equation and Line weaver-Burk plots (Table 11.1). 
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The data obtained from enzyme kinetics showed that CJ DHQase has the lowest 
Km value, while CA DHQase has a Km values similar to SC DHQase. The Km values 
of DHQases from different microorganisms indicated that the substrate binds 
most tightly to the CJ DHQase and most weakly to HP DHQase. The binding 
affinity in descending order is given as 
 
CJ DHQase > MTB DHQase > CA DHQase= SC DHQase > HP DHQase 
 
The Kcat value was highest for SC DHQase and lowest for CA DHQase. The Kcat 
values for different DHQases in descending order are given as 
 
SC DHQase > CJ DHQase > MTB DHQase > CA DHQase > HP DHQase 
 
The kinetic data indicated no loss in the enzyme activity of the samples after 
lyophilization. There was a small difference observed between calculated and 
reported values which could be due to slight changes in pH or temperature or a 
high concentration of NaCl in the lyophilized samples.  
 
11.4 Crystal structure of C.jejuni DHQase 
CJ DHQase was over expressed and purified by Sabine Schwartz (Project student 
B.Sc (Hons)).  To obtain the crystal structure of the enzyme substrate complex 
(ESC) crystallization trials were carried out at a range of conditions. The best 
Km (µM) Kcat (s
-1) Kcat/Km (s
-1 M-1)  
DHQase cal* rep* cal* rep* cal* rep* 
HP 200 205.8 0.91 0.94 4.55×103 4.55×103 
MTB 32.8 23.8 3.3 5.2 1.0 x105 2.18×105 
SC 157.3 99.2 110.6 124.8 7.03 x105 12.5×105 
CJ 17.3 - 6.2 - 3.58×105 - 
CA 157.2 - 1.17 - 7.44×103 - 
Table  11.1 Comparison of Km and Kcat values of DHQases from different microorganism, all 
the enzyme assays were carried out  at pH : 7.0 @ 25°C  ( - = values not determined, cal = 
values calculated in the project work, rep* = reported values from L.D.B Evans Thesis, 2003) 
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conditions to grow crystals were identified under the microscope. Initially the 
crystals were obtained from the crystallization trials of M-Screen (M1-M114) at 
M88 and M75. These conditions were then slightly optimized to get better 
crystals. The most promising individual large crystals were obtained at [0.1M 
MOPS (pH: 6.5), 15 % ME2K PEG, 0.2M MgCl2].   
11.4.1 Crystallographic Data collection and processing 
X-ray diffraction data were collected for CJ DHQase in house on a Mar345dtb 
image plate & Rigaku Micromax 007 X-ray generator with Osmic mirrors. The 
crystal was briefly soaked with 2mM DHQ in the crystallisation mother liquor 
along with 30% glycerol and then flash frozen at 100K in a stream of gaseous 
nitrogen using an Oxford cryostream. 180 degrees of data was collected from a 
single CJ DHQase crystal. The data was indexed as face-centered cube with unit 
cell dimensions a = b = c = 127.53Å by using the program IMosflm. This meant 
that the data was highly redundant and a unique dataset required only 30 
degrees of data. Typical diffraction image is shown in figure 11.8. Altogether 
360 frames were collected with an oscillation angle of 0.5°. Data collection and 
processing statistics for the first 60 degrees are given in table 11.2. 
                                                                         
Figure  11.8 A typical diffraction image obtained from a crystal of CJ DHQase  
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The crystal was very mosaic with a refined mosaicity of 1.5°. The diffraction was 
strong around 2.8Å resolution, but extended weakly to 2.4Å resolution. The data 
was complete with an average multiplicity of 6.1 and Rmerge of 21.9 %. The X-ray 
data processing and subsequent calculations were carried out using programs 
from the CCP4 suite of programs {185}. The structure was solved by using the HP 
DHQase monomer coordinates (PDB: 2C4V). The search model (PDB: 2C4V) was 
employed by using the program PHASER. The program gave a unique solution 
with rotation function Z-score of 5.7 and a translation function Z-score of 20.5 
and a final log likelihood gain of 294. The structure was refined and adjusted by 
iterative cycles of refinement using the program REFMAC5. The model was built 
by using the program COOT®. The representative electron density for the 
structure is shown in figure 11.9. Interestingly the crystal structure had the 
product (3-dehydroshikimate) in the active site. Figure 11.10 shows the final 
electron density around the product (Dehydroshikimate, DHS) in the active site 
of the enzyme. The final structure had good geometry as assessed by PROCHECK. 
The structure gave an excellent Ramachandron plot with 91% of amino acid 
residues within the most favorable region and none in disallowed regions (Figure 
11.11). The refined structure had an R-factor of 19.8 % and a free R-factor of 
26.5 %.  
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Data collection statistics  
Data set CJ DHQase and 3-
dehydroshikimate 
Space group F23 
Unit cell a=b=c =127.53Å 
wavelength 1.5418Å 
Crystal to Detector distance(mm) 220 
Resolution range/ High Resolution 38.47-2.36Å (2.49-2.36Å)  
completeness 97.4% (82.6%) 
Unique reflections 6971 
Merging R-factor 0.219 
Wilson B-value 34.0 
Multiplicity  6.1 (5.1) 
Mean [I/Sd(I)] 7.7 (1.7) 
Refinement statistics 
Resolution range  36.8-2.37Å  
Overall R-factor  0.1986 
Free R-factor  0.2649 
Over all B-value 43.4 
RMS bond length deviation 0.0142Å 
RMS bond angle deviation 1.2637Å 
 
Table  11.2 X-ray crystallographic data for CJ DHQase 
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Figure  11.9 Electron density map for CJ DHQase at a resolution of 2.4Å (figure generatd by 
Coot®) 
 
 
Figure  11.10 Electron density map for 3-Dehydro shikimate in the active site of CJ DHQase 
at a resolution of 2.4Å (figure generated by Coot®)  
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Figure  11.11 Ramachandron plot for crystal structure of CJ DHQase obtained by using 
PROCHECK 
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11.4.2 Structure analysis 
The visualization of the final structure in Coot indicated that DHS formed good 
H-bonds with the surrounding active site residues.  The catalytic reaction 
product 3-dehydroshikimate was observed in the subunits (the substrate was 
converted into product during crystallization). The binding of DHS is stabilized 
by hydrogen-bonding interactions with the backbone amides of Ile102 and 
Ser103, with the side-chain atoms of Arg19, Asn75, His81, Arg112 and Asp88* (* 
indicates residues from an adjacent subunit) and by hydrophobic interactions of 
its cyclohexene moiety with the sidechain atoms of Tyr24, His101, Leu13, 
Val105, Arg112 and the C alphas of Ala77 and Gly78. The dodecameric structure 
shows that DHS is located at the interface of two subunits (Figure 11.12). 
 
 
Figure  11.12  Ribbon Diagram for the dodecameric structure of CJ DHQase along with DHS 
(CPK model) in the active site of the protein (Figure generated by Pymol). 
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A comparative study of the x-ray structures of DHQases including CJ DHQase, 
MTB DHQase and SC DHQase demonstrated that MTB DHQase and CJ DHQase 
contain a Glycine 78 residue while the SC DHQase has an Alanine at this position 
in the active site. The superimposed structures through Coot® indicated that 
DHS fits well in the active site of CJ DHQase & MTB DHQase while in case of SC 
DHQase it has a different conformation. The different conformation of DHS in SC 
DHQase can be due to the presence of Alanine residue which is replaced by a 
Gly78 in CJ DHQase & MTB DHQase (Figure 11.13).   
 
 
Figure  11.13 Superimposed C-Alphas structures of C.jejuni, M.tuberculosis & S.coelicolor. 
DHS structure in blue and red color is from the structures of CJ & MTB while the DHS in 
green color is from the structure of SC DHQase. 
 
The sequence analysis of active site of different DHQases shows that this Glycine 
is unique only in CJ DHQase & MTB DHQase but is replaced by an Alanine in other 
DHQases like SC DHQase, HP DHQase & CA DHQase. Interestingly the Km value is 
the lowest for the former DHQases but is significantly high for the latter 
DHQases (Table 11.3). 
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DHQase Active Site Sequence Km (µM) 
CJ N A A G Y T H 17.3 
MTB N A G G L T H 32.8 
SC N P A A Y S H 157.3 
CA N A G A Y T H 157.0 
HP N P G A F S H 200.0 
 
Table  11.3 Comparative account of amino acid sequences of different DHQases and their 
respective Km values (the residue numbering for CJ DHQase is N75, A76, A77, G78, Y79, 
T80, H81) 
 
The presence of a Gly residue within the active site provides more room for the 
surrounding active site residues to form close contacts with DHS but in case of 
SC DHQase the presence of Ala at the same position moves the same residues a 
little away from DHS. Further study of the superimposed structures revealed 
that the presence of Alanine in place of Gly78 in the structure of S.coelicolor 
causes a slight movement of the symmetry related Asp 88# and other adjacent 
residues away from the DHS. A lower Km value for CJ DHQase & MTB DHQase is 
consistent to the presence of this glycine residue which is lacking in other 
DHQases like SC DHQase, HP DHQase and CA DHQase (Table 12.3).  
 
To analyze the interactions between DHS and different DHQases, the H-bond 
distances and angles were measured for CJ DHQase, MTB DHQase & SC DHQase 
by using Coot®. When compared to MTB & SC DHQase it appeared that CJ 
DHQase formed better H-bond distances and angles towards the carboxyl moiety 
of DHS (Table 12.4). Further towards the six membered ring of DHS the H-bond 
distances were relatively better between His81 and CJ DHQase than MTB & SC 
DHQase. In case of Arg112 an opposite trend was observed where the H-bonding 
was better for SC & MTB DHQase than CJ DHQase. The over all H-bond data 
showed that in general the interactions between DHS and the active site 
residues were better for CJ DHQase than MTB & SC DHQase. 
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Residue number bonding atoms CJ DHQase MTB DHQase SC DHQase 
Arg17 NH1…O3—C3 2.83 (125.09) 2.94  (134.1) — 
Ala77^ CB…O3—C3 3.13 (112.35) — 3.21 (94.50) 
Gly78 N…OH4—C4 3.13 (117.89) 3.11 (125.0) — 
Asp88# OD2…OH4—C4 2.57 (111.45) 2.47 (119.3) 2.68 (116.42) 
NH1…OH4—C4 2.96 (85.84) 3.22 (83.64) 2.98 (140.56) Arg112 
NH1…OH5—C5 2.93 (108.80) 2.83 (115.7) 2.81 (115.64) 
His81 NE2…OH5—C5 2.63 (115.42) 2.68 (119.8) 2.77 (113.34) 
Ile102 N…2O7—C7 2.78 (105.48) 2.90 (100.0) 3.08 (100.14) 
OG…1O7—C7 2.61 (143.31) 2.84 (138.8) 2.59 (154.22) Ser103 
N…1O7—C7 2.66 (104.71) 2.80 (134.9) 2.88 (140.66) 
Asn75 ND2…2O7—C7 2.99 (158.69) 3.15 (148.5) 3.03 (150.83) 
 
Table 11.4 Comparative data for H-bond lengtha and angles between DHS and active site 
residues of different DHQases. ^ = short contact, # = contact from the adjacent subunit, — = 
residue absent, the distances are in Å and corresponding angles are given in parenthesis. 
 
11.5 Future work 
Based on the low Km values obtained for different DHQases and the sequence 
analysis it would be sensible to mutate the Glycine residue with Alanine in CJ 
DHQase and MTB DHQase and then carrying out the enzyme assay on mutated 
form of these enzymes for measuring the Km values. To Further confirm these 
studies a reverse study can be carried out by mutating the Alanine residue to 
Glycine in the active site of DHQases with high Km values like SC DHQase, HP 
DHQase & CA DHQase. These experiments could reveal in finding out the crucial 
role of Glycine (Gly78) in the active site of the DHQases. Obtaining the X-ray 
structure of these mutated versions would be helpful in exploring the nature of 
interactions of surrounding residues between themselves and with the true 
ligand in the active site of the enzymes. 
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12. HISdhL (Haemophilus Influenzae SdhL) 
The shikimate dehydrogenase (SDH) represents a widely distributed protein 
enzyme family and performs essential roles in the secondary metabolism of 
microbes and plants. The shikimate pathway occupies a central position for 
aromatic biosynthesis in microbes and plants but is absent in humans and other 
higher animals. The absence of the shikimate pathway in animals makes it an 
ideal target for herbicide and for the anti-microbial drug design. Recently the 
shikimate pathway was identified in apicomplexan parasites, including 
Toxoplasma gondii and Plasmodium falciparum, which has renewed interest in 
better understanding of the enzymes in the pathway. To date 5 classes of 
shikimate dehydrogenases have been identified and characterized, namely AroE, 
YdiB, YdiB2, SdhL, and RifI {186, 187}. 
 The combination of biochemical, phylogenetic, and genomic approaches has 
revealed a broad extent functional diversity in the SDH enzyme superfamily. All 
the classes in the family show clear biochemical and functional differences 
ranging from amino acid biosynthesis to antibiotic production {186}. YdiB is a 
bifunctional enzyme that catalyzes the reversible reductions of dehydroquinate 
to quinate and dehydroshikimate to shikimate (Figure 12.1) in the presence of 
either NADH or NADPH as a co-factor {187}. Another analogue of the SDH family 
is HISdhL whose kinetic properties are remarkably different from those of AroE 
and YdiB. In comparison to YdiB, HISdhL catalyzes the oxidation of shikimate to 
dehydroshikimate but not quinate. HISdhL turnover rate for the oxidation of 
shikimate is 1000-fold lower as compared with that of AroE. The kinetic 
properties of HISdhL suggest that both shikimate and quinate are not its 
preferred substrates {186, 187}. 
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Figure  12.1 Role of different shikimate dehydrogenases in the shikimate/quinate pathway,  * 
= quinate hydrolyase, image modified from {186} 
 
The previous kinetic studies, carried out in our group (L.D.B Evans PhD Thesis 
University of Glasgow) have revealed that HISdhL and HIAroE are both NAD+/ 
NADP+ dependant dehydrogenases. Both are able to utilize shikimate in the 
presence of co-factors (NAD+, NADP+), except HIAroE which is able to utilize 
even quinate in the presence of both co-factors. The data shows that HIAroE 
binds more tightly to NADP+ (KNADP = 20µM) than HISdhL (KNADP = 380µM) but 
weaker to NAD+ (KNAD = 8500µM) in comparison to HISdhL (KNAD = 1400µM). Further 
the data shows that HIAroE binds more tightly to shikimate (Km = 0.02mM) than 
HISdhL (Km = 0.38mM), similarly the Kcat values for HIAroE are much higher than 
HISdhL i.e.; 194 and 19 respectively. Based on interrogation of the active site of 
HISdhL by our group, it was proposed that a potential substrate could be 
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Mannose-6-phosphate. The kinetic studies carried out for HISdhL with different 
substrates (Table 12.1) confirmed that mannose-6-phosphate is indeed a much 
better substrate of HISdhL  with a Km values of 56 µM in comparison to shikimate 
with a Km value of 30500 µM (unpublished data). The specificity factor (Kcat/Km) 
for mannose-6-phosphate is not particularly high suggesting that it may not be 
the true substrate for the enzyme, however there is a significant difference in 
kinetic parameters compared to the only other identified substrate i.e. 
shikimate. 
 
As till date no structure of HISdhL has been determined with the co-factor 
and/or substrate, the determination of the crystal structure of HISdhL along with 
mannose-6-phosphate would significantly help in understanding the true function 
of this class of enzymes.  
12.1 Expression and purification  
HISdhL is a protein comprising of 277 amino acids with a molecular weight of 
30.7 Kda. The Non-His tagged version of the protein has been previously purified 
by using a different construct (L.B Evans PhD thesis, 2004 University of Glasgow). 
Recently the gene for HISdhL was cloned from the PTb361 into to another vector 
to form a new His tagged vector called PTbL2. The aim of attaching His-tag to 
the enzyme was easy and short cut purification of the protein. The PTbL2 
Substrate Kcat (s
-1) Km (µM) Kcat/Km (M
-1s-1) 
Shikimate 4.5 30500 148 
Quinate — — — 
Mannose <0.005 — — 
Glucose <0.005 — — 
Mannose-6-phosphate 0.47 56 8393 
Glucose-6-phosphate <0.005 — — 
Table  12.1 Kinetic data for HISdhL against different potential substrates (— = Not 
obtainable, unpublished data) 
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plasmid was successfully transformed into BL21 (DE3) competent cells. The over-
expression of the protein was carried out in LB media at 37°C however, the yield 
was very low (Figure 12.2). In order to increase the over-expression of protein 
the cultures were first grown at 37°C and as the O.D600 reached to 0.6, the 
cultures were put in slushy ice for 5 minutes and then induced with 1mM IPTG 
and left for overnight induction at 13°C. The induction at 13°C significantly 
improved the over-expression (Figure 12.3). Precision plus proteinTM BioRad, cat# 
161-0373 molecular weight marker was used in all the SDS-PAGE analysis. 
 
 
Figure  12.2 SDS-PAGE analysis for HISdhL expressed in LB media at 37°C 1=molecular 
weight marker, 2= uninduced sample, 3=overnight induced sample, 4= overnight induced 
sample at 13°C) 
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Figure  12.3 .SDS-PAGE analysis for HISdhL expressed in LB media at 37°C 1=molecular 
weight marker, 2= uninduced sample, 3=overnight induced sample, 4= overnight induced 
sample at 13°C) 
 
As the His-tagged version of the protein did not bind very tightly to the Ni-
column (Figure 12.4.) which posed some problems during the purification of the 
protein. Attempts were made to design a step wise plan for the purification of 
the protein to get the maximum yield. 
 
Figure  12.4 SDS-PAGE analysis for HISdhL after Nickel Purification: 1=marker, 2=flow 
through, 3=75mM Imidazole wash, 4=300mM Imidazole elute, 5=marker 
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The over-expressed N-terminal His tagged protein was purified by first passing 
through Ni-column and then subjected to sulphate cuts. The sulphate cuts (5-
40%) were performed on the flow through from Ni-purification by adding 
powdered ammonium sulphate to the flow through with a magnetic stirrer at 
4°C on a magnetic plate and then centrifuged at 20000xg for 20 minutes at 4°C. 
The precipitate (protein) obtained was redissolved in the buffer (50mM Tris, 
500mM NaCl, pH: 7.5) and to the supernatant additional powdered ammonium 
sulphate was added to increase the %age of ammonium sulphate and was then 
processed in the same way. The samples obtained were analyzed by running on a 
SDS-PAGE gel (Figure 12.5)  
 
 
Figure  12.5 SDS-PAGE analysis for HISdhL after sulphate cuts 1 = marker, 2 = precipitate 
after 5% cut, 3 = precipitate after 10% cut, 4 = precipitate after 15% cut, 5 = precipitate after 
20% cut, 6 = precipitate after 25% cut, 7 = precipitate after 30% cut, 8 = precipitate after 35% 
cut, 9 = precipitate after 40% cut, 10 = marker 
 
The gel image showed that the maximum amount of protein is precipitated out 
at 20-25% of ammonium sulphate (Figure 12.6). The protein samples with 20% 
and 25% ammonium sulphate were pooled. The excess amount of ammonium 
sulphate was removed from the protein sample by buffer exchanging and 
concentrating down by using vivaspin in 100mM tris, 1mM DTT pH: 7.4 buffer.  
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Figure  12.6 SDS-PAGE analysis for HISdhL after sulphate cuts 1 = marker, 2 = precipitate 
after 20% cut, 3 = supernatant from 20% cut, 4 = precipitate from 25%cut, 5 = supernatant 
from 25% cut, 6 = precipitate from 30% cut, 7 = supernatant from 30%cut, 8 = marker, 9 = 
marker 
 
The concentrated protein sample was then loaded on phenyl sepharose column 
(HIC). The protein was eluted from the column (Figure 12.7) with a gradient of 
500-0 mM NaCl of Buffer B (100mM Tris, 500mM NaCl, 1mM DTT, pH: 7.4) against 
Buffer A (100mM Tris, 1mM DTT, pH: 7.4).  
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Figure  12.7 Chromatogram image for HISdhL after passing through phenyl sepharose 
column (HIC) 
 
The SDS-PAGE analysis on the fractions obtained after HIC showed that the 
protein did not bind to the column. Therefore to further purify the protein the 
pooled fractions were loaded on SP sepharose column (ion exchange 
chromatography), as described in section 2.14.1. The fractions (Figure 12.8) 
obtained from SP sepharose column were subjected to SDS-PAGE analysis for 
checking the purity of the samples (Figure 12.9). The pure fractions were 
concentrated down to the desired values and further used for setting up co-
crystallizations. 
 
Figure  12.8 Chromatogram image for HISdhL after passing through SP sepharose column 
(Ion exchange chromatography) 
 
Chapter  12   295 
 
 
Figure  12.9 SDS-PAGE analysis for HISdhL after passing through sp sepharose column 1 = 
marker, 2 = A2, 3=A3, 4 = B5 
12.2 Crystallization of HISdhL 
Through the enzyme assays carried out previously it has been confirmed that 
mannose-6-phosphate is a substrate of HISdhL and the co-factor for HISdhL is 
NADP+ and NAD+. The objective of co-crystallizing the protein was to obtain a 
crystal structure of the protein along with the potential ligand to help in 
understanding the active site interactions with the ligand and thereby assisting 
in knowing the functional mechanism of the protein. Crystallizations were 
performed by using sitting-drop vapour-diffusion method. Various crystallization 
conditions were carried out to co-crystallize the protein along with the substrate 
and co-factor.  After initial difficulties in generating crystals, some small 
crystals were obtained at a number of conditions. The conditions at which best 
crystals grew are given in (Table 12.2). In order to obtain better crystals the 
crystallization conditions were further optimized and individual crystals were 
obtained (Figure 12.10). To prevent damage to the crystals, cryoprotector was 
prepared for each condition at which the crystals were obtained. Crystals were 
dipped in the respective cryoprotector containing 30% glycerol prior to 
diffraction. The best crystals were selected for diffraction.  
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C.No 0.1M Buffer/ pH %age of PEG 
3350  
Crystals of  
1 Na-Acetate/5.4 9 Protein+ mannose-6-   
phosphate (substrate) 
2 Citrate/6.6 18 Protein + NADP+ (co-factor) 
3 Citrate/6.3 19 Protein only 
4 Citrate/6.6 17 Protein+ co-factor 
5 Citrate/5.88 20 Protein only 
6 Citrate/5.88 17 Protein+ substrate+ co-
factor 
7 Citrate/5.88 15 Protein+ co-factor 
8 Citrate/5.88 16.5 Protein only  
9 Citrate/5.88 18 Protein+ co-factor 
10 Citrate/5.88 16 Protein only 
Table  12.2 Crystallization conditions for individual crystals of HISdhL along with the 
substrate and co-factor 
 
Figure  12.10 Images of HISdhL crystals obtained from conditions No 3, 4, 6, 7 & 9 
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It was observed that all the crystals diffracted up to a maximum resolution of 
3.0Å and no more than that. To get the resolvable electron density for substrate 
and co-factor it was tried to get the diffraction images at a higher resolution 
below 3.0Å. After a number of attempts, the crystals diffracted to a maximum 
resolution of 3.0Å (Figure 12.11) and no diffraction pattern was visible at a 
higher resolution. 
 
Figure  12.11 Diffraction pattern for HISdhL crystals from C.No 4, 6 & 9  
12.3 Conclusions and future work 
The co-crystallisation and diffraction studies were tried until it became clear 
that no improvements were going to be forthcoming. The absence of an over 
expressing  PTB361 clone of HISdhL stopped the possibility of purifying the 
native protein, which may have resulted in better diffraction of the crystals and 
ultimately a crystal structure in the presence of Mannose 6-phosphate.  It is well 
known that the histidine tag can be detrimental to the success of crystallization 
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trials.  Future work should focus on obtaining diffraction quality crystals which 
could diffract to ~2.0Å which has been achieved previously (Kirsty Stewart, PhD 
Thesis 2005 University of Glasgow). The soaking of crystals with mannose-6-
phosphate would be the simplest approach for obtaining a complex crystal 
structure. Another route and potentially time consuming would be to use NMR to 
solve the solution structure, however this would have been beyond the scope of 
this thesis. 
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Appendices (Appendix 1) 
Legend key 
e.d.a = electron density absent 
     -   = protein structure not subjected to pharmacophore searching 
Rows highlighted green = protein structures subjected to pharmacophore searching 
Rows highlighted yellow = protein structures without electron density 
Rows highlighted blue = protein structures visualized in Coot for viewing unknown ligands along with electron density 
 
PDB 
code 
visual description of unknown ligand(s) and binding domain of the target protein 
 
  
structure 
selected for 
pharmacopho
re searching 
comments about pharmacophore search hits 
1FSC no electron density available for the protein structure e.d.a   
1O5U cluster of electron density , may be coordinating water molecules -   
1O5Z Small ligand with low electron density in the binding site of protein -   
1OR8 no electron density available for the protein structure e.d.a   
1ORI no electron density available for the protein structure e.d.a   
1S01 no electron density available for the protein structure e.d.a   
1SVV metal site with disordered electron density -   
1TVF medium size ligand with good electron  density in the binding domain  þ among other hits citric acid and its derivatives 
efficiently satisfy the model 
1UEH ligand with good electron  density only in B chain, but not in the active site  -   
1VJ0 no electron density available for the protein structure e.d.a   
1VJ2 ligand with partially disordered electron density, not covalently bound to the manganese  
atom in the active site, may be water molecules 
-   
1VJL small ligand with disordered electron density and not in the binding site -   
1VK2 very small ligand, may be a water molecule in active site -   
1VK8 well defined ligand in the active site with good electron density þ thiamine and its derivatives satisfy the 
pharmacophore 
1VK9 ligand with poor resolution, probably metal ion with coordinating waters molecules -   
1VKE no electron density available for the protein structure e.d.a   
1VKM medium size ligand with well defined electron density close to the metal centre  in the 
active site 
þ As a unique hit D-erythritol 4-phosphate logically fits 
both the electron density and the pharmacophore 
model  
1VKY ligand not with well defined electron density -   
1VL0  ligand with good electron density but present out side the active site of the protein and 
only in chain A, and absent in chain B 
þ the stereo chemistry fits reasonably to  aldehydo-D-
allose as a hit which is not in the crystallization 
conditions, possibly a potential candidate as a true 
ligand 
1VMG no electron density available for the protein structure e.d.a   
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1VP4 very small ligand,probably a water molecule in active site -   
1VP8 ligand with not a well defined electron density, may be a metal ion coordinating with water 
molecules 
-   
1VPY small ligand covalently bounded to cysteine out side the active site of the protein -   
1VQ0 no electron density available for the protein structure e.d.a   
1VQZ ligand with good electron density ,covalently bonded to glutamate, but not in the active 
site of the protein 
-   
1VR3 no electron density available for the protein structure e.d.a   
1VRA no electron density available for the protein structure e.d.a   
1VRM small ligand with disordered electron density, with in the active site -   
1YBA no electron density available for the protein structure e.d.a   
1YQ3 17 very small ligands scattered far a part from each other , majority  at the periphery of the 
protein, probably water molecules 
-   
1Z8H well defined 5 member ring ligand covalently bonded to serine(in all A,B,C and D chains ),in 
the active site 
-   
1ZKG  small ligand with low electron density in a more hydrophobic pocket of the protein with 
provision of very few interactions ,probably a small fatty acid or PEG molecule  in binding 
pocket 
-   
2A06 17 small ligands scattered far a part , majority  at the periphery, may be these are water 
molecules 
-   
2A0N large ligand covalently bound to cysteine in the binding pocket, can be peptide  with 
disulphide linkage to cysteine residue of the protein 
-   
2A6A ligand with reasonable electron density in the binding site, appears like  sausage 
hydrophobic group 
-   
2AAM reasonably long ligand with fair electron density in the binding pocket, found in all 
A,B,C,D,E and F chains of the protein 
þ beta-D-galacturonic acid seems a logical hit by 
forming additional H-bond interactions at position 1 
and 4 
2AJ6 small ligand with fair electron density, looks like a water molecule in the binding site -   
2F1L two ligands with poor electron density , only in chain A -   
2F46 poor density small ligand at the interface of chain B only and not in A -   
2F4P medium size ligand with poor electron densities  in Chain A, B,C and D -   
2F6R small ligand with reasonably good electron density in the active site þ among hits citramalic acid is convincingly satisfying 
the model 
2FBW 17 small ligands scattered far a part , majority  at the periphery, may be these are water 
molecules 
-   
2FCL small size ligand with disordered electron density -   
2FTR small ligand in the binding site with reasonable electron density þ Few good hits like homo-serine, L-leucine, L-
homoserine, creatine, L-aspartic acid and L-
asparagine comply with the pharmacophore model. 
2FTZ two ligands in two binding sites in the same chain with poor electron density -   
2G8L small ligand in each chain(A and B) with poor electron density -   
2GFG small ligand with poor electron density  in each binding pocket(A,B and C chain) -   
2GNO small ligand in the binding pocket with reasonable electron density , possibly water -   
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molecules 
2GVI small ligand with good electron density, covalently bounded to cysteine ,near to the zinc 
metal ion in the active site 
-   
2GVK very small ligand, possibly a metal ion. -   
2H1N small ligand with poor electron density  -   
2H88 17 small ligands scattered far a part , majority  at the periphery, may be these are water 
molecules 
-   
2H89 no electron density available for the protein structure e.d.a   
2HBW small ligand doesn't match the electron density.  -   
2HSZ small sausage shaped ligand with low electron density, may be a PEG molecule  -   
2I5N no electron density found around the ligand. -   
2I8D small ligand , may be water molecules, no bonding electron density visible between the 
ligand fraction 
-   
2IG6 ligand with good electron density in the binding pocket, looks like nitro benzene only in 
chain A and not in chain B  
-   
2ITB in Chain B ligand with reasonable electron density, fraction of ligand covalently bounded to 
Fe, but absent in Chain A. 
-   
2NQL poor electron density ligands looks like nitro benzene, located in the binding pocket, both in 
chain A and B 
-   
2O08 long ligand with fair electron density in the binding site of chain A, but absent in chain B -   
2O7T two separate long ligands some what like fatty acids, with fair density in the binding 
pocket. Might be a PEG molecule 
-   
2OC5 long sausage like ligand with good electron density, covalently linked to Fe. -   
2OH1 small parts of ligands in Chain A,B and D and absent in C, may be 3-4  water molecules -   
2OLM no electron density available e.d.a   
2OPK ligand like 5 member ring, with reasonable electron density ,located well inside the binding 
pocket in all A,B,C and D chains, possibly a imidazole ring. 
-   
2OUW medium size ligand with fair electron density in the binding pocket in both A and B chains -   
2OWN ligand like medium size fatty acid in the binding site with good electron density in both 
chains 
þ L-arginine, N-(2-aminoethyl)butane-1,4-diamine and 
hexyl isocyanate were the best hits, satisfying both 
the electron density and the pharmacophore model 
2OZH small ligand with good electron density in the binding pocket, possibly a water molecule -   
2PBL good electron density ligand like benzamidine in all A,B,C and D chains of the protein -   
2PCS  very big ligand with low electron density, located in the binding site -   
2PEB  small  ligand with good electron density in the active site near Zn  -   
2PNK ligand with good electron density, looks like a phosphate in the binding pocket ,present only 
in chain B and absent among chains A-L. 
-   
2PY6 medium size ligand with good electron density in the active site of the protein þ best hits included some amino acids and sugars  
2Q02 very small ligand with low electron density covalently bound to Zn in the active site -   
2Q0Y small ligand with low electron density in the binding site -   
2Q83  medium size ligand with low electron density, present in the binding site in both chains -   
2Q9K fairly large ligand with disordered electron density in the binding pocket -   
2QDR cluster of electron density probably reminiscent of metal ion and  coordinating water -   
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molecules, no bonding electron density present between the ligand atoms  
2QE8 low electron density small ligand, looks like a fatty acid or PEG molecule  in binding pocket -   
2QGG long ligand at the periphery of the protein, bonding electron density absent between the 
atoms 
-   
2QIW medium size ligand with low electron density, present in chain A but absent in chain B -   
2RAU very large ligand with good atomic and bonding electron density ,well inside the binding 
pocket ,some what like long chain fatty acid 
-   
2W87 well defined ligand , with good atomic and bonding electron density, covalently attached to 
glucuronic acid  in both chains at the periphery of the protein 
-   
2WQY 12  small ligands with poor electron density scattered far a part from each other , majority  
at the periphery, probably water molecules 
-   
2WSC protein structure comprised of 19 chains with poor electron density -   
2WSE protein structure comprised of 19 chains with poor electron density -   
2WSF protein structure comprised of 19 chains with poor electron density -   
2WTL no electron density available for the protein structure e.d.a   
3ARC structure comprised of 52 chains, with low electron density -   
3B9Y small ligand, electron density not matching with the ligand atoms -   
3B9Z small ligand with low electron density in the binding site -   
3BI7 no electron density available for the protein structure e.d.a   
3BN8 medium size sausage shape ligand with good atomic and bonding electron density in the 
binding site in chain A but absent in chain B 
-   
3BOG no electron density available for the protein structure e.d.a   
3C5E medium size ligand with low electron density in the binding pocket -   
3C5I Very small ligand with good electron density blob, probably a metal ion. present in chain 
B,C and D but absent in chain A 
-   
3CNX medium size ligand with low electron density in the binding pocket in all chains, but 
bonding electron density absent between the atoms 
-   
3CSW medium size ligand with low electron density, present in the binding pocket of all the chains 
but bonding electron density absent between the atoms 
-   
3CT8 very long ligand with good electron density and  covalently attached to Zn in the active site þ pharmacophore not pulling out any ligands 
3CWB  protein structure comprised of 20 chains, with poor electron density - - 
3D1C very small scattered ligand with poor electron density in the binding site, probably 
scattered water molecules   
-   
3D82  ligand like benzamidine with low electron density, covalently linked to Ni in the active site 
in all A,B,C,D and E chains of the protein 
-   
3D9R no electron density available for the protein structure e.d.a   
3DDL 10 fragments of medium and large size ligands with low electron density in both chains -   
3E5D a very large ligand with low electron density in the binding pocket -   
3E8O  small ligand with low electron density in the binding pocket in both chains but bonding 
electron density absent between the ligand atoms 
-   
3E8V very small ligand with good electron density in the binding site, may be an ion or metal ion -   
3EBT fragmented ligand with low electron density in the binding pocket, may be water molecules  -   
3ECF  ligand like benzamidine with low electron density, present in the active site in all A,B,C -   
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and D  chains of the protein 
3ED4 small ligand with low electron density present in the binding pocket and in the periphery  in  
all A, B, C and D chains of the protein 
-   
3EJK very small ligand with good electron density in the binding pocket, may be a water molecule  -   
3EJV  ligand like benzamidine with low electron density in the binding pocket of the protein -   
3EK3 no electron density available for the protein structure e.d.a   
3EZ0 very long ligand  with low electron density in the binding pocket in all A,B,C and D chains, 
probably a PEG molecule  
-   
3EZU medium size ligand with good electron density  in the binding pocket of the protein þ 2-ethylhexan-1-ol and diethylaminoethanol fit the 
electron density and the model and can be potential 
ligands of the protein 
3F0H no electron density available for the protein structure e.d.a   
3F7S no electron density available for the protein structure e.d.a   
3F7W no electron density available -   
3F7X very small ligand with good electron density  in the binding pocket at two different sites 
,probably an ion  
-   
3FDE small scattered ligands  in and around protein with good electron density , in all chains, 
probably water molecules  
-   
3FF0 ligand like benzamidine with poor electron density, present at two binding sites of chain A 
but absent in chain B 
-   
3FGV fragmented ligand with good electron density in the binding site in both chains -   
3FGY very small ligand with poor electron density in the binding site in both chains, can be an ion  -   
3FH1 medium size ligand with good electron density  in the binding pocket  þ hits like pantothenate,  D-galactonic acid and L-
citrulline reasonably fitted the pharmacophore model 
3FKA  medium size ligand with good electron density in the binding site in all A,B,C and D chains  
of the protein 
-   
3FLJ small ligand with good electron density in the binding pocket  -   
3FSD fragmented ligand with poor electron density in the binding pocket -   
3G16  medium size ligand with good electron density in the binding pocket in both chains -   
3G23  medium size ligand with low electron density in the binding site of chain A, but absent in 
chain B 
-   
3GBH medium size ligand with low electron density ligand in the binding site, in all A,B,C and D 
chains of the protein 
-   
3GBN no electron density for protein. -   
3GE5 benzamidine like ligand with good electron density in the binding pocket in both chains  -   
3GGD medium size ligand with good electron density in the binding site -   
3GI7 medium size ligand with low electron density in the binding site in both chains -   
3GIW ligand like benzene ring with low electron density in the binding pocket of the protein -   
3GQQ fragmented ligand with good electron density in the active site present in all A-F chains of 
the protein 
-   
3GR3 medium size fragmented ligand  with good electron density in the binding site in both chains -   
3GWR benzamidine like ligand in the binding site with good electron density in both chains  -   
3GZA fragmented medium size ligand with low electron density in chain B only but absent in chain -   
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A 
3GZI medium size fragmented ligand with low electron density in the binding site -   
3GZR benzamidine like fragmented ligand with good electron density in the binding site in both 
chains  
-   
3H1H protein comprised of 20 chains with poor electron density -   
3H1I protein comprised of 20 chains with poor electron density -   
3H1J protein comprised of 20 chains with poor electron density -   
3H1K protein comprised of 20 chains with poor electron density -   
3H1L protein comprised of 20 chains with poor electron density -   
3H3H medium size ligand with low electron density in the binding pocket in both chains -   
3H4Q fragmented medium size ligand with low electron density in the binding site -   
3H51  small ligand with low electron density in the binding site in both chains -   
3H7A medium size ligand with low electron density in the binding pocket in chains C and D only, 
but absent in chains A and B, probably a PEG molecule  
-   
3HFT  small ligand with low electron density in the active site near the metal Zn. -   
3HL1 fragmented ligand with low electron density in the binding site in both chains  -   
3HM4 medium size ligand with low electron density in the binding pocket in chain A only and 
absent in chain B 
-   
3HMZ medium size fragmented ligand with poor electron density   in the binding site  -   
3HOI  small ligand with poor electron density in the periphery of the protein. -   
3HRG  fragmented ligand with low electron density in the binding site, probably water molecules  -   
3HX8 medium size ligand with good electron density in the active site in all  A,B,C and D chains of 
the protein 
-   
3I0Y medium size ligand with good electron density in the active site in all A,B,C and D chains of 
the protein 
-   
3IEH medium size ligand with fair electron density in the active site near the Zn, probably a 
glycerol molecule 
-   
3JR1 medium size ligand with low electron density in the binding pocket of both chains of the 
protein  
-   
3JTW medium size ligand with low electron density in the binding site in chain A only but absent 
in chain B, probably a PEG molecule 
-   
3JVG  fairly long two ligands with poor electron density at two different sites  in the binding site 
in chains A and B only but absent in chains C and D 
-   
3KL7   small ligand with poor electron density covalently linked to Zn in the active site -   
3KS6  small ligand with good electron density, covalently linked to Mg in the active site in all  A, 
B, C and D chains, probably an acetate molecule 
-   
3KTC good density, medium size fragmented ligand, covalently linked to Fe in the active site in 
both chains 
-   
3KTS medium size ligand with poor electron density in the binding site in all chains A-H of the 
protein 
-   
3KWK very small ligand, with fair electron density, probably a single atom ion or water molecule -   
3KY8 medium size fragmented ligand with low electron density, in the binding site in both chains  -   
3L12  medium size ligand with god electron density, covalently linked to Mg in the active site in -   
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both chains  
3L2N small ligand with low electron density covalently linked to Ca ion in the active site in both 
chains of the protein 
-   
3L49  medium size ligand with low electron density in the binding pocket in all A,B,C and D chains  -   
3L60  ligand like benzamidine with good electron density in the active site -   
3L74 protein structure comprised of 26 chains with poor electron  density -   
3L75 protein structure comprised of 26 chains with poor electron  density -   
3LB5 benzamidine like ligand with good electron density in the binding pocket in all A,B,C and D 
chains of the protein  
-   
3LOT  small ligand with low electron density covalently linked to Zn in the active site in all chains 
A,B,C and D ,probably a water molecule  
-   
3LOU  small fragmented  ligand with poor electron density in the binding site in A chain only and 
absent in B,C and D chains 
-   
3LWU medium size ligand with low electron density, covalently linked to Zn in the active site -   
3LYG  ligand like benzamidine with low electron density in the active site -   
3M5K  fragmented ligand with poor electron density in the binding site in both chains  -   
3MHO  medium size ligand with low electron density in the binding site , probably a PEG molecule  -   
3MPR fragmented ligand with low electron density in the binding site of the protein in chain A 
only and absent in chain B,C and D  
-   
3MST medium size ligand with low electron density in the binding site, probably a PEG molecule -   
3N5L  medium size ligand with low electron density in the binding site in both chains -   
3N7O medium size ligand with good electron density  in the binding site. -   
3NDO  medium size ligand with good electron density in both chains -   
3NE7 small fragmented ligand with low electron density in the binding site -   
3NF6 no electron density available for the protein structure e.d.a   
3NF7 no electron density available for the protein structure e.d.a   
3NF8 no electron density available for the protein structure e.d.a   
3NF9 no electron density available for the protein structure e.d.a   
3NG3 medium size ligand with good electron density in the binding site in all Chain A-D -   
3NNR comparatively long ligand with good electron density  in the binding site of the protein þ Among other long chain fatty acids as hits, palmitic 
acid fits the model in the best way 
3NO4 very small ligand with low electron density near the Ni atom in the active site in all A-C 
chains , probably an ion   
-   
3NRB benzamidine like good electron density ligand in the binding site in chain A only and absent 
in chains B,C and D 
-   
3NRJ no electron density available for the protein structure e.d.a   
3OE4 no electron density available for the protein structure e.d.a   
3OE5 no electron density available e.d.a   
3OF4 fragmented ligand with good electron density, located in the  periphery of the protein in 
Chain A only and absent in chains B,C and D 
-   
3OKH no electron density available for the protein structure e.d.a   
3OKI no electron density available for the protein structure e.d.a   
3OLF no electron density available for the protein structure e.d.a   
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3OLQ no electron density available for the protein structure e.d.a   
3OMK no electron density available for the protein structure e.d.a   
3OOF no electron density available for the protein structure e.d.a   
3OOK no electron density available for the protein structure e.d.a   
3OP7 purine ring like ligand with good electron density in the binding site of the protein -   
3OS5 electron density not matching with the atoms positions, ligand in chain A only and not in 
chain B   
-   
3OYV very small ligand, with good electron density in the binding pocket, probably a water 
molecule 
-   
3OZR no electron density available for the protein structure e.d.a   
3OZS no electron density available for the protein structure e.d.a   
3OZT no electron density available for the protein structure e.d.a   
3P6K Purine ring like ligand with good electron density in the binding site in chain B but absent in 
chain A 
þ among other hits, pyridoxilactone fits the model 
comparatively in a better manner 
3PCV very small ligands with poor electron density , scattered far a part from each other, in the 
periphery of the protein 
-   
3PIK medium size ligand with poor electron density in the binding site , covalently linked to 
cysteine of the protein 
-   
3PM9  fragmented ligand with poor electron density in the binding site in all chains A-F of the 
protein 
-   
3PMI medium size ligand with low electron density, present in the binding site in C and D chains 
only, but absent in chains A and B 
-  
3PPL  fragmented ligand with low electron density in the binding site in both chains of the 
protein 
-  
3QC0  medium size ligand with fair electron density in the active site covalently linked to Zn ion -  
3QK8  benzamidine like ligand with fair electron density in the binding site in all chains A-F, 
except B of the protein 
-  
3QQV no electron density available -  
3QUA Very small ligand with good electron density in the binding pocket, possibly a water 
molecule or a metal ion 
-  
3QUQ medium size ligand with good electron density in the active site near the Mg ion  -  
3QYP good electron density small  ligand in the binding site in chain B only and not in A -  
3RH2 very long ligand with good electron density in the binding site -  
 
Legend key 
e.d.a = electron density absent 
     -   = protein structure not subjected to pharmacophore searching 
Rows highlighted green = protein structures subjected to pharmacophore searching 
Rows highlighted yellow = protein structures without electron density 
Rows highlighted blue = protein structures visualized in Coot for viewing unknown ligands along with electron density 
